<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/264229-new-imidazolone-derivatives-preparation-thereof-as-drugs-pharmaceutical-compositions-and-use-thereof-as-protein-kinase-inhibitors-in-particular-cdc7 by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 00:21:06 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 264229:NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL, COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL, COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The invention relates to products of the formula(I) in which : X-Y is NH-C(S), N=C-NR7R8, N=C-SR, N=C-R or N=C-OR; R and R1 are H or optionally substituted cycloalkyl, alkyl, heterocycloalkyl, aryl or heteroaryl,; R2 is H, Hal or alkyl; R3 is H, Hal, OH, alkyl or alkoxy; R4 is H, Hal, CN or alkyl; R5 is essentially H, Hal, OH, NR7R8, cycloalkyl, alkyl, alkoxy, heterocycloalkyl, aryl or heteroaryl, optionally substituted; R6 is H, Hal, OH, NH2, NHalk, N(alk)2, alkyl or alkoxy; with R7 et R8 being such that one is H or optionally substituted alk, while the other is H or optionally substituted cycloalkyl, alkyl, heterocycloalkyl, heteroaryl or aryl; or with R7 and R8 forming together with N an optionally substituted cyclic radical optionally containing O, S or N. The invention also relates to isomers and salts thereof used as drugs and essentially as protein kinase inhibitors, in particular CDC7.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>NEW IMIDAZOLINE DERIVATIVES, PREPARATION THEREOF AS<br>
DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS<br>
PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7<br>
The present invention relates to novel derivatives of<br>
imidazolones, the method of preparation thereof, the<br>
novel intermediates obtained, their application as<br>
medicinal products, pharmaceutical compositions<br>
containing them and novel uses of said imidazolone<br>
derivatives.<br>
The invention thus relates to novel derivatives of<br>
imidazolones having inhibitory effects with respect to<br>
protein kinases.<br>
The products of the present invention can thus notably<br>
be used for the prevention or the treatment of<br>
disorders that can be controlled by inhibiting the<br>
activity of protein kinases.<br>
The products of the present application, as inhibitors<br>
of protein kinases, can be used quite particularly for<br>
the treatment or prevention of cancers. Cancer is a<br>
disease for which existing treatments are still<br>
inadequate. Certain protein kinases play an important<br>
role in many cancers. Inhibition of these protein<br>
kinases is potentially important in the chemotherapy of<br>
cancers, notably for suppressing tumour growth or<br>
survival.<br>
The present invention therefore relates to the<br>
identification of novel products which inhibit said<br>
protein kinases.<br>
The inhibition and regulation of protein kinases<br>
notably represent a powerful new mechanism of action<br>
for the treatment of a broad number of solid tumours.<br><br>
Disorders that can be treated with the products of the<br>
present application are therefore quite particularly-<br>
solid tumours.<br>
Protein kinases<br>
The protein kinases constitute a group of enzymes that<br>
catalyse the phosphorylation of hydroxy groups of<br>
specific protein residues such as tyrosine, serine or<br>
threonine residues. Said phosphorylations can<br>
extensively modify the function of proteins; thus, the<br>
protein kinases play an important role in the<br>
regulation of a great variety of cellular processes,<br>
notably including metabolism, cellular proliferation,<br>
cell differentiation or cell survival. Among the<br>
various cellular functions in which the activity of a<br>
protein kinase is involved, certain processes represent<br>
attractive targets for treating certain diseases. As an<br>
example, we may notably mention angiogenesis and<br>
control of the cell cycle, in which the protein kinases<br>
can play an essential role. These processes are<br>
essential for the growth of solid tumours as well as<br>
for the development of other diseases.<br>
The protein kinases participate in signalling events<br>
that control the activation, growth and differentiation<br>
of cells in response either to extracellular mediators,<br>
or to changes in the environment. In general, these<br>
kinases belong to two groups: those which phosphorylate<br>
serine and/or threonine residues preferentially, and<br>
those which phosphorylate tyrosine residues<br>
preferentially [S.K. Hanks and T. Hunter, FASEB. J.,<br>
1995, 9, pages 576-596]. The serine/threonine kinases,<br>
for example, are isoforms of protein kinases C [A.C.<br>
Newton, J. Biol. Chem., 1995, 270, pages 28495-28498]and a group of cyclin-dependent kinases, such as Cdc2<br><br>
(Cdk1) [J. Pines, Trends in Biochemical Sciences, 1995,<br>
18, pages 195-197]. The tyrosine kinases include growth<br>
factor receptors, such as the epidermal growth factor<br>
(EGF) receptor [S. Iwashita and M. Kobayashi, Cellular<br>
Signalling, 1992, 4, pages 123-132], and cytosolic<br>
kinases such as p56tck, p59fYn, ZAP-70 and the csk<br>
kinases [C. Chan et al. , Ann. Rev. Immunol., 1994, 12,<br>
pages 555-592].<br>
Abnormally high levels of protein kinase activity have<br>
been associated with many diseases, resulting in<br>
abnormal cellular functions. This can occur either<br>
directly or indirectly, from a malfunction in the<br>
control mechanisms of kinase activity, connected for<br>
example with a mutation, overexpression or<br>
inappropriate activation of the enzyme, or with<br>
overproduction or underproduction of cytokines or of<br>
growth factors, which are also involved in signal<br>
transduction upstream or downstream of the kinases. In<br>
all these cases, selective inhibition of the action of<br>
the kinases offers hope of a beneficial effect.<br>
Among these protein kinases, we may mention quite<br>
particularly protein kinase Cdc7.<br>
Cdc7 is a serine/threonine kinase that has been<br>
characterized at the molecular level as a factor that<br>
is essential for initiating DNA replication.<br>
The catalytic activity of Cdc7, which is conserved<br>
throughout the eukaryotes, is dependent on its Dbf4<br>
regulatory subunit. Although the expression of Cdc7 (at<br>
the level of messenger and protein RNA) is constant<br>
throughout the cell cycle, the level of expression of<br>
Dbf4 is in contrast dependent on the cell cycle, which<br>
induces an increase in Cdc7 kinase activity during the<br><br>
G1-S transition. For this reason, Cdc7 is given the<br>
designation DDK (Dbf4-dependent kinase).<br>
The principal activity of the Cdc7/Dbf4 complex occurs<br>
on initiation of DNA replication during the S phase. It<br>
phosphorylates MCM2 which thus activates the MCM (Mini-<br>
Chromosome Maintenance) complex, which is an essential<br>
component of DNA-helicase activity.<br>
Cdc7 also plays an important role in mutagenesis,<br>
mainly induced by action at the level of the DNA-damage<br>
pathways and checkpoints, in particular at the ATR-<br>
dependent checkpoint, which prevents the initiation of<br>
DNA replication in response to damage of the single-<br>
stranded type caused by chemical agents such as<br>
etoposide.<br>
Cdc7 and Dbf4 are overexpressed in human tumour cell<br>
lines and in many tumour samples (lung, breast,<br>
thyroid, colon-rectum, oesophagus, uterus, testicle,<br>
liver (Hess et al., 1998 and internal data)) in<br>
comparison with the corresponding normal tissues.<br>
Experiments in suppressing Cdc7 expression using RNA<br>
interference (RNAi) technology show that inhibition of<br>
Cdc7 expression induces arrest of the cell cycle and<br>
prevents cellular proliferation of the human tumour<br>
cell lines HeLa and HCT116, but has a limited effect on<br>
normal cells (normal human skin fibroblasts) . This is<br>
reflected in a prolonged stoppage in G1 that induces<br>
apoptosis in cells lacking p53 (&gt; 50% of tumours) but<br>
is reversible in normal cells [A. Montagnoli et al.,<br>
CANCER RESEARCH 64, 7110-7116, October 1, 2004].<br>
The inhibitors of Cdc7 kinase activity can constitute a<br>
novel category of targeted cytotoxic therapy as well as<br><br>
of inhibitors of DNA replication. Such inhibitors would<br>
inhibit replication before the replication forks are<br>
established, thus blocking replication without damaging<br>
the DNA.<br>
The present application thus relates in particular to<br>
novel inhibitors of protein kinase Cdc7 that can be<br>
used notably for the treatment of abnormal cellular<br>
proliferation and more particularly in oncology.<br>
The present invention thus relates to the products of<br>
formula (I):<br><br>
in which:<br>
X-Y represents NH-C(S), N=C-NR7R8, N=C-SR, N=C-R or<br>
N=C-OR;<br>
R1 represents a hydrogen atom, a cycloalkyl radical or<br>
an alkyl, heterocycloalkyl, aryl or heteroaryl radical,<br>
all these radicals being optionally substituted;<br>
R, which may be identical to or different from R1, is<br>
selected from the values of R1;<br>
R2 represents a hydrogen atom, a halogen atom or an<br>
alkyl radical;<br>
R3 represents a hydrogen atom, a halogen atom, a<br>
hydroxyl radical or an alkyl or alkoxy radical;<br><br>
R4 represents a hydrogen atom, a halogen atom or a<br>
cyano, CF3 or alkyl radical;<br>
R5 represents a hydrogen atom, a halogen atom, a<br>
hydroxyl, cyano, NR7R8, CONR7R8, NR11C0R12 radical, or<br>
a cycloalkyl, alkyl, alkoxy, heterocycloalkyl, aryl or<br>
heteroaryl radical, all these last-mentioned radicals<br>
being optionally substituted;<br>
R6 represents a hydrogen atom, a halogen atom or an<br>
NR7R8, alkyl or alkoxy radical;<br>
R7 and R8 are such that:<br>
either R7 and R8, which may be identical or different,<br>
are such that one of R7 and R8 represents a hydrogen<br>
atom or an alkyl radical, optionally substituted; and<br>
the other one of R7 and R8 represents a hydrogen atom<br>
or a cycloalkyl, alkyl, heterocycloalkyl, heteroaryl or<br>
aryl radical, all these radicals being optionally<br>
substituted;<br>
or R7 and R8 form, together with the nitrogen atom to<br>
which they are attached, a cyclic radical formed from 3<br>
to 7 ring members optionally containing one or more<br>
other heteroatoms selected from O, S or N, N being<br>
optionally substituted with R11, said cyclic radical<br>
itself being optionally substituted;<br>
all the alkyl, alkoxy, cycloalkyl, heterocycloalkyl,<br>
heteroaryl and aryl radicals, as well as the cyclic<br>
radical that R7 and R8 can form together with the<br>
nitrogen atom to which they are attached, indicated as<br>
optionally substituted, thus being optionally<br>
substituted with one or more radicals, which may be<br>
identical or different, selected from the halogen atoms<br>
and the hydroxyl, cyano, nitro, CF3, NR9R10, NHCOR11,<br><br>
NHC02R11, NHCONR9R10, NHSO2R13, COOH, COOalk, CONR9R10,<br>
SO2NR9R10, alkoxy, alkylthio, haloalkoxy,<br>
haloalkylthio, alkyl, fluoroalkyl, hydroxyalkyl,<br>
cycloalkyl, heterocycloalkyl, heteroaryl and phenyl<br>
radicals, these last-mentioned heteroaryl, aryl and<br>
phenyl radicals themselves being optionally substituted<br>
with one or more radicals, which may be identical or<br>
different, selected from the halogen atoms and the<br>
hydroxyl, NH2, NH(alk), N(alk)2, alkyl, hydroxyalkyl<br>
and alkoxy radicals;<br>
R9 and R10 are such that:<br>
either R9 and R10, which may be identical or different,<br>
are such that one of R9 and R10 represents a hydrogen<br>
atom or an alkyl radical optionally substituted with<br>
one or more radicals, which may be identical or<br>
different, selected from the halogen atoms and the<br>
hydroxyl and alkoxy radicals; and the other one of R9<br>
and R10 represents a hydrogen atom or a cycloalkyl,<br>
alkyl, heterocycloalkyl, heteroaryl or aryl radical,<br>
all these radicals themselves being optionally<br>
substituted with one or more radicals, which may be<br>
identical or different, selected from the halogen atoms<br>
and the hydroxyl, NH2, NH(alk), N(alk)2, alkyl,<br>
hydroxyalkyl and alkoxy radicals;<br>
or R9 and R10 form, together with the nitrogen atom to<br>
which they are attached, a cyclic radical formed from 3<br>
to 7 ring members optionally containing one or more<br>
other heteroatoms selected from O, S or N, N being<br>
optionally substituted with R12, said cyclic radical<br>
itself being optionally substituted with one or more<br>
radicals, which may be identical or different, selected<br>
from the halogen atoms and the hydroxyl, NH2, NH(alk),<br>
N(alk)2, alkyl, hydroxyalkyl and alkoxy radicals;<br><br>
R11 and R12, which may be identical or different,<br>
represent a hydrogen atom or an alkyl or phenyl<br>
radical, optionally substituted with one or more<br>
radicals, which may be identical or different, selected<br>
from the halogen atoms and the hydroxyl and alkoxy<br>
radicals, the phenyl radical itself being optionally<br>
substituted with one or more alkyl radicals;<br>
R13 represents an alkyl or phenyl radical, optionally<br>
substituted with one or more radicals, which may be<br>
identical or different, selected from the halogen atoms<br>
and the hydroxyl and alkoxy radicals, the phenyl<br>
radical itself being optionally substituted with one or<br>
more alkyl radicals;<br>
all the above alkyl (alk) and alkoxy radicals being<br>
linear or branched and containing at most 12 carbon<br>
atoms;<br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
Among the products of formula (I) as defined above, we<br>
may exclude the products of formula (I) in which all<br>
the following conditions are fulfilled:<br>
-	R2 represents hydrogen;<br>
-	R3 represents hydrogen or alkyl;<br>
-	X-Y represents N=C-NR7R8, N=C-SR or N=CR in which X<br>
represents N and Y represents =C-NR7R8, =C-SR or =CR<br>
and R represents aryl or heteroaryl;<br>
-	R1 represents H or alk;<br><br>
- and R4, R5 and R6 are such that two of them represent<br>
H and the other represents hydrogen, NH2 or NHalk.<br>
The present invention thus notably relates to the<br>
products of formula (I) as defined above in which:<br>
R1 represents a hydrogen atom, or an alkyl radical, all<br>
these radicals being optionally substituted as stated<br>
above or hereunder;<br>
and R5 represents a halogen atom, a hydroxyl, cyano,<br>
NR7R8, CF3 radical or a cycloalkyl, alkyl, alkoxy,<br>
heterocycloalkyl, aryl or heteroaryl radical,<br>
all these last-mentioned radicals being optionally<br>
substituted as stated above or hereunder;<br>
the other substituent radicals R2, R3, R4, R6 and X-Y<br>
having the values as defined above or hereunder,<br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
The present invention thus notably relates to the<br>
products of formula (I) as defined above in which:<br>
R2 represents a hydrogen atom;<br>
and R5 represents a halogen atom, a hydroxyl, cyano,<br>
NR7R8, CF3 radical or a cycloalkyl, alkyl, alkoxy,<br>
heterocycloalkyl, aryl or heteroaryl radical, all these<br>
last-mentioned radicals being optionally substituted as<br>
stated above or hereunder;<br><br>
the other substituent radicals R1, R3, R4, R6 and X-Y<br>
having the values as defined above or hereunder,<br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
The present invention thus notably relates to the<br>
products of formula (I) as defined above in which:<br>
R3 represents a hydrogen atom;<br>
and R5 represents a halogen atom, a hydroxyl, cyano,<br>
CONR7R8 radical or a cycloalkyl, alkyl, alkoxy,<br>
heterocycloalkyl, aryl or heteroaryl radical, all these<br>
last-mentioned radicals being optionally substituted as<br>
stated above or hereunder;<br>
the other radicals R2, R3, R4, R6 and X-Y having the<br>
values as defined above or hereunder,<br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
The present invention thus notably relates to the<br>
products of formula (I) as defined above in which:<br>
X-Y represents NH-C(S), N=C-NR7R8 or N=C-R;<br>
Rl represents a hydrogen atom, a cycloalkyl radical or<br>
an alkyl, heterocycloalkyl, aryl or heteroaryl radical,<br>
all these radicals being optionally substituted as<br>
stated above or hereunder;<br><br>
R, which may be identical to or different from R1, is<br>
selected from the values of Rl as defined above or<br>
hereunder with the exception of aryl and heteroaryl;<br>
the other substituents R2, R3, R4, R5 and R6 having, the<br>
values as defined above or hereunder;<br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
The present invention notably relates to the products<br>
of formula (I) as defined above in which<br>
X-Y represents NH-C(S), N=C-NR7R8, N=C-SR, N=C-R or<br>
N=C-OR;<br>
Rl represents a hydrogen atom, a cycloalkyl	radical or<br>
an alkyl, heterocycloalkyl, phenyl or	heteroaryl<br>
radical, these last-mentioned radicals being	optionally<br>
substituted;<br>
R, which may be identical to or different from R1, is<br>
selected from the values of R1;<br>
R2 represents a hydrogen atom, a halogen atom or an<br>
alkyl radical;<br>
R3 represents a hydrogen atom, a halogen atom, a<br>
hydroxyl radical or an alkyl or alkoxy radical;<br>
R4 represents a hydrogen atom, a halogen atom or a<br>
cyano, CF3 or alkyl radical;<br>
R5 represents a hydrogen atom, a halogen atom, a<br>
hydroxyl, cyano, NR7R8, CONR7R8, NR11C0R12 radical or a<br><br>
cycloalkyl, alkyl, alkoxy, heterocycloalkyl, phenyl or<br>
heteroaryl radical, all these last-mentioned radicals<br>
being optionally substituted;<br>
R6 represents a hydrogen atom, a halogen atom or an<br>
NR7R8, alkyl or alkoxy radical;<br>
R7 and R8 are such that:<br>
either R7 and R8, which may be identical or different,<br>
are such that one of R7 and R8 represents a hydrogen<br>
atom or an alkyl radical optionally substituted with<br>
one or more radicals, which may be identical or<br>
different, selected from the halogen atoms and the<br>
hydroxyl and alkoxy radicals;<br>
and the other one of R7 and R8 represents a hydrogen<br>
atom or a cycloalkyl, alkyl, heterocycloalkyl,<br>
heteroaryl or phenyl radical, all these radicals being<br>
optionally substituted;<br>
or R7 and R8 form, together with the nitrogen atom to<br>
which they are attached, a cyclic radical formed from 3<br>
to 7 ring members optionally containing one or more<br>
other heteroatoms selected from O, S or N, N being<br>
optionally substituted with R11, said cyclic radical<br>
itself being optionally substituted;<br>
all the alkyl, alkoxy, cycloalkyl, heterocycloalkyl,<br>
heteroaryl and aryl radicals, as well as the cyclic<br>
radical that R7 and R8 can form together with the<br>
nitrogen atom to which they are attached, indicated as<br>
optionally substituted, thus being optionally<br>
substituted with one or more radicals, which may be<br>
identical or different, selected from the halogen atoms<br>
and the hydroxyl, cyano, nitro, CF3, NR9R10, NHCOR11,<br>
NHSO2R13, COOH, COOalk, CONR9R10, SO2NR9R10, alkoxy,<br><br>
haloalkoxy, alkyl, fluoroalkyl, hydroxyalkyl,<br>
cycloalkyl, heterocycloalkyl, heteroaryl and phenyl<br>
radicals, these last-mentioned heteroaryl and phenyl<br>
radicals themselves being optionally substituted with<br>
one or more radicals, which may be identical or<br>
different, selected from the halogen atoms and the<br>
hydroxyl, NH2, NH(alk), N(alk)2, alkyl, hydroxyalkyl<br>
and alkoxy radicals;<br>
R9 and R10 are such that:<br>
either R9 and R10, which may be identical or different,<br>
are such that one of R9 and R10 represents a hydrogen<br>
atom or an alkyl radical and the other one of R9 and<br>
RIO represents a hydrogen atom or an alkyl, phenyl or<br>
phenylalkyl radical, themselves optionally substituted<br>
with one or more radicals, which may be identical or<br>
different, selected from the halogen atoms and the<br>
hydroxyl, NH2, NH(alk), N(alk)2, alkyl, hydroxyalkyl<br>
and alkoxy radicals;<br>
or R9 and RIO form, together with the nitrogen atom to<br>
which they are attached, a pyrrolidinyl, morpholine,<br>
piperidyl, azepinyl or piperazinyl radical optionally<br>
substituted with an alkyl or phenyl radical, itself<br>
optionally substituted with one or more radicals, which<br>
may be identical or different, selected from the<br>
halogen atoms and the alkyl, hydroxyl, NH2, NH(alk),<br>
N(alk)2, alkyl, hydroxyalkyl and alkoxy radicals;<br>
R11 and R12, which may be identical or different,<br>
represent a hydrogen atom or an alkyl or phenyl<br>
radical;<br>
R13 represents an alkyl or phenyl radical;<br><br>
all the above alkyl (alk) and alkoxy radicals being<br>
linear or branched and containing at most 6 carbon<br>
atoms;<br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
When R9 and R10 form, together with the nitrogen atom<br>
to which they are attached, a cyclic radical, notably<br>
R9 and R10 form, together with the nitrogen atom to<br>
which they are attached, a pyrrolidinyl, morpholine,<br>
piperidyl or piperazinyl radical optionally substituted<br>
with an alkyl radical.<br>
The present invention relates in particular to the<br>
products of formula (I) as defined above in which:<br>
X-Y represents NH-C(S), N=C-NR7R8, N=C-SR, N=C-R or<br>
N=C-OR;<br>
R1 represents a hydrogen atom or an alkyl or phenyl<br>
radical, optionally substituted;<br>
R represents a hydrogen atom; a cycloalkyl, an alkyl,<br>
heterocycloalkyl, phenyl, or heteroaryl radical, all<br>
these radicals being optionally substituted;<br>
R2 represents a hydrogen atom, a halogen atom or an<br>
alkyl radical;<br>
R3 represents a hydrogen atom, a halogen atom, a<br>
hydroxyl radical or an alkyl radical;<br>
R4 represents a hydrogen atom, a halogen atom or an<br>
alkyl radical;<br><br>
R5 represents a hydrogen atom; a halogen atom; a<br>
hydroxyl, cyano, NR7R8, alkyl, alkoxy,<br>
heterocycloalkyl, phenyl, or heteroaryl radical, all<br>
these last-mentioned radicals as well as the phenyl<br>
residue in NHphenyl and NH(phenylalk) being optionally<br>
substituted;<br>
R6 represents a hydrogen atom, a halogen atom, or an<br>
NH2, NHalk, N(alk)2, alkyl or alkoxy radical;<br>
R7 and R8 are such that:<br>
either R7 and R8, which may be identical or different,<br>
are such that one of R7 and R8 represents a hydrogen<br>
atom or an alkyl radical; and the other one of R7 and<br>
R8 represents a hydrogen atom, or an alkyl or<br>
cycloalkyl radical, optionally substituted; or R7 and<br>
R8 form, together with the nitrogen atom to which they<br>
are attached, a cyclic radical selected from the<br>
azetidyl, piperidyl, azepanyl, morpholinyl,<br>
thiomorpholinyl, pyrrolidinyl, imidazolidinyl,<br>
piperazinyl radicals optionally substituted on the<br>
second nitrogen atom with an alkyl or phenyl radical,<br>
themselves optionally substituted; and homopiperazinyl,<br>
all these cyclic radicals being optionally substituted;<br>
all the alkyl, alkoxy, heterocycloalkyl, heteroaryl and<br>
phenyl radicals, as well as the cyclic radical that R7<br>
and R8 can form together with the nitrogen atom to<br>
which they are attached being optionally substituted<br>
with one or more radicals, which may be identical or<br>
different, selected from the halogen atoms and the<br>
hydroxyl, NH2, NH(alk), N(alk)2, NHphenyl,<br>
NH(phenylalk), alkyl, CF3, alkoxy, OCF3, cycloalkyl,<br>
heterocycloalkyl, heteroaryl and phenyl radicals; these<br>
last-mentioned heteroaryl and phenyl radicals, as well<br><br>
as the phenyl residue in the NHphenyl and NH(phenylalk)<br>
radicals, themselves being optionally substituted with<br>
one or more radicals, which may be identical or<br>
different, selected from the halogen atoms and the<br>
hydroxyl, NH2, NHAlk, N(Alk)2, alkyl, hydroxyalkyl and<br>
alkoxy radicals;<br>
all the above alkyl (alk) and alkoxy radicals being<br>
linear or branched and containing at most 6 carbon<br>
atoms;<br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers) , as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
In the products of formula (I) and hereinafter:<br>
- the term alkyl radical or alk denotes the linear and<br>
branched radicals containing at most 12 carbon atoms,<br>
such as for example the methyl, ethyl, propyl, isopro-<br>
pyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl,<br>
isopentyl, hexyl, isohexyl and also heptyl, octyl,<br>
nonyl and decyl radicals as well as their linear or<br>
branched positional isomers; the term notably<br>
represents the linear and branched radicals containing<br>
at most 6 carbon atoms selected from those defined<br>
above and also the linear and branched radicals<br>
containing at most 4 carbon atoms selected from those<br>
defined above;<br>
- the term alkylthio radical denotes the -S-alkyl<br>
radicals in which the alkyl radical has the meaning<br>
stated above;<br><br>
-	the terms haloalkyl and haloalkylthio represent the<br>
alkyl and alkylthio radicals as defined above<br>
substituted with one or more halogen atoms;<br>
the term hydroxyalkyl radical denotes the alkyl<br>
radicals stated above substituted with at least one<br>
hydroxyl radical;<br>
the term alkoxy radical denotes the linear and<br>
branched radicals containing at most 12 carbon atoms,<br>
such as for example the methoxy, ethoxy, propoxy,<br>
isopropoxy, linear, secondary or tertiary butoxy;<br>
pentoxy or hexoxy radicals as well as their linear or<br>
branched positional isomers; the term notably<br>
represents the linear and branched radicals containing<br>
at most 6 carbon atoms selected from those defined<br>
above and also the linear and branched radicals<br>
containing at most 4 carbon atoms selected from those<br>
defined above;<br>
-	the terms NH(alk) and N(alk)2 denote amino radicals<br>
substituted respectively with one or two alkyl<br>
radicals, said alkyl radicals being linear or branched<br>
and selected from the alkyl radicals as defined above,<br>
preferably containing at most 6 carbon atoms;<br>
-	in the groups above and hereunder, NR7R8, CONR7R8,<br>
NR11COR12, NR9R10, NHCOR11, NHCO2R11, NHCONR9R10,<br>
NHS02R13, CONR9R10 and SO2NR9R10, the radicals R7, R8,<br>
R9, R10, R11, R12 and R13 can assume all the values<br>
stated for these radicals;<br>
-	the term halogen atom denotes the chlorine, bromine,<br>
iodine or fluorine atoms and preferably the chlorine,<br>
bromine or fluorine atom;<br><br>
the term cycloalkyl radical denotes a saturated<br>
carbocyclic radical containing 3 to 10 carbon atoms and<br>
thus notably denotes the cyclopropyl, cyclobutyl,<br>
cyclopentyl and cyclohexyl radicals and quite<br>
particularly the cyclopentyl and cyclohexyl radicals;<br>
the term heterocycloalkyl radical thus denotes a<br>
monocyclic or bicyclic carbocyclic radical interrupted<br>
by one or more heteroatoms, which may be identical or<br>
different, selected from the oxygen, nitrogen or<br>
sulphur atoms: we may mention for example the radicals<br>
morpholinyl, thiomorpholinyl, aziridyl, azetidyl,<br>
piperazinyl, piperidyl, homopiperazinyl, pyrrolidinyl,<br>
imidazolidinyl, pyrazolidinyl, tetrahydrofuryl,<br>
tetrahydrothienyl,	hexahydropyran,<br>
oxodihydropyridazinyl radicals, all these radicals<br>
being optionally substituted;<br>
- the terms aryl and heteroaryl denote unsaturated or<br>
partially unsaturated radicals, respectively<br>
carbocyclic and heterocyclic, monocyclic or bicyclic,<br>
containing at most 12 ring members, and can optionally<br>
contain a -C(O) group, the heterocyclic radicals<br>
containing one or more heteroatoms which may be<br>
identical or different selected from 0, N, or S, with<br>
N, if necessary, optionally substituted;<br>
the term aryl radical thus denotes monocyclic or<br>
bicyclic radicals containing 4 to 12 ring members such<br>
as for example the phenyl, naphthyl, biphenyl, indenyl,<br>
fluorenyl and anthracenyl radicals, more particularly<br>
the phenyl and naphthyl radicals and even more<br>
particularly the phenyl radical. It may be noted that a<br>
carbocyclic radical containing a -C(O) group is for<br>
example the tetralone radical;<br><br>
- the term heteroaryl radical thus denotes -monocyclic<br>
or bicyclic radicals containing 4 to 12 ring members:<br>
monocyclic heteroaryl radicals such as for example the<br>
thienyl radicals such as 2-thienyl and 3-thienyl, furyl<br>
such as 2-furyl, 3-furyl, pyranyl, pyrrolyl,<br>
pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, pyridyl<br>
such as 2-pyridyl, 3-pyridyl and 4-pyridyl, pyrazinyl,<br>
pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl,<br>
isothiazolyl, diazolyl, thiadiazolyl, thiatriazolyl,<br>
oxadiazolyl, isoxazolyl such as 3- or 4-isoxazolyl,<br>
furazanyl, tetrazolyl whether free or salified, all<br>
these radicals being optionally substituted, among<br>
which more particularly the thienyl radicals such as 2-<br>
thienyl and 3-thienyl, furyl such as 2-furyl, pyrrolyl,<br>
pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl,<br>
oxazolyl, isoxazolyl, pyridyl, pyridazinyl, these<br>
radicals being optionally substituted; bicyclic<br>
heteroaryl radicals such as for example the<br>
benzothienyl radicals such as 3-benzothienyl,<br>
benzothiazolyl, quinolyl, isoguinolyl, dihydroquinolyl,<br>
quinolizinyl, tetrahydroquinolizinyl, quinolone,<br>
tetralone, adamentyl, benzofuryl, isobenzofuryl,<br>
dihydrobenzofuran, ethylenedioxyphenyl, thianthrenyl,<br>
benzopyrrolyl, benzimidazolyl, benzoxazolyl,<br>
thionaphthyl, indolyl, azaindolyl, indazolyl, purinyl,<br>
thienopyrazolyl,	tetrahydroindazolyl,<br>
tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl,<br>
tetrahydropyrrolopyrazolyl,<br>
oxotetrahydropyrrolopyrazolyl,<br>
tetrahydropyranopyrazolyl, tetrahydropyridinopyrazolyl<br>
or oxodihydropyridino-pyrazolyl, all these radicals<br>
being optionally substituted.<br>
As examples of heteroaryl radicals, we may mention more<br>
particularly the pyrimidinyl, pyridyl, pyrrolyl,<br><br>
azaindolyl, indazolyl or pyrazolyl radicals, optionally<br>
substituted with one or more substituents which may be<br>
identical or different as stated above.<br>
the term phenylalkyl denotes an alkyl radical as<br>
defined above in which the alkyl radical is linear or<br>
branched, preferably containing at most 4 carbon atoms<br>
and the phenyl radical is optionally substituted with<br>
one or more radicals as defined previously or<br>
hereunder;<br>
The carboxy radical or radicals of the products of<br>
formula (I) can be salified or esterified by the<br>
various groups known to a person skilled in the art,<br>
among which we may mention, for example:<br>
among the salification compounds, inorganic bases<br>
such as, for example, an equivalent of sodium, of<br>
potassium, of lithium, of calcium, of magnesium or of<br>
ammonium or organic bases such as, for example,<br>
methylamine, propylamine, trimethylamine, diethylamine,<br>
triethylamine, N,N-dimethylethanolamine, tris(hydroxy-<br>
methyl) aminomethane, ethanolamine, pyridine, picoline,<br>
dicyclohexylamine, morpholine, benzylamine, procaine,<br>
lysine, arginine, histidine, N-methylglucamine,<br>
among the esterification compounds, the alkyl<br>
radicals for forming alkoxycarbonyl groups such as, for<br>
example, methoxycarbonyl, ethoxycarbonyl, tert-<br>
butoxycarbonyl or benzyloxycarbonyl, and said alkyl<br>
radicals can be substituted with radicals selected for<br>
example from the halogen atoms, the hydroxyl, alkoxy,<br>
acyl, acyloxy, alkylthio, amino or aryl radicals such<br>
as, for example, in the chloromethyl, hydroxypropyl,<br>
methoxymethyl, propionyloxymethyl, methylthiomethyl,<br>
dimethylaminoethyl, benzyl or phenethyl groups.<br><br>
The salts of addition of the products of formula (I)<br>
with organic or inorganic acids can be, for example,<br>
the salts formed with hydrochloric, hydrobromic,<br>
hydriodic, nitric, sulphuric, phosphoric, propionic,<br>
acetic, trifluoroacetic, formic, benzoic, maleic,<br>
fumaric, succinic, tartaric, citric, oxalic, glyoxylic,<br>
aspartic, ascorbic acids, the alkylmonosulphonic acids<br>
such as for example methanesulphonic acid,<br>
ethanesulphonic acid, propanesulphonic acid,<br>
alkyldisulphonic acids such as for example<br>
methanedisulphonic acid, alpha, beta-ethanedisulphonic<br>
acid, arylmonosulphonic acids such as benzenesulphonic<br>
acid and the aryldisulphonic acids.<br>
It may be recalled that stereoisomerism can be defined<br>
broadly as the isomerism of compounds having the same<br>
structural formulae, but in which the various groups<br>
are arranged differently in space, such as notably in<br>
monosubstituted cyclohexanes in which the substituent<br>
can be in the axial or equatorial position, and the<br>
various possible rotational conformations of the<br>
derivatives of ethane. However, there is another type<br>
of stereoisomerism, due to the different spatial<br>
arrangements of substituents that are fixed either on<br>
double bonds, or on rings, which is often called<br>
geometric isomerism or cis-trans isomerism. The term<br>
stereoisomers is used in the present application in its<br>
broadest sense and therefore applies to all of the<br>
compounds stated above.<br>
The present invention thus relates to the products of<br>
formula (I) as defined above in which<br>
X-Y represents NH-C(S), N=C-NR7R8, N=C-SR, N=C-R or<br>
N=C-OR;<br><br>
R1 represents a hydrogen atom or an alkyl or phenyl<br>
radical, optionally substituted;<br>
R, which may be identical to or different from R1, is<br>
selected from the values of R1;<br>
R2 represents a hydrogen atom, a halogen atom or an<br>
alkyl radical;<br>
R3 represents a hydrogen atom, a halogen atom, a<br>
hydroxyl radical or an alkyl radical;<br>
R4 represents a hydrogen atom, a halogen atom or an<br>
alkyl radical;<br>
R5 represents a hydrogen atom, a halogen atom, a<br>
hydroxyl radical, an NH2, NHalk, N(alk)2, NR7R8,<br>
NHphenyl, NH(phenylalk) radical or an alkyl,<br>
heterocycloalkyl, alkoxy, phenyl or heteroaryl radical,<br>
these last-mentioned radicals as well as the phenyl<br>
residue in NHphenyl and NH(phenylalk) being optionally<br>
substituted;<br>
R6 represents a hydrogen atom, a halogen atom, or an<br>
NH2, NHalk, N(alk)2, alkyl or alkoxy radical;<br>
R7 and R8 are such that:<br>
either R7 and R8, which may be identical or different,<br>
are such that one of R7 and R8 represents a hydrogen<br>
atom or an alkyl radical;<br>
and the other one of R7 and R8 represents a hydrogen<br>
atom, or an alkyl or cycloalkyl radical, optionally<br>
substituted;<br>
or R7 and R8 form, together with the nitrogen atom to<br>
which they are attached, a cyclic radical containing 4<br><br>
to 6 ring members selected from azetidyl; piperidyl;<br>
morpholinyl; thiomorpholinyl; pyrrolidinyl;<br>
imidazolidinyl; piperazinyl; and homopiperazinyl, these<br>
radicals being optionally substituted;<br>
all the alkyl, alkoxy, heteroaryl and phenyl radicals,<br>
as well as the cyclic radical that R7 and R8 can form<br>
together with the nitrogen atom to which they are<br>
attached, indicated as optionally substituted, thus<br>
being optionally substituted with one or more radicals,<br>
which may be identical or different, selected from the<br>
halogen atoms and the hydroxyl, NH2, NH(alk), N(alk)2,<br>
NHphenyl, NH(phenylalk), alkyl, CF3, alkoxy, OCF3,<br>
cycloalkyl, heterocycloalkyl, heteroaryl and phenyl<br>
radicals; these last-mentioned heteroaryl and phenyl<br>
radicals, as well as the phenyl residue in the NHphenyl<br>
and NH(phenylalk) radicals, themselves being optionally<br>
substituted with one or more radicals, which may be<br>
identical or different, selected from the halogen atoms<br>
and the hydroxyl, NH2, NHAlk, N(Alk)2, alkyl,<br>
hydroxyalkyl and alkoxy radicals;<br>
all the above alkyl (alk) and alkoxy radicals being<br>
linear or branched and containing at most 6 carbon<br>
atoms;<br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers) , as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
In the products of formula (I) according to the present<br>
invention, the substituents X-Y, R1, R2, R3, R4, R5 and<br>
R6 can notably have, independent of one another, the<br>
following values i) to vii):<br><br>
i) notably X-Y represents NH-C(S), N=C-NR7R8 or N=C-R<br>
with NR7R8 and R as defined above or hereunder;<br>
ii) notably R1 represents a hydrogen atom or an alkyl<br>
or phenyl radical, optionally substituted with N(alk)2,<br>
morpholinyl or pyrrolidinyl, alkoxy or phenyl;<br>
iii) notably R2 represents a hydrogen atom, or an alkyl<br>
radical;<br>
iv) notably R3 represents a hydrogen atom;<br>
v) notably R4 represents a hydrogen atom or a halogen<br>
atom;<br>
vi) notably R5 represents a hydrogen atom; a halogen<br>
atom; a hydroxyl, cyano, NH2, NHalk, N(alk)2, NHphenyl,<br>
NH(phenylalk), CF3 radical; alkyl radical optionally<br>
substituted with phenyl; alkoxy; heterocycloalkyl such<br>
as for example morpholinyl; phenyl optionally<br>
substituted with a heterocyclic radical such as for<br>
example piperazinyl; or heteroaryl such as for example<br>
thienyl, these last-mentioned radicals as well as<br>
phenyl and the phenyl residue in NHphenyl and<br>
NH(phenylalk), being optionally substituted;<br>
vii) notably R6 represents a hydrogen atom or a halogen<br>
atom;<br>
all the alkyl, alkoxy, heterocycloalkyl, heteroaryl and<br>
phenyl radicals being optionally substituted with one<br>
or more radicals which may be identical or different as<br>
stated above or hereunder,<br>
it being understood that for each of the values i) to<br>
vii), the other substituents of said products of<br>
formula (I) can have any one of the values defined<br>
above or hereunder,<br><br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers) , as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
In the products of formula (I) according to the present<br>
invention, in the radical X-Y, R notably represents a<br>
hydrogen atom; a cycloalkyl radical; alkyl radical;<br>
heterocycloalkyl radical such as notably morpholino,<br>
tetrahydropyran; phenyl; or heteroaryl such as notably<br>
pyridine,	quinoline,	quinolizinyl,<br>
tetrahydroquinolizinyl, indolyl, thienyl, furanyl,<br>
pyrrolyl and pyrazolyl; all these radicals being<br>
optionally substituted as stated above or hereunder.<br>
More precisely R represents a hydrogen atom; or a<br>
cycloalkyl radical such as notably cyclohexyl; an alkyl<br>
radical optionally substituted notably with cycloalkyl<br>
such as for example cyclopropyl, cyclobutyl,<br>
cyclopentyl, with phenyl or with heteroaryl such as<br>
notably pyridine, all these radicals being optionally<br>
substituted as stated above or hereunder;<br>
heterocycloalkyl such as notably morpholino or<br>
tetrahydropyran; phenyl or heteroaryl such as notably<br>
pyridine, quinolyl, thienyl, furanyl, pyrrolyl and<br>
pyrazolyl optionally substituted as stated above or<br>
hereunder.<br>
When the products of formula (I) according to the<br>
present invention bear a radical NR7R8, notably R7 and<br>
R8 are such that either R7 and R8, which may be<br>
identical or different, are such that one of R7 and R8<br>
represents a hydrogen atom or an alkyl radical; and the<br>
other one of R7 and R8 represents a hydrogen atom, or<br>
an alkyl radical optionally substituted with<br><br>
cycloalkyl; or R7 and R8 form, together with the<br>
nitrogen atom to which they are attached, a piperidyl;<br>
azepinyl; morpholinyl; pyrrolidinyl; piperazinyl<br>
radical optionally substituted on its second nitrogen<br>
atom with alkyl or phenyl; these radicals being<br>
optionally substituted as stated above or hereunder.<br>
The present invention thus relates to the products of<br>
formula (I) as defined above in which<br>
X-Y, R2, R3, R4 and R6 have the meanings stated above,<br>
R1 represents a hydrogen atom or an alkyl radical,<br>
optionally substituted;<br>
R5 represents a hydrogen atom, a halogen atom, a<br>
hydroxyl, CF3, NH2, NHalk, N(alk)2 radical or an alkyl,<br>
alkoxy or phenyl radical, optionally substituted;<br>
the alkyl radical that can be represented by R1 or the<br>
alkyl, alkoxy or phenyl radical that can be represented<br>
by R5, being optionally substituted with one or more<br>
radicals, which may be identical or different, selected<br>
from the halogen atoms and the hydroxyl, NHalk,<br>
N(alk)2, alkoxy, cycloalkyl, heterocycloalkyl,<br>
heteroaryl and phenyl radicals, these last-mentioned<br>
heteroaryl and phenyl radicals being optionally<br>
substituted with one or more radicals, which may be<br>
identical or different, selected from the halogen atoms<br>
and the hydroxyl, NH2, NHAlk, N(Alk)2, alkyl,<br>
hydroxyalkyl and alkoxy radicals;<br>
R7 and R8 are such that:<br>
either R7 and R8, which may be identical or different,<br>
are such that one of R7 and R8 represents a hydrogen<br>
atom or an alkyl radical,<br><br>
and the other one of R7 and R8 represents a hydrogen<br>
atom, an alkyl radical optionally substituted with one<br>
or more radicals, which may be identical or different,<br>
selected from the halogen atoms, the hydroxyl, NH2,<br>
NHalk, N(alk)2, NH(phenyl), NH(phenylalk) , alkoxy,<br>
OCF3, cycloalkyl radicals, and the pyrrolidinyl,<br>
piperazinyl, piperidyl, morpholinyl and phenyl<br>
radicals, all these last-mentioned cyclic radicals, as<br>
well as the phenyl residue in the phenylalkyl radical,<br>
themselves being optionally substituted with one or<br>
more radicals, which may be identical or different,<br>
selected from the halogen atoms and the hydroxyl, NH2,<br>
NHAlk, N(alk)2, alkoxy, alkyl and hydroxyalkyl<br>
radicals;<br>
or R7 and R8 form, together with the nitrogen atom to<br>
which they are attached, a radical preferably selected<br>
from the piperidyl, morpholinyl radicals, and the<br>
pyrrolidinyl, piperazinyl and homopiperazinyl radicals<br>
optionally substituted with one or more radicals, which<br>
may be identical or different, selected from the alkyl<br>
and phenyl radicals, themselves optionally substituted<br>
with one or more radicals selected from the halogen<br>
atoms and the hydroxyl, NH2, NHAlk, N(Alk)2, alkoxy and<br>
cycloalkyl radicals;<br>
all the above alkyl (alk) and alkoxy radicals being<br>
linear or branched and containing at most 6 carbon<br>
atoms;<br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers) , as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br><br>
The present invention thus relates to the products of<br>
formula (I) as defined above in which<br>
X-Y represents NH-C(S), N=C-NR7R8 or N=C-R,<br>
R7, R8 and R being selected from all the values defined<br>
above for R7, R8 and R and the other substituents R1,<br>
R2, R3, R4, R5 and R6 of said products of formula (I)<br>
being selected from all the values defined above<br>
respectively for R1, R2, R3, R4, R5 and R6,<br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
The present invention thus relates to the products of<br>
formula (I) as defined above in which<br>
X-Y represents NH-C(S), N=C-NR7R8 or N=C-R;<br>
Rl represents a hydrogen atom or an alkyl radical<br>
optionally substituted with one or more radicals, which<br>
may be identical or different, selected from the<br>
halogen atoms and the N(alk)2 and alkoxy radicals;<br>
R, which may be identical to or different from Rl, is<br>
selected from the values of Rl;<br>
R2 represents a hydrogen atom, a halogen atom or an<br>
alkyl radical;<br>
R3 represents a hydrogen atom or an alkyl radical;<br>
R4 represents a hydrogen atom or a halogen atom,<br>
R5 represents a hydrogen atom, a halogen atom or a<br>
hydroxyl, NH2, NHalk, N(alk)2, alkyl, alkoxy or phenyl<br><br>
radical, the alkyl radical being optionally substituted<br>
with an alkoxy, N(alk)2 or heterocycloalkyl radical and<br>
the phenyl radical being optionally substituted with<br>
one or more radicals, which may be identical or<br>
different, selected from the halogen atoms and the<br>
hydroxyl, NH2, NHalk, N(alk)2, alkyl and alkoxy<br>
radicals;<br>
R6 represents a hydrogen atom, a halogen atom or an<br>
alkyl radical;<br>
and R7 and R8 are such that:<br>
either R7 and R8, which may be identical or different,<br>
are such that one of R7 and R8 represents a hydrogen<br>
atom or an alkyl radical, and the other one of R7 and<br>
R8 represents an alkyl radical optionally substituted<br>
with a cycloalkyl radical;<br>
or R7 and R8 form, together with the nitrogen atom to<br>
which they are attached, a pyrrolidinyl, morpholine,<br>
piperidyl or piperazinyl radical optionally substituted<br>
with an alkyl radical;<br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
In the products of formula (I) as defined above, we may<br>
note quite particularly the products for which R3<br>
represents a hydrogen atom, the other substituents R1,<br>
R2, R4, R5, R6 and X-Y of said products of formula (I)<br>
being selected from any one of the values defined<br>
above,<br><br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
The present invention thus relates to the products of<br>
formula (I) as defined above in which<br>
X-Y represents NH-C(S), N=C-NR7R8 or N=C-R;<br>
R1 and R2, which may be identical or different,<br>
represent a hydrogen atom or an alkyl radical;<br>
R3 represents a hydrogen atom;<br>
R4, R5 and R6, which may be identical or different,<br>
represent a hydrogen atom or a halogen atom;<br>
R7 and R8 represent the values defined in any one of<br>
the above claims;<br>
all the above alkyl (alk) radicals being linear or<br>
branched and containing at most 4 carbon atoms;<br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
The present invention relates notably to the products<br>
of formula (I) as defined above in which<br>
X-Y represents N=C-NR7R8 or N=C-R,<br>
R7, R8 and R being selected from all the values defined<br>
above for R7, R8 and R and the other substituents R1,<br>
R2, R3, R4, R5 and R6 of said products of formula (I)<br><br>
being selected from all the values defined above<br>
respectively for R1, R2, R3, R4, R5 and R6,<br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
The present invention relates notably to the products<br>
of formula (I) as defined above in which<br>
X-Y represents N=C-NR7R8,<br>
R7 and R8 being selected from all the values defined<br>
above for R7 and R8 and the other substituents R1, R2,<br>
R3, R4, R5 and R6 of said products of formula (I) being<br>
selected from all the values defined above respectively<br>
for R1, R2, R3, R4, R5 and R6,<br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
The present invention relates notably to the products<br>
of formula (I) as defined above in which<br>
X-Y represents N=C-R,<br>
R being selected from all the values defined above for<br>
R7, R8 and R and the other substituents R1, R2, R3, R4,<br>
R5 and R6 of said products of formula (I) being<br>
selected from all the values defined above respectively<br>
for R1, R2, R3, R4, R5 and R6,<br><br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers) , as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
The present invention relates notably to the products<br>
of formula (I) as defined above in which<br>
X-Y represents N=C-OR,<br>
R being selected from all the values defined above for<br>
R7, R8 and R and the other substituents R1, R2, R3, R4,<br>
R5 and R6 of said products of formula (I) being<br>
selected from all the values defined above respectively<br>
for R1, R2, R3, R4, R5 and R6,<br>
said products of formula (I) being in all possible<br>
tautomeric and isomeric forms (racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
The present invention relates more particularly to the<br>
products of formula (I) as defined above, having the<br>
following names:<br>
-	(5Z)-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-2-<br>
thioxoimidazolidin-4-one<br>
-	(5Z)-5-t(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one<br>
-	(5Z)-2-[(cyc1opropylmethyl)amino]-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylene)-3,5-dihydro-4H-imidazol-4-one<br><br>
-	(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-[(cyclopropylmethyl)amino]-3,5-dihydro-<br>
4H-imidazol-4-one<br>
-	(5Z)-5-[(6-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-[(cyclopropylmethyl)amino]-3,5-dihydro-<br>
4H-imidazol-4-one<br>
-	(5Z)-2-[(cyclopropylmethyl)amino]-3-methyl-5-(1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylene)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
-	(5Z)-2-butyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylene)-3,5-dihydro-4H-imidazol-4-one<br>
-	(5Z)-2-azepan-1-yl-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one<br>
-	(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-piperidin-1-yl-3,5-dihydro-4H-<br>
imidazol-4-one<br>
-	(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[methyl(2-methylpropyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one<br>
-	(5Z)-5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(cyclopropylmethyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one<br>
-	(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-methoxy-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
-	(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-fluoro-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br><br>
-	(5Z)-2-azepan-1-yl-5-[(5-fluoro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one<br>
-	3-[(Z)-{2-[(cyclopropylmethyl)amino]-5-oxo-l,5-<br>
dihydro-4H-imidazol-4-ylidene}methyl]-1H-pyrrolo[2,3-<br>
b]pyridine-5-carbonitrile<br>
-	(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-phenyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
-	(5Z)-2-[(cyclopropylmethyl)amino]-5-{[5-<br>
(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl]methylidene}-3,5-dihydro-4H-imidazol-4-one<br>
-	(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-(methylsulphanyl)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
-	(5Z)-2-butyl-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3,5-dihydro-4H-imidazol-4-one<br>
-	(5Z)-2-(3-methylbutyl)-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one<br>
-	(5Z)-2-cyclohexyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one<br>
-	(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-<br>
3,5-dihydro-4H-imidazol-4-one<br>
-	(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-(2-methylpropyl)-3,5-<br>
dihydro-4H-imidazol-4-one<br><br>
-	(5Z)-2-(cyclopropylmethyl)-5-(5-chloro-1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
-	(5Z)-2-(1-methylethyl)-5-(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one<br>
-	(5Z)-2-[benzyl(methyl)amino]-5-[(5-chloro-1H-<br>
pyrrolo [2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
-	(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(2-methoxyethyl)(methyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one<br>
said products of formula(I)being in all possible<br>
isomeric forms: racemates, enantiomers and<br>
diastereoisomers, as well as salts of addition of said<br>
products of formula (I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
The products of formula (I) as defined above can be<br>
prepared by the general methods known by a person<br>
skilled in the art and more particularly can be<br>
prepared using the methods of synthesis described in<br>
the following Schemes 1 to 7.<br>
The present invention thus also relates to methods of<br>
preparation of the products of formula (I), and notably<br>
the methods defined hereunder in Schemes 1 to 7 which<br>
are used for the preparation of compounds described in<br>
tables presented below.<br>
The tables and schemes that follow are related as<br>
follows:<br><br>
-	Tables 1, 2 and 4 describe products of formula (I)<br>
that can be prepared according to Scheme 1<br>
-	Table 6 describes products of formula (I) that can be<br>
prepared according to Scheme 2<br>
-	Table 3 describes a product of formula (I) that can<br>
be prepared according to Scheme 3<br>
-	Table 5 describes products of formula (I) that can be<br>
prepared according to Schemes 3 and 5<br>
-	Table 7 describes products of formula (I) that can be<br>
prepared according to Scheme 6 or 7<br>
-	Table 8 describes products of formula (I) that can be<br>
prepared according to Schemes 1 to 7<br>
Scheme 1: The case when X-Y equals N=C-NR7R8 and NH-<br>
C(S) :<br><br>
In a first stage, the (5Z)-5-[(1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-ones<br>
(la) are obtained by Knoevenagel reaction between a 2-<br>
thioxoimidazolidin-4-one (III) and an aldehyde, ketone<br>
or ester of formula (II) derived from 1H-pyrrolo[2,3-<br>
b]pyridine, in the presence of a base such as<br>
piperidine in a solvent such as ethanol. The<br>
temperature of choice for carrying out this reaction is<br>
between room temperature and the reflux temperature.<br><br>
All other usual conditions for a reaction of the<br>
Knoevenagel type can be used.<br>
Table 1 gives examples of compounds (Ia) prepared<br>
according to Scheme 1:<br><br><br><br><br><br><br>
In a second stage, the (5Z)-5-[(1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-amino-3,5-dihydro-4H-<br>
imidazol-4-ones (Ib) are obtained by reaction between<br>
(5Z)-5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-<br>
thioxoimidazolidin-4-one (1a) and a primary or<br>
secondary amine of general structure (IV) (with R7 and<br>
R8 as defined in general formula (I) for example in<br>
ethanol at a temperature varying from 120 to 170C in a<br>
sealed tube under microwave irradiation.<br>
Table 2 gives examples of compounds (Ib) prepared<br>
according to Scheme 1:<br><br><br>
Table 4 gives examples of compounds I(b) prepared<br>
according to Scheme 1: these products of formula (I)<br><br>
are described hereunder as examples in the experimental<br>
section.<br><br><br><br><br>
Scheme 2 : The case when X-Y equals N=C-SR and N=C-<br>
NR7R8:<br><br>
Alternatively, the (5Z)-5-[(1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-amino-3,5-dihydro-4H-imidazol-4-ones<br>
(Ic) can be prepared according to Scheme 2. The (5Z)-5-<br>
[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-<br>
thioxoimidazolidin-4-ones (Ia) are reacted with an<br>
alkylating agent (preferably, for example, methyl<br>
iodide) in the presence of a base such as<br>
diisopropylethylamine or sodium hydroxide, to give a<br>
thioalkylated derivative (Ic) . The thioalkyl group is<br>
finally replaced in a second stage with an amine<br>
R7R8NH, to obtain the derivatives (Ib). Said<br>
replacement is carried out in a solvent such as<br>
acetonitrile or ethanol, at a temperature between room<br>
temperature and the reflux temperature, or<br>
alternatively in a sealed tube under microwave<br>
irradiation.<br>
Table 6 gives examples of compounds I(c) prepared<br>
according to Scheme 2: these products of formula (Ic)<br>
are described hereunder as examples in the experimental<br>
section.<br>
Table 6<br><br><br>
Scheme 3: The case when X-Y equals N=C-R; 1st synthetic<br>
route:<br><br>
The (5Z)-5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-<br>
3,5-dihydro-4H-imidazolidin-4-ones (Id) are obtained by<br>
Knoevenagel reaction between an imidazolidin-4-one (V)<br>
and an aldehyde, ketone or ester of formula (II)<br>
derived from 1H-pyrrolo[2,3-b]pyridine, in the presence<br>
of a base such as piperidine in a solvent such as<br>
ethanol, according to Scheme 3. The temperature of<br>
choice for carrying out this reaction is between room<br>
temperature and the reflux temperature. All other usual<br>
conditions for a reaction of the Knoevenagel type, such<br>
as acidic conditions, can be used. The imidazolidin-4-<br>
ones (V) can be prepared according to J. Org. Chem.<br>
1999, 64(22), 8084.<br>
An example of preparation of a product of formula (I)<br>
according to Scheme 3 is given in the experimental<br><br>
section hereunder as Example 13 as presented in Table<br>
3.<br><br>
In a first stage, the (5Z)-5-[(1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-oxoimidazolidin-4-ones<br>
(VII) are obtained by Knoevenagel reaction between a 2-<br>
oxoimidazolidin-4-one (VI) and an aldehyde, ketone or<br>
ester of formula (II) derived from lH-pyrrolo [2,3-<br>
b]pyridine, in the presence of a base such as<br>
piperidine in a solvent such as ethanol, according to<br>
Scheme 4. The temperature of choice for carrying out<br>
this reaction is between room temperature and reflux.<br>
Any other usual conditions for a reaction of the<br>
Knoevenagel type, such as acidic conditions, can be<br>
used.<br><br>
In a second stage, the (5Z)-5-[(1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-alkoxy-3,5-dihydro-4H-<br>
imidazol-4-ones (Ie) are obtained by reaction between<br>
the (5Z)-5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-<br>
2-oxoimidazolidin-4-ones (VII) and an alkylating agent<br>
RX (VIII) in an inert solvent at a temperature varying<br>
from room temperature to reflux. Alkylating agents VIII<br>
that are known to promote O-alkylation, such as halides<br>
or salts of oxonium tetrafluoroborate are preferred.<br>
Scheme 5: The case when X-Y equals N=C-R: 2nd synthetic<br>
route<br><br>
Alternatively, the (5Z)-5-[(1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-3,5-dihydro-4H-imidazolidin-4-ones (Id)<br>
are obtained from an oxazolone of formula (X) . In a<br>
first stage, the cyclo-condensation of an N-acylated<br>
amide derivative of glycine (IX) on an aldehyde, ketone<br>
or ester of formula (II) , in the presence of a base<br>
such as sodium acetate in acetic anhydride and at a<br>
temperature between room temperature and the reflux<br>
temperature, gives an oxazolone of formula (X). This<br><br>
reaction with indole derivatives has been described: J.<br>
Am. Chem. Soc. 1946, 647. In a second stage, the<br>
reaction of the oxazolone (X) with an excess of amine<br>
of formula R1NH2, or of ammonia, gives an imidazolone<br>
(Id). This reaction is carried out in a solvent such as<br>
methanol or ethanol, at a temperature between room<br>
temperature and the reflux temperature. Alternatively,<br>
this reaction can be carried out in a sealed tube under<br>
microwave irradiation, at a temperature between 80C<br>
and 200C.<br>
Table 5 The products of formula (I) in Table 5 can be<br>
prepared according to Scheme 3 or 5 above and are<br>
described as examples in the experimental section<br>
hereunder.<br><br><br><br>
Scheme 6: The case when X-Y equals N=C-OR<br><br><br>
The compounds of type (Ie) can be prepared by analogy<br>
with the derivatives of imidazopyridines described for<br>
example in J. Org. Chem 2001, 66(20), 6576-6584.<br>
Scheme 7: The case when X-Y equals N=C-OR<br><br>
Alternatively, the molecules of type (Ie) can be<br>
prepared by first forming the imidazolone according to<br>
a method similar to that described for example in Bull.<br>
Korean Chem. Soc. 2007, 28(6), 913-914. In a first<br>
stage, the dehydration of a urea (XIV), with for<br>
example bromine and triphenylphosphine, gives a<br>
carbodiimide of formula (XV). In a second stage,<br><br>
addition of an alcohol and cyclization gives the<br>
imidazolone of formula (XVI). Finally, condensation on<br>
an aldehyde or ketone of formula (II) gives a compound<br>
(Ie).<br>
The examples in Table 7 can be prepared according to<br>
Scheme 6 or 7.<br><br>
Table 8: the compounds in Table 8 can be prepared<br>
according to the methods described above in Schemes 1<br>
to 7:<br><br><br><br><br><br><br><br><br><br><br><br>
Said products obtained by the above schemes can be<br>
products of formula (I) or alternatively, to obtain<br>
products of formula (I) or for transformation to other<br>
products of formula (I) , can be submitted, if desired<br>
and if necessary, in any order, to one or more<br>
transformation reactions known by a person skilled in<br>
the art, for example the following reactions:<br>
a) a reaction of esterification or of amidation of an<br>
acid function,<br><br>
b)	if applicable, a reaction of oxidation of an<br>
alkylthio group to the corresponding sulphoxide or<br>
sulphone,<br>
c)	a reaction of reduction of the free or esterified<br>
carboxy function to an alcohol function,<br>
d)	a reaction of transformation of an alkoxy function<br>
to a hydroxyl function, or alternatively of a hydroxyl<br>
function to an alkoxy function,<br>
e)	a reaction of elimination of the protecting groups<br>
that protected reactive functions may be carrying,<br>
f)	a reaction of salification with an inorganic or<br>
organic acid or with a base to obtain the corresponding<br>
salt,<br>
g)	a reaction for resolving racemic forms to resolved<br>
products,<br>
said products of formula (I) thus obtained being in all<br>
possible isomeric forms: racemates, enantiomers and<br>
diastereoisomers.<br>
It should be noted that said reactions of<br>
transformation of substituents into others substituents<br>
can also be carried out on the starting products as<br>
well as on the intermediates as defined above before<br>
continuing the synthesis according to the reactions<br>
stated in the method described above.<br>
The methods described in the above schemes can be<br>
carried out according to the usual conditions known by<br>
a person skilled in the art and notably according to<br>
the reaction conditions described hereunder for<br>
preparation of the examples of the present application.<br><br>
Among the starting products used for preparation of the<br>
products of formula (I) according to the present<br>
invention, some are available commercially or can be<br>
prepared according to the usual methods known by a<br>
person skilled in the art.<br>
It is also possible, notably, to prepare some starting<br>
products from products that are known or are available<br>
commercially, for example by submitting them to one or<br>
more reactions known by a person skilled in the art.<br>
The experimental section hereunder gives examples of<br>
said starting products.<br>
For preparation of the products of formula (I)<br>
according to the present invention, the various<br>
reactive functions that can be carried by some<br>
compounds of the reactions defined above can, if<br>
necessary, be protected: this relates for example to<br>
free hydroxyl, acyl, carboxy radicals or alternatively<br>
amino and monoalkylamino radicals which can be<br>
protected with appropriate protecting groups.<br>
We may mention the following list, which is not<br>
exhaustive, of examples of protection of reactive<br>
functions:<br>
- hydroxyl groups can be protected for example with<br>
alkyl radicals such as tert-butyl, trimethylsilyl,<br>
tert-butyldimethylsilyl,	methoxy-methyl,<br>
tetrahydropyranyl, benzyl or acetyl,<br>
- amino groups can be protected for example with<br>
acetyl, trityl, benzyl, tert-butoxycarbonyl, BOC,<br>
benzyloxycarbonyl, phthalimido or other radicals known<br>
in peptide chemistry,<br><br>
-	acyl groups such as the formyl group can be protected<br>
for example in the form of cyclic or acyclic ketals or<br>
thioketals such as dimethyl or diethylketal or ethylene<br>
dioxyketal, or diethylthioketal or ethylenedithioketal,<br>
-	the acid functions of the products described above<br>
can, if desired, be amidated with a primary or<br>
secondary amine for example in methylene chloride in<br>
the presence, for example, of 1-ethyl-3-<br>
(dimethylaminopropyl) carbodiimide hydrochloride at<br>
room temperature,<br>
-	the acid functions can be protected for example in<br>
the form of esters formed with easily cleavable esters<br>
such as benzyl or tert-butyl esters or the esters known<br>
in peptide chemistry.<br>
Notably, NH or 1H-pyrrolo[2,3-b]pyridine can be<br>
protected if necessary with paratoluenesulphonyl,<br>
phenylsulphonyl, acetyl, triisopropylsilyl, tert-<br>
butyldimethylsilyl or trimethylsilylethoxymethyl.<br>
Reactions a) to g) can be carried out, for example, as<br>
stated hereunder.<br>
a) The products described above can if desired undergo,<br>
on any carboxy functions present, reactions of<br>
esterification or amidation, which can be carried out<br>
according to the usual methods known by a person<br>
skilled in the art. The reactions of amidation can<br>
notably be carried out in the presence of a coupling<br>
agent such as a carbodiimide derivative. We may mention<br>
as examples N-(3-dimethylaminopropyl), N1-<br>
ethylcarbodiimide (EDCI), N,N' -diisopropyl-carbodiimide<br>
(DIC) or N,N'-dicyclohexyl-carbodiimide.<br><br>
b)	Any alkylthio groups in the products described above<br>
can, if desired, be transformed into the corresponding<br>
sulphoxide or sulphone functions in the usual<br>
conditions known by a person skilled in the art, for<br>
example with peracids such as peracetic acid or<br>
metachloroperbenzoic acid or alternatively with ozone,<br>
oxone, sodium periodate in a solvent such as methylene<br>
chloride or dioxan at room temperature.<br>
Production of the sulphoxide function can be promoted<br>
with an equimolar mixture of the product containing an<br>
alkylthio group and of the reagent such as notably a<br>
peracid.<br>
Production of the sulphone function can be promoted<br>
with a mixture of the product containing an alkylthio<br>
group with an excess of the reagent such as notably a<br>
peracid.<br>
c)	Any free or esterified carboxy functions in the<br>
products described above can, if desired, be reduced to<br>
an alcohol function by the methods known to a person<br>
skilled in the art: any esterified carboxy functions<br>
can, if desired, be reduced to an alcohol function by<br>
the methods known by a person skilled in the art and<br>
notably with lithium and aluminium hydride in a solvent<br>
such as tetrahydrofuran or alternatively dioxan or<br>
ethyl ether.<br>
Any free carboxy functions in the products described<br>
above can, if desired, be reduced to an alcohol<br>
function notably with boron hydride.<br>
d)	Any alkoxy functions such as notably methoxy in the<br>
products described above can, if desired, be<br>
transformed to hydroxyl functions in the usual<br><br>
conditions known by a person skilled in the art, for<br>
example with boron tribromide in a solvent such as<br>
methylene chloride, with pyridine hydrobromide or<br>
hydrochloride or alternatively with hydrobromic or<br>
hydrochloric acid in water or trifluoroacetic acid<br>
under reflux.<br>
It is to be understood that the reactions described<br>
above can be carried out as stated or alternatively, if<br>
applicable, according to other usual methods known by a<br>
person skilled in the art.<br>
e)	The elimination of protecting groups, for example<br>
those stated above, can be carried out in the usual<br>
conditions known to a person skilled in the art,<br>
notably by acid hydrolysis carried out with an acid<br>
such as hydrochloric, benzenesulphonic or para-<br>
toluenesulphonic, formic or trifluoroacetic acid or<br>
alternatively by catalytic hydrogenation.<br>
The phthalimido group can be eliminated with hydrazine.<br>
A list of various protecting groups that can be used is<br>
given for example in patent BF 2 499 995.<br>
f)	The products described above can, if desired,<br>
undergo reactions of salification for example by an<br>
inorganic or organic acid or by an inorganic or organic<br>
base according to the usual methods known by a person<br>
skilled in the art: said reaction of salification can<br>
be performed for example in the presence of<br>
hydrochloric acid or alternatively tartaric, citric or<br>
methanesulphonic acid, in an alcohol such as ethanol or<br>
methanol.<br>
g)	Any optically active forms of the products described<br>
above can be prepared by resolution of racemates<br><br>
according to the usual methods known by a person<br>
skilled in the art.<br>
The products of formula (I) as defined above as well as<br>
their salts of addition with acids display interesting<br>
pharmacological properties notably on account of their<br>
kinase inhibiting properties as mentioned above.<br>
It should be noted that as certain protein kinases play<br>
a key role in the initiation, development and<br>
completion of the events of the cell cycle, molecules<br>
that inhibit said kinases are likely to limit<br>
undesirable cellular proliferation such as that<br>
observed in cancers, and can be used in the prevention,<br>
control or treatment of neurodegenerative diseases such<br>
as Alzheimer's disease or neuronal apoptosis.<br>
The products of the present invention can notably be<br>
used for the treatment of tumours.<br>
The products of the invention can thus also enhance the<br>
therapeutic effects of antitumour agents currently<br>
used.<br>
The products of formula (I) of the present invention<br>
therefore possess quite particularly antiproliferative<br>
properties.<br>
These properties justify their application in therapeu-<br>
tics and the invention relates in particular to the<br>
products of formula (I) as defined above as medicinal<br>
products, said products of formula (I) being in all<br>
possible isomeric forms: racemates, enantiomers and<br>
diastereoisomers, as well as salts of addition of said<br>
products of formula (I) with pharmaceutically<br>
acceptable inorganic and organic acids or inorganic and<br>
organic bases.<br><br>
The invention relates in particular to, as medicinal<br>
products, the products described hereunder in the<br>
examples and notably the products having the following<br>
names:<br>
- (5Z)-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-2-<br>
thioxoimidazolidin-4-one<br>
- (5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-(1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylene)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
- (5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-[(cyclopropylmethyl)amino]-3,5-dihydro-<br>
4H-imidazol-4-one<br>
- (5Z)-5-[(6-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-[(cyclopropylmethyl)amino]-3,5-dihydro-<br>
4H-imidazol-4-one<br>
- (5Z)-2-[(cyclopropylmethyl)amino]-3-methyl-5-(1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylene)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
- (5Z)-2-butyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylene)-3,5-dihydro-4H-imidazol-4-one<br>
- (5Z)-2-azepan-1-yl-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one<br>
- (5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-piperidin-1-yl-3,5-dihydro-4H-<br>
imidazol-4-one<br><br>
- (5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[methyl(2-methylpropyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one<br>
- (5Z)-5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(eyelopropylmethyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one<br>
- (5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-methoxy-<br>
1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-<br>
4H-imidazol-4-one<br>
- (5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-fluoro-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
- (5Z)-2-azepan-1-yl-5-[(5-fluoro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one<br>
- 3-[(Z)-{2-[(cyclopropylmethyl)amino]-5-oxo-1,5-<br>
dihydro-4H-imidazol-4-ylidene}methyl]-1H-pyrrolo[2,3-<br>
b]pyridine-5-carbonitrile<br>
- (5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-phenyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
- (5Z)-2-[(cyclopropylmethyl)amino]-5-{[5-<br>
(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl]methylidene}-3,5-dihydro-4H-imidazol-4-one<br>
- (5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-(methylsulphanyl)-3,5-dihydro-4H-<br>
imidazol-4-one<br><br>
- (5Z)-2-butyl-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one<br>
- (5Z)-2-(3-methylbutyl)-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one<br>
- (5Z)-2-cyclohexyl-5-(1H-pyrrolo [2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one<br>
- (5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-<br>
3,5-dihydro-4H-imidazol-4-one<br>
- (5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-(2-methylpropyl)-3,5-<br>
dihydro-4H-imidazol-4-one<br>
- (5Z)-2-(cyclopropylmethyl)-5-(5-chloro-1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
- (5Z)-2-(1-methylethyl)-5-(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one<br>
- (5Z)-2-[benzyl(methyl)amino]-5-[(5-chloro-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
- (5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(2-methoxyethyl)(methyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one<br>
- (5Z)-2-azepan-1-yl-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one<br><br>
- (5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-piperidin-1-yl-3,5-dihydro-4H-<br>
imidazol-4-one<br>
- (5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[methyl(2-methylpropyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one<br>
- (5Z)-5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(cyclopropylmethyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one<br>
- (5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-methoxy-<br>
1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-<br>
4H-imidazol-4-one<br>
- (5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-fluoro-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
- (5Z)-2-azepan-1-yl-5-[(5-fluoro-1H-pyrrolo [2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one<br>
- 3-[(Z)-{2-[(cyclopropylmethyl)amino]-5-oxo-l,5-<br>
dihydro-4H-imidazol-4-ylidene}methyl]-1H-pyrrolo [2,3-<br>
b]pyridine-5-carbonitrile<br>
- (5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-phenyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
- (5Z)-2-[(cyclopropylmethyl)amino]-5-{[5-<br>
(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl]methylidene}-3,5-dihydro-4H-imidazol-4-one<br><br>
- (5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-(methylsulphanyl)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
- (5Z)-2-butyl-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one<br>
- (5Z)-2-(3-methylbutyl)-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one<br>
- (5Z)-2-cyclohexyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethy1idene)-3,5-dihydro-4H-imidazol-4-one<br>
- (5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-<br>
3,5-dihydro-4H-imidazol-4-one<br>
- (5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-(2-methylpropyl)-3,5-<br>
dihydro-4H-imidazol-4-one<br>
- (5Z)-2-(cyclopropylmethyl)-5-(5-chloro-1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
- (5Z)-2-(1-methylethyl)-5-(5-chloro-1H-pyrrolo [2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one<br>
- (5Z)-2-[benzyl(methyl)amino]-5-[(5-chloro-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
- (5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(2-methoxyethyl)(methyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one<br><br>
said products of formula (I) being in all possible<br>
isomeric forms: racemates, enantiomers and<br>
diastereoisomers, as well as salts of addition of said<br>
products of formula (I) with pharmaceutically<br>
acceptable inorganic and organic acids or inorganic and<br>
organic bases.<br>
The invention also relates to pharmaceutical<br>
compositions containing, as active principle, at least<br>
one of the products of formula (I) as defined above or<br>
a pharmaceutically acceptable salt of this product or a<br>
prodrug of this product and, if applicable, a<br>
pharmaceutically acceptable carrier.<br>
The invention thus extends to pharmaceutical<br>
compositions containing, as active principle, at least<br>
one of the medicinal products as defined above.<br>
Said pharmaceutical compositions of the present<br>
invention can also, if applicable, contain active<br>
principles of other antimitotic medicinal products such<br>
as notably those based on taxol, cisplatin, DNA<br>
intercalating agents and others.<br>
These pharmaceutical compositions can be administered<br>
orally, parenterally or locally by topical application<br>
on the skin and the mucosae or by intravenous or<br>
intramuscular injection.<br>
These compositions can be solid or liquid and can be in<br>
all the pharmaceutical forms commonly used in human<br>
medicine, for example plain or coated tablets, pills,<br>
lozenges, capsules, drops, granules, injectable<br>
preparations, ointments, creams or gels; they are<br>
prepared according to the usual methods. The active<br>
principle can be incorporated in them with the<br><br>
excipients usually employed in said pharmaceutical<br>
compositions, such as talc, gum arabic, lactose,<br>
starch, magnesium stearate, cocoa butter, aqueous or<br>
non-aqueous vehicles, fats of animal or vegetable<br>
origin, paraffinic derivatives, glycols, various<br>
wetting agents, dispersants or emulsifiers,<br>
preservatives.<br>
The usual posology, which varies according to the<br>
product used, the subject treated and the disorder in<br>
question, can be for example from 0.05 to 5 g per day<br>
in an adult, or preferably from 0.1 to 2 g per day.<br>
The present invention also relates to the use of the<br>
products of formula (I) as defined above or of<br>
pharmaceutically acceptable salts of these products for<br>
the preparation of a medicinal product intended to<br>
inhibit the activity of a protein kinase.<br>
The present invention also relates to the use of<br>
products of formula (I) as defined above for the<br>
preparation of a medicinal product intended for the<br>
treatment or prevention of a disease characterized by<br>
disturbance of the activity of a protein kinase.<br>
Said medicinal product can notably be intended for the<br>
treatment or prevention of a disease in a mammal.<br>
The present invention also relates to the use as<br>
defined above in which the protein kinase is a serine-<br>
threonine protein kinase.<br>
The present invention notably relates to the use<br>
defined above in which the protein kinase is Cdc7.<br>
The present invention also relates to the use defined<br>
above in which the protein kinase is in a cell culture.<br><br>
The present invention also relates to the use defined<br>
above in which the protein kinase is in a mammal.<br>
The present invention relates in particular to the use<br>
of a product of formula (I) as defined above for the<br>
preparation of a medicinal product intended for the<br>
treatment or prevention of a disease selected from the<br>
following group: disorders of proliferation of blood<br>
vessels, fibrotic disorders, disorders of proliferation<br>
of mesangial cells, metabolic disorders, allergies,<br>
asthmas, thromboses, diseases of the nervous system,<br>
retinopathy, psoriasis, rheumatoid arthritis, diabetes,<br>
muscular degeneration and cancers.<br>
The present invention relates more particularly to the<br>
use of a product of formula (I) as defined above for<br>
the preparation of a medicinal product intended for the<br>
treatment or prevention of a disease selected from the<br>
following group: disorders of proliferation of<br>
mesangial cells, psoriasis, rheumatoid arthritis,<br>
diabetes, muscular degeneration and cancers.<br>
The present invention relates quite particularly to the<br>
use of a product of formula (I) as defined above for<br>
the preparation of a medicinal product intended for the<br>
prevention or treatment of diseases associated with<br>
uncontrolled cellular proliferation, for the<br>
preparation of a medicinal product intended for the<br>
treatment of diseases in oncology and notably intended<br>
for the treatment of cancers.<br>
Among these cancers, we are notably interested in the<br>
treatment of solid tumours, and the treatment of<br>
cancers that are resistant to cytotoxic agents.<br><br>
Among these cancers, we are notably interested in the<br>
treatment of cancers of the breast, stomach, ovaries,<br>
colon, lung, brain, larynx, lymphatic system,<br>
urogenital tract including bladder and prostate,<br>
cancers of the bones and of the pancreas, and quite<br>
particularly treatment of cancers of the breast, of the<br>
colon or of the lung.<br>
The present invention also relates to the use of	the<br>
products of formula (I) as defined above for the<br>
preparation of medicinal products intended for the<br>
chemotherapy of cancers.<br>
Said medicinal products intended for the chemotherapy<br>
of cancers can be used alone or in combination.<br>
The products of the present application can notably be<br>
administered alone or in combination with chemotherapy<br>
or radiotherapy or alternatively in combination for<br>
example with other therapeutic agents.<br>
Said therapeutic agents can be antitumour agents that<br>
are currently used.<br>
As kinase inhibitors, we may mention butyrolactone,<br>
flavopiridol and 2(2-hydroxyethyl-amino)-6-benzylamino-<br>
9-methylpurine, called olomucin.<br>
The present invention relates in particular to the<br>
products of formula (I) as defined above as inhibitors<br>
of Cdc7.<br>
The present invention relates quite particularly to the<br>
products of formula (I) which constitute Examples 1 to<br>
99 of the present invention.<br><br>
The 99 products that follow thus illustrate formula (I)<br>
of the present invention more precisely, though without<br>
limiting it.<br>
In the preparation of the 99 products given as examples<br>
in the present application, the following devices were<br>
used:<br>
1H-NMR spectrum at 400 MHz on BRUKER AVANCE DRX-400<br>
spectrometer with chemical shifts ( in ppm), in the<br>
solvent dimethylsulphoxide-d6 (DMSO-d6) referenced at<br>
2.50 ppm at a temperature of 303K.<br>
1H-NMR spectrum at 3 00 MHz on BRUKER AVANCE DPX-3 00<br>
spectrometer with chemical shifts (8 in ppm), in the<br>
solvent dimethylsulphoxide-d6 (DMSO-d6) referenced at<br>
2.50 ppm at a temperature of 303K.<br>
LC-MS-DAD-ELSD analysis (MS: Waters ZQ; electrospray<br>
mode +/-; mass-to-charge ratio m/z = 100-1200; LC:<br>
Agilent HP 1100; LC column: X Bridge, 18C Waters 3.0 x<br>
50 mm - 2.5 m; LC furnace: 60C; flow rate of mobile<br>
phase: 1.1 ml/minute.<br>
Eluents: A: Water + 0.1% formic acid, B: acetonitrile<br>
with the following gradient:<br><br><br>
DAD: wavelength considered  = 210-400 nm<br>
ELSD: Sedere SEDEX 85<br>
SM-EI-CI-Direct injection-DCI analysis (EI = electron-<br>
impact ionization, CI: chemical ionization, DCI:<br>
desorption chemical ionization) (MS: Finnigan SSQ7000);<br>
energy of the electrons: 70 eV; mass-to-charge ratio<br>
m/z = 29-900; temperature of ionization source = 70C;<br>
reactant gas in CI: ammonia.<br>
(1): Routine LC/MS analysis:<br>
Mass detector: ZQ (Waters)<br>
LC: column: X Bridge 18C Waters 3.0 x 50 mm - 2.5 urn;<br>
flow = 1.1 ml/minute.<br>
Eluents: A: Water + 0.1% formic acid, B: Acetonitrile<br>
with the following gradient:<br><br><br><br>
(2): Microwaves: BIOTAGE INITIATOR MICROWAVE<br>
SYNTHESIZER<br>
Maximum irradiation power 300 watts<br>
It should be noted that in the examples described<br>
below, the compounds 1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehydes (II) can be obtained from 1H-pyrrolo[2,3-<br>
b]pyridine derivatives by reaction with 1,3,5,7-<br>
tetraazatricyclo[3.3.1.1~3,7~]decane (A. Verbiscar J.<br>
Med. Chem. 1972, 15, 149) or by the Vilsmeier reaction<br>
(M-C Viaud et al. Heterocycles. 1999, 50, 1065).<br>
Example 1<br>
(5Z)-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-2-<br>
thioxoimidazolidin-4-one<br>
(5Z)-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-2-<br>
thioxoimidazolidin-4-one can be prepared as follows:<br>
Add 0.1 cm3 of piperidine and 400 mg of 2-<br>
thioxoimidazolidin-4-one to a suspension of 500 mg of<br>
1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde in 10 cm3 of<br>
ethanol. Reflux the reaction mixture - the solid goes<br>
into solution. After heating for thirty minutes, a<br>
precipitate forms. Turn off the heating and filter the<br>
reaction mixture at a temperature close to 25C. 561 mg<br>
of (5Z)-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-2-<br>
thioxoimidazolidin-4-one is obtained in the form of<br>
orange powder with the following characteristics:<br>
1H-NMR spectrum at 400 MHz: 6.80 (s: 1H); 7.20 (dd, J =<br><br>
5 and 8 Hz: 1H) ; from 8.26 to 8.34 (m: 2H) ; 8.55 (s:<br>
1H); from 11.7 to 12.2 (m spread out: 2H); from 12.3 to<br>
12.6 (m spread out: 1H)<br>
Mass spectrum: LC-MS-DAD-ELSD: 243 (-) = (M-H)(-);<br>
245 ( + ) = (M+H) ( + )<br>
Example 2<br>
(5Z)-5-[(4-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one<br>
a)	(5Z)-5-[(4-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one can be<br>
prepared as in Example 1 but from 182 mg of 4-chloro-<br>
1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde in 3 cm3 of<br>
ethanol, 117 mg of 2-thioxoimidazolidin-4-one and<br>
0.1 cm3 of piperidine. After refluxing for two hours,<br>
250 mg of a mixture containing 60% of (5Z)-5-[(4-<br>
chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-<br>
thioxoimidazolidin-4-one is obtained in the form of<br>
orange powder. The characteristics of the isomer (5Z)<br>
are as follows:<br>
1H-NMR spectrum at 400 MHz: 7.26 (s: 1H); 7.30 (m: 1H);<br>
8.24 (d, J = 5 Hz: 1H) ; 8.58 (s: 1 H) ; from 11.5 to<br>
13.0 (m very broad: 3H)<br>
Mass spectrum: LC-MS-DAD-ELSD: 243(-)= (M-H)(-);<br>
245 ( + ) = (M+H) ( + )<br>
b) 4-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde<br>
4-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde can<br>
be prepared as follows:<br>
Add	1.4 g	of	1,3,5,7-<br>
tetraazatricyclo[3.3.1.1~3,7~]decane to a suspension of<br>
1 g of 4-chloro-1H-pyrrolo[2,3-b]pyridine in a mixture<br>
of 7 cm3 of water and 3.5 cm3 of acid acetic. Reflux the<br>
reaction mixture for one hour and thirty minutes. On<br>
returning to a temperature close to 25C, add water and<br>
ice. There is formation of a precipitate in the form of<br><br>
gum. Take up the latter in two times 2 0 cm3 of ethyl<br>
acetate. Combine the organic phases, wash with water,<br>
dry over magnesium sulphate, filter and concentrate to<br>
dryness at reduced pressure. Take up the residue in<br>
5 cm3 of ethyl acetate. The precipitate obtained is<br>
filtered and dried at reduced pressure. 82 mg of 4-<br>
chloro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde is<br>
obtained. The filtrate is concentrated to dryness at<br>
reduced pressure and after flash chromatography on a<br>
silica column [eluent: dichloromethane/methanol<br>
(gradient from 99/1 to 90/10 by volume)], 160 mg of 4-<br>
chloro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde is<br>
obtained with the following characteristics:<br>
LC/MS (1): Retention time: 2.69 min<br>
Mass spectrum (1): (ES+): m/z = 181 [MH+]<br>
c) 4-chloro-1H-pyrrolo[2,3-b]pyridine can be prepared<br>
as described in C. Thibault et al. : Org. Lett. 2003,<br>
5(26) ; 5023.<br>
Example 3<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one<br>
a)	(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one can be<br>
prepared as in Example 1 but from 400 mg of 5-chloro-<br>
1H-pyrrolo [2,3-b]pyridine-3-carbaldehyde in 15 cm3 of<br>
ethanol, 257 mg of 2-thioxoimidazolidin-4-one and<br>
0.22 cm3 of piperidine. After refluxing for two hours,<br>
320 mg of (5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one is obtained in<br>
the form of orange powder with the following<br>
characteristics:<br>
1H-NMR spectrum at 400 MHz: 6.79 (s: 1H); 8.29 (d, J =<br>
3 Hz: 1H) ; 8.54 (d, J = 3 Hz: 1H) ; 8.57 (s: 1H) ; from<br>
7.00 to 8.30 (m very broad: 2H) ; from 11.4 to 12.5 (m<br><br>
spread out: 1H)<br>
Mass spectrum: LC-MS-DAD-ELSD: 279( + ) = (M+H)(+) (1<br>
chlorine atom Cl present)<br>
b) 5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde<br>
can be prepared as described in WO05/95400.<br>
Example 4<br>
(5Z)-5-[(6-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one<br>
a)	(5Z)-5-[(6-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one can be<br>
prepared as in Example 1 but from 140 mg of 6-chloro-<br>
1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde in 5 cm3 of<br>
ethanol, 90 mg of 2-thioxoimidazolidin-4-one and<br>
0.08 cm3 of piperidine. After refluxing for two hours,<br>
180 mg of (5Z)-5-[(6-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one is obtained in<br>
the form of a powder with the following<br>
characteristics:<br>
1H-NMR spectrum at 400 MHz: 6.57 (s: 1H) ; 7.20 (d, J =<br>
8 Hz: 1H) ; 8.40 (s: 1H) ; 8.49 (d, J = 8 Hz: 1H) ; from<br>
9.40 to 10.5 (m spread out: 3H)<br>
Mass spectrum: LC-MS-DAD-ELSD: 279(+)= (M+H)(+) (1<br>
chlorine atom Cl present)<br>
b) 6-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde<br>
can be prepared as described in WO01/98299.<br>
Example 5<br>
(5Z)-5-[(2-methyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one<br>
a) (5Z)-5-[(2-methyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one can be<br>
prepared as in Example 1 but from 400 mg of 2-methyl-<br>
lH-pyrrolo[2,3-b]pyridine-3-carbaldehyde in 15 cm3 of<br>
ethanol, 290 mg of 2-thioxoimidazolidin-4-one and<br><br>
0.25 cm3 of piperidine. After four hours of reflux,<br>
463 mg of a mixture containing 65% of (5Z)-5-[(2-<br>
methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-<br>
thioxoimidazolidin-4-one is obtained in the form of<br>
orange powder which will be used as such for the next<br>
stage, and has the following characteristics:<br>
1H-NMR spectrum at 400 MHz: 2.45 (s: 3H) ; 6.70 (s<br>
broad: 1H) ; 7.12 (dd, J = 5 and 8 Hz: 1H) ; 7.88 (m:<br>
1H) ; 8.20 (dd, J = 1.5 and 5 Hz: 1H) ; 11.55 (s broad:<br>
1H); from 12.0 to 12.2 (m spread out: 2H)<br>
Mass spectrum: LC-MS-DAD-ELSD: mixture containing the<br>
expected structure 259 (+) = (M+H) (+)<br>
b) 2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde<br>
2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde can<br>
be prepared as in Example 2 but from 83 5 mg of 2-<br>
methyl-1H-pyrrolo[2,3-b]pyridine in a mixture of<br>
5.3 cm3 of water and 1.6 cm3 of acid acetic and 1.32 g<br>
of 1,3,5,7-tetraazatricyclo[3.3.1.1~3,7~]decane. 580 mg<br>
of a mixture containing 6 0% of 2-methyl-1H-pyrrolo[2,3-<br>
b]	pyridine-3-carbaldehyde is obtained in the form of a<br>
beige solid. The characteristics for 2-methyl-1H-<br>
pyrrolo[2,3-b]pyridine-3-carbaldehyde are as follows:<br>
LC/MS (1): Retention time: 1.7 min<br>
Mass spectrum (1): (ES+): m/z = 161 [MH+]<br>
c)	2-methyl-1H-pyrrolo[2,3-b]pyridine<br>
2-methyl-1H-pyrrolo[2,3-b]pyridine can be prepared as<br>
follows:<br>
Add 8.2 g of potassium hydroxide to a solution of 2.2 g<br>
of	2-methyl-1-[ (4-methylphenyl)sulphonyl]-1H-<br>
pyrrolo [2,3-b]pyridine in 70 cm3 of methanol. Stir the<br>
reaction mixture at a temperature close to 20C for<br>
five hours then reflux for five hours. Then concentrate<br>
the medium (or mixture) to half at reduced pressure: a<br>
precipitate forms. The solid is filtered and the<br><br>
filtrate is concentrated to dryness at reduced<br>
pressure, taken up in 100 cm3 of water, then once<br>
100 cm3 and twice 50 cm3 of ethyl acetate. The combined<br>
organic phases are dried over magnesium sulphate,<br>
filtered and concentrated to dryness at reduced<br>
pressure. After flash chromatography on a silica column<br>
[eluent: heptane/ethyl acetate (gradient from 80/20 to<br>
40/60 by volume)], 835 mg of 2-methyl-1H-pyrrolo[2,3-<br>
b]pyridine is obtained in the form of a beige solid<br>
with the following characteristics:<br>
Rf TLC silica = 0.4 9 [eluent: heptane/ethyl acetate<br>
(60/40 by volume)]<br>
Mass spectrum: LC-MS-DAD-ELSD: 133(+) = (M+H)(+)<br>
SM-EI: 132(+) = M(+)<br>
d)	2-methyl-1-[(4-methylphenyl)sulphonyl]-1H-<br>
pyrrolo[2,3-b]pyridine.<br>
2-methyl-1-[(4-methylphenyl)sulphonyl]-1H-pyrrolo [2,3-<br>
b]pyridine can be prepared as follows:<br>
Cool a solution of 2 g of 1-[(4-<br>
methylphenyl)sulphonyl]-1H-pyrrolo[2,3-b]pyridine in<br>
20 cm3 of tetrahydrofuran to a temperature close to<br>
-70C using a dry ice/acetone bath. At this temperature<br>
and under argon, add dropwise 9.2 cm3 of a 1.6M<br>
solution of n-butyllithium in hexane. Stir the reaction<br>
medium (or mixture) at this temperature for thirty<br>
minutes then add 1.3 7 cm3 of methyl iodide. Stir the<br>
mixture under argon at a temperature close to -70C for<br>
three hours. After heating the mixture to a temperature<br>
close to 0C, add 20 cm3 of water, then allow the<br>
temperature to approach 20 C and extract with three<br>
times 50 cm3 of ethyl acetate. Wash the combined<br>
organic phases with a saturated aqueous solution of<br>
sodium chloride, dry over magnesium sulphate, filter<br>
and concentrate to dryness at reduced pressure. 2.2 g<br><br>
of	2-methyl-1-[(4-methylphenyl)sulphonyl]-1H-<br>
pyrrolo[2,3-b]pyridine is obtained in the form of a<br>
beige powder with the following characteristics:<br>
XH-NMR spectrum at 400 MHz: 2.30 (s: 3H); 2.32 (s: 3H);<br>
2.69 (s broad: 3H) ; 6.59 (s broad: 1H) ; 7.15 (s broad:<br>
1H); 7.17 (dd, J = 5 and 8 Hz: 1H); 7.26 (d broad, J =<br>
8 Hz: 1H) ; 7.90 (dd, J = 2 and 8 Hz: 1H) ; 7.97 (d, J =<br>
8 Hz: 1H); 8.08 (dd, J = 2 and 5 Hz: 1H)<br>
Mass spectrum: LC-MS-DAD-ELSD: 301(+) = (M+H)(+); 299(-<br>
) = (M-H) (-)<br>
e) 1-[(4-methylphenyl)sulphonyl]-1H-pyrrolo [2,3-<br>
b]pyridine<br>
1-[(4-methylphenyl)sulphonyl]-1H-pyrrolo[2,3-b]pyridine<br>
can be prepared as follows:<br>
Introduce, i.e. add, 100 mg of N,N,N-tributylbutane-1-<br>
ammonium hydrogen sulphate and 8.75 g of 4-<br>
methylbenzenesulphonyl chloride to a solution of 4.72 g<br>
of lH-pyrrolo[2,3-b]pyridine in 110 cm3 of toluene. To<br>
the mixture cooled to 0C, add a solution of 20.8 g of<br>
sodium hydroxide in 110 cm3 of water. Stir the reaction<br>
mixture under argon at a temperature close to 20C for<br>
four hours then add 100 cm3 of water. Extract the<br>
resultant mixture with 200 cm3 then 100 cm3 of ethyl<br>
acetate. Wash the combined organic phases with a<br>
saturated aqueous solution of sodium chloride, dry over<br>
magnesium sulphate, filter and concentrate to dryness<br>
at reduced pressure. 10.9 g of 1-[(4-<br>
methylphenyl)sulphonyl]-1H-pyrrolo[2,3-b]pyridine is<br>
obtained in the form of a white powder with the<br>
following characteristics:<br>
Rf TLC silica = 0.34 [eluent: heptane/ethyl acetate<br>
(70/30 by volume)]<br>
Mass spectrum: LC-MS-DAD-ELSD: 273 (+) = (M+H) (+) 295(+)<br>
= (M+Na)(+)<br><br>
Example 6<br>
(5Z)-3-methyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylene)-2-thioxoimidazolidin-4-one<br>
(5Z)-3-methyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylene)-2-thioxoimidazolidin-4-one can be prepared<br>
as in Example 1 but from 225 mg of 1H-pyrrolo[2,3 -<br>
b]pyridine-3-carbaldehyde in 10 cm3 of ethanol, 200 mg<br>
of 3-methyl-2-thioxoimidazolidin-4-one and 0.061 cm3 of<br>
piperidine. After refluxing for five hours, 271 mg of a<br>
mixture containing 85% of the isomer (5Z)-3-methyl-5-<br>
(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-2-<br>
thioxoimidazolidin-4-one and 15% of the isomer (5E) is<br>
obtained in the form of an orange-yellow powder. The<br>
characteristics of the isomer 5Z are as follows:<br>
1H-NMR spectrum at 400 MHz: 3.21 (s: 3H); 6.96 (s: 1H);<br>
7.20 (dd, J = 5 and 8 Hz: 1H) ; from 8.27 to 8.37 (m:<br>
2H); 8.59 (d, J = 3 Hz: 1H); 12.05 (s broad: 1H); 12.5<br>
(s broad: 1H)<br>
Mass spectrum: LC-MS-DAD-ELSD: 257(-) = (M-H)(-);<br>
259(+) = (M+H)(+)<br>
Example 7<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylene)-3,5-dihydro-4H-imidazol-4-one<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylene)-3,5-dihydro-4H-imidazol-4-one<br>
can be prepared as follows:<br>
Put 100 mg of (5Z)-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylene)-2-thioxoimidazolidin-4-one, 1 cm3 of<br>
ethanol and 290 mg of 1-cyclopropylmethanamine in a<br>
microwave oven reactor. Close the reactor hermetically<br>
and irradiate the mixture with microwave radiation for<br>
twenty minutes at a temperature of 140C, then thirty<br>
minutes at a temperature of 150C. On returning to a<br>
temperature close to 20C, the precipitate that has<br><br>
formed is filtered, washed with ethanol and dried at<br>
reduced pressure. 40 mg of (5Z)-2-<br>
[(cyclopropylmethyl)amino]-5-(1H-pyrrolo[2,3-b]pyridin-<br>
3-ylmethylene)-3,5-dihydro-4H-imidazol-4-one	is<br>
obtained in the form of a yellow powder with the<br>
following characteristics:<br>
1H-NMR spectrum at 400 MHz: 0.3 0 (m: 2H) ; 0.4 8 (m: 2H) ;<br>
1.13 (m: 1H) ; 3.23 (t broad, J = 6.5 Hz: 2H) ; 6.61 (s<br>
broad: 1H) ; 7.11 (d, J = 5 Hz: 1H) ; 7.24 (m: 1H) ; from<br>
8.15 to 8.30 (m: 2H) ; 8.55 (d broad, J = 7 Hz: 1H) ;<br>
from 9.70 to 10.7 (m spread out: 1H) ; 11.6 (m spread<br>
out: 1H)<br>
Mass spectrum: SM-EI: 281(+) = M(+)<br>
Example 8<br>
(5Z)-5-[(4-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-[(cyclopropylmethyl)amino]-3,5-dihydro-<br>
4H-imidazol-4-one<br>
(5Z)-5-[(4-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-[(cyclopropylmethyl)amino]-3,5-dihydro-<br>
4H-imidazol-4-one can be prepared as in Example 7 but<br>
from 190 mg of (5Z)-5-[(4-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one,<br>
4 cm3 of ethanol and 485 mg of 1-<br>
cyclopropylmethanamine. After one hour at a temperature<br>
of 145C under microwave irradiation and thirty minutes<br>
at a temperature of 150C, 100 mg of (5Z)-5-[(4-chloro-<br>
1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-<br>
[(cyclopropylmethyl)amino]-3,5-dihydro-4H-imidazol-4-<br>
one is obtained in the form of orange powder with the<br>
following characteristics:<br>
1H-NMR spectrum at 400 MHz: 0.28 (m: 2H) ; 0.48 (m: 2H) ;<br>
1.12 (m: 1H) ; 3.22 (m partially masked: 2H) ; 7.10 (s<br>
broad: 1H) ; 7.22 (d, J = 5 Hz : 1H) ; 7.37 (m: 1H) ; 8.18<br>
(d, J = 5 Hz: 1H) ; 8.58 (s broad: 1H) ; from 10.25 to<br><br>
10.8 (m spread out: 1H) ; from 12.0 to 12.6 (m spread<br>
out: 1H)<br>
Mass spectrum: LC-MS-DAD-ELSD: 314(-)= (M-H)(-);<br>
316(+)= (M+H)(+) (1 chlorine atom Cl present)<br>
Example 9<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-[(cyclopropylmethyl)amino]-3,5-dihydro-<br>
4H-imidazol-4-one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-[(cyclopropylmethyl)amino]-3,5-dihydro-<br>
4H-imidazol-4-one can be prepared as in Example 7 but<br>
from 200 mg of (5Z)-5-[(5-chloro-1H-pyrrolo [2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one,<br>
4 cm3 of ethanol and 511 mg of 1-<br>
cyclopropylmethanamine, after thirty minutes at a<br>
temperature of 14 5C under microwave irradiation. The<br>
medium (or mixture) is then concentrated, and purified<br>
by flash chromatography on a silica column [eluent:<br>
dichloromethane/methanol (gradient from 95/5 to 70/30<br>
by volume)]. 20 mg of (5Z)-5-[(5-chloro-1H-pyrrolo [2,3-<br>
b]pyridin-3-yl)methylene]-2-[(cyclopropylmethyl)amino]-<br>
3,5-dihydro-4H-imidazol-4-one is obtained in the form<br>
of a pale yellow powder with the following<br>
characteristics:<br>
1H-NMR spectrum at 400 MHz: 0.30 (m: 2H) ; 0.48 (m: 2H) ;<br>
1.16 (m: 1H) ; 3.24 (m partially masked: 2H) ; 6.58 (s:<br>
1H) ; 7.25 (m: 1H) ; 8.16 (s broad: 1H); 8.22 (s broad:<br>
1H) ; 9.15 (s broad: 1H) ; from 10.25 to 10.7 (m spread<br>
out: 1H); from 11.9 to 12.4 (m spread out: 1H)<br>
Mass spectrum: LC-MS-DAD-ELSD: 314(-) = (M-H)(-);<br>
316(+)= (M+H)(+) (1 chlorine atom Cl present)<br>
Example 10<br>
(5Z)-5-[(6-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br><br>
yl)methylene]-2-[(eyelopropylmethy1)amino]-3,5-dihydro-<br>
4H-imidazol-4-one<br>
(5Z)-5-[(6-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-[(cyclopropylmethyl)amino]-3,5-dihydro-<br>
4H-imidazol-4-one can be prepared as in Example 7, but<br>
from 150 mg of (5Z)-5-[(6-chloro-1H-pyrrolo [2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one,<br>
3.75 cm3 of ethanol and 383 mg of 1-<br>
cyclopropylmethanamine. After fifteen minutes at a<br>
temperature of 140C, then thirty minutes at a<br>
temperature of 150C under microwave irradiation, 55 mg<br>
of (5Z)-5-[(6-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-[(cyclopropylmethyl)amino]-3,5-dihydro-<br>
4H-imidazol-4-one is obtained in the form of a pale<br>
yellow powder with the following characteristics:<br>
1H-NMR spectrum at 400 MHz: 0.30 (m: 2H); 0.48 (m: 2H);<br>
1.12 (m: 1H) ; 3.24 (t, J = 6. 5 Hz: 2H) ; 6.57 (s: 1H) ;<br>
7.16 (d, J = 8 Hz: 1H) ; from 7.20 to 7.35 (m spread<br>
out: 1H) ; 8.18 (m: 1H) ; 8.73 (m: 1H) ; from 9.80 to<br>
10.70 (m very broad: 1H) ; from 11.5 to 12.3 (m very<br>
broad: 1H)<br>
Mass spectrum: LC-MS-DAD-ELSD: 316(+)= (M+H)(+) (1<br>
chlorine atom Cl present)<br>
Example 11<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-[(2-methyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-[(2-methyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylene]-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 200 mg of a mixture containing 65% of (5Z)-5-[(2-<br>
methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-<br>
thioxoimidazolidin-4-one, 2 cm3 of ethanol and 551 mg<br>
of 1-cyclopropylmethanamine, after fifteen minutes at a<br><br>
temperature of 140C and fifteen minutes at 145C under<br>
microwave irradiation. The mixture obtained is then<br>
purified by flash chromatography on a silica column<br>
[eluent: dichloromethane/methanol (gradient from 98/2<br>
to 90/10 by volume)]. 35 mg of (5Z)-2-<br>
[(cyclopropylmethyl)amino]-5-[(2-methyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-3,5-dihydro-4H-imidazol-4-one<br>
is obtained in the form of a pale yellow powder with<br>
the following characteristics:<br>
1H-NMR spectrum at 400 MHz: 0.29 (m: 2H); 0.47 (m: 2H) ;<br>
1.13 (m: 1H); 2.50 (s partially masked: 3H); 3.23 (t, J<br>
= 6.5 Hz: 2H) ; 6.48 (s: 1H) ; 7.00 (m: 1H) ; 7.08 (m:<br>
1H) ; 8.10 (d broad, J = 4 Hz: 1H) ; 9.42 (d, J = 8 Hz:<br>
1H) ; from 10.3 to 10.6 (m spread out: 1H) ; 11.8 (s<br>
broad: 1H)<br>
Mass spectrum: LC-MS-DAD-ELSD: 294 (-) = (M-H)(-);<br>
296( + ) = (M+H) ( + )<br>
Example 12<br>
(5Z)-2-[(cyclopropylmethyl)amino]-3-methyl-5-(1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylene)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-2-[(cyclopropylmethyl)amino]-3-methyl-5-(1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylene)-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 100 mg of (5Z)-3-methyl-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylene)-2-thioxoimidazolidin-4-one,<br>
4 cm3 of ethanol and 2 75 mg of 1-<br>
cyclopropylmethanamine. After fifteen minutes at a<br>
temperature of 140C, forty minutes at 150C and forty-<br>
five minutes at 160C under microwave irradiation,<br>
39 mg of (5Z)-2-[(cyclopropylmethyl)amino]-3-methyl-5-<br>
(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-3,5-dihydro-<br>
4H-imidazol-4-one is obtained in the form of a yellow<br>
powder with the following characteristics:<br><br>
1H-NMR spectrum at 400 MHz: 0.35 (m: 2H); 0.51 (m: 2H);<br>
1.22 (m: 1H) ; 3.07 (s: 3H) ; 3.33 (t, J = 6.5 Hz: 2H) ;<br>
6.74 (s: 1H); 7.11 (dd, J = 5 and 8 Hz: 1H); 7.55 (t, J<br>
= 6.5 Hz: 1H) ; from 8.20 to 8.27 (m: 2H) ; 8.61 (d, J =<br>
8 Hz: 1H); 11.9 (s broad: 1H)<br>
Mass spectrum: LC-MS-DAD-ELSD:	294(-) = (M-H)(-);<br>
296 (+) = (M+H)(+)<br>
Example 13<br>
(5Z)-2-butyl-5-[(1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3,5-dihydro-4H-imidazol-4-one<br>
Preparation A of Example 13<br>
(5Z)-2-butyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylene)-3,5-dihydro-4H-imidazol-4-one<br>
(5Z)-2-butyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylene)-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as in Example 1, but adding 0.15 cm3 of<br>
piperidine and 324 mg of 2-butyl-3,5-dihydro-4H-<br>
imidazol-4-one (prepared for example according to J.<br>
Org. Chem. 1999, 64, 8084-8089) to 198 mg of 1H-<br>
pyrrolo[2,3-b]pyridine-3-carbaldehyde in 15 cm3 of<br>
ethanol. Reflux the reaction mixture for three hours<br>
and concentrate the mixture under vacuum. On adding a<br>
little ethanol, a yellow solid forms, which is<br>
filtered, washed with 3 cm3 of dichloromethane, and<br>
dried under vacuum to obtain 65 mg. This solid is<br>
combined with the 66 mg of solid obtained in an<br>
identical reaction on 245 mg of lH-pyrrolo[2,3-<br>
b]pyridine-3-carbaldehyde. The solids are taken up in<br>
20 cm3 of water and extracted with two times 3 0 cm3 of<br>
ethyl acetate. The organic phases are dried over<br>
magnesium sulphate, filtered and concentrated at<br>
reduced pressure, obtaining 88 mg of (5Z)-2-butyl-5-<br>
(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-3,5-dihydro-<br><br>
4H-imidazol-4-one in the form of a yellow powder with<br>
the following characteristics:<br>
1H-NMR spectrum at 400 MHz: 0.95 (t, J = 7.5 Hz, 3H);<br>
1.40 (m, 2H) ; 1.71 (m, 2H) ; 2.54 (t, J = 7.5 Hz, 2H);<br>
7.16 (s, 1H) ; 7.18 (dd, J = 5.0 and 8.0 Hz, 1H) ; 8.28<br>
(dd, J = 1.5 and 5.0 Hz, 1H) ; 8.34 (s, 1H) ; 8.92 (d<br>
broad, J = 8.0 Hz, 1H) ; 11.1 (m spread out, 1H) ; 12.4<br>
(m spread out, 1H)<br>
Preparation B of Example 13<br>
(5Z)-2-butyl-5-[(1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3,5-dihydro-4H-imidazol-4-one<br>
a)	(5Z)-2-butyl-5-[(1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as follows:<br>
A mixture of 0.32 g of raw 2-butyl-3,5-dihydro-4H-<br>
imidazol-4-one, 0.2 g of 1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde, 0.14 cm3 of piperidine and 15 cm3 of<br>
ethanol is refluxed for four hours. The yellow solid is<br>
filtered, washed with a little methylene chloride then<br>
dried under vacuum to obtain 65 mg of (5Z)-2-butyl-5-<br>
[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-<br>
dihydro-4H-imidazol-4-one in the form of a yellow<br>
powder with the following characteristics:<br>
1H-NMR spectrum at 400 MHz: 0.95 (t, J = 7.5 Hz, 3H) ;<br>
1.40 (m, 2H) ; 1.71 (m, 2H) ; 2.54 (t, J = 7.5 Hz, 2H) ;<br>
7.17 (s, 1H) ; 7.20 (dd, J = 5.0 and 8.0 Hz, 1H) ; 8.29<br>
(dd, J = 1.5 and 5.0 Hz, 1H) ; 8.34 (s, 1H) ; 8.92 (d<br>
broad, J = 8.0 Hz, 1H) ; 11.1 (m spread out, 1H) ; 12.4<br>
(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 269(+) = (M+H)(+); 267(-) = (M-H)(-).<br><br>
b)	2-butyl-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as follows:<br>
A solution of 63 mg of sodium hydroxide in 2 cm3 of<br>
ethanol is added slowly to 0.2 g of methyl glycinate<br>
hydrochloride at -10C. After 5 min, a solution of<br>
0.18 g of methyl pentanimidoate in 5 cm3 of toluene is<br>
added and the mixture is stirred at room temperature<br>
for 20 min. The pH is then adjusted to pH 7 with a<br>
solution of 1M HCl. The mixture obtained is<br>
concentrated under vacuum at room tempex-ature. The<br>
residue is taken up in dichloromethane and the<br>
insoluble solid is filtered. Evaporation of the<br>
filtrate gives 0.32 g of 2-butyl-3,5-dihydro-4H-<br>
imidazol-4-one.<br>
c)	Methyl pentanimidoate can be prepared as follows:<br>
Slowly add a 6M solution of potassium hydroxide<br>
(10.6 cm3) to a solution of 0.3 g of methyl<br>
pentanimidoate hydrochloride in 5 cm3 of ether at<br>
10 oC. Stir the mixture for 10 min then extract with<br>
ether (2x20 cm3) . Wash the organic phases with water<br>
(20 cm3) , dry over magnesium sulphate and concentrate<br>
under vacuum to obtain 179 mg of methyl pentanimidoate.<br>
d)	Methyl pentanimidoate hydrochloride can be prepared<br>
as follows:<br>
Gaseous hydrogen chloride is bubbled for 30 min in a<br>
solution of 5 cm3 of butane carbonitrile in a mixture<br>
of methanol (2.1 cm3) and ether (5 cm3), cooled to -<br>
10C. Allow the temperature to rise to 0C and put the<br>
reaction mixture in a refrigerator overnight. On<br>
concentrating the solution, 6.9 g of methyl<br><br>
pentanimidoate hydrochloride is obtained in the form of<br>
a white solid.<br>
UPLC-MS-DAD-ELSD analysis (MS = Quattro Premier XE<br>
Waters; electrospray +/-; mass-to-charge ratio m/z =<br>
100-1100; UPLC Waters; Acquity UPLC BeH C18 1.7 p<br>
column.<br>
3mm, 50mm; furnace UPLC = 70C, flow =0.7 ml/minute.<br>
Eluents: A = water + 0.1% formic acid, B = acetonitrile<br>
+ 0.1% formic acid with the gradient:<br><br>
DAD wavelength considered A = 210-400 nm<br>
ELSD: Sedere SEDEX 85; spraying temperature = 35 C;<br>
spraying pressure = 3.7 bar<br>
Example 14<br>
(5Z)-5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one<br>
a)	(5Z)-5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one can be<br>
prepared as in Example 1 but from 655 mg of 5-bromo-1H-<br>
pyrrolo[2,3-b]pyridine-3-carbaldehyde in 6 cm3 of<br>
ethanol, 340 mg of 2-thioxoimidazolidin-4-one and<br>
0.28 cm3 of piperidine. After refluxing for two hours,<br>
700 mg of (5Z)-5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-<br><br>
yl)methylene]-2-thioxoimidazolidin-4-one is obtained in<br>
the form of orange powder with the following<br>
characteristics:<br>
1H-NMR spectrum at	400 MHz:	6.82 (s, 1H); 8.37 (d, J =<br>
2.0 Hz, 1H) ; 8.57	(s, 1H) ;	8.64 (d, J = 2.0 Hz, 1H) ;<br>
from 11.6 to 12.3	(m very	broad, 2H) ; 12.6 (m spread<br>
out, 1H).<br>
Mass spectrum: HPLC-MS-DAD-ELSD: 323(+) = (M+H) (+) ;<br>
321 (-) = (M-H) (-) (1 bromine atom Br present) .<br>
b) 5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde can<br>
be prepared as follows:<br>
Add, at 0C, 0.93 g of 5-bromo-1H-pyrrolo[2,3-<br>
b]pyridine to a suspension of 3.35 g of aluminium<br>
chloride in 5 0 cm3 of dichloromethane. Stir the<br>
reaction mixture for 15 minutes, then add dropwise<br>
1.4 cm3 of dichloro(methoxy)methane. Stir the reaction<br>
mixture for three hours at 0C, then dilute at 0C by<br>
adding 5 cm3 of methanol. Pour the mixture obtained<br>
into a mixture of 100 cm3 of ice water, then adjust to<br>
basic pH by adding 5M sodium hydroxide. Separate the<br>
phases, and wash the dichloromethane phase with water,<br>
then dry over sodium sulphate. Extract the aqueous<br>
phase again with two times 100 cm3 of ethyl acetate.<br>
Combine the two extracts, wash with water, dry over<br>
sodium sulphate and combine with the dichloromethane<br>
organic phase above. After concentration under vacuum,<br>
0.61 g of 5-bromo-1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde is obtained in the form of ochre powder<br>
with the following characteristics:<br>
1H-NMR spectrum at 400 MHz: 8.44 (d, J = 2Hz, 1H) ; 8.51<br>
(m, 2H); 9.92 (s, 1H).<br><br>
LC-MS (1): retention time: 3.08 min, LC-MS-DAD-ELSD:<br>
223(-) = (M-H)(-); 225(+) = (M+H)(+) (1 Br present).<br>
c) 5-bromo-1H-pyrrolo[2,3-b]pyridine can be prepared as<br>
described in D. Mazeas et al.: Heterocycles. 1999,<br>
50 (2) ; 1065-1080.<br>
Example 15<br>
(5Z)-5-[(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one<br>
a) (5Z)-5-[(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one can be<br>
prepared as in Example 1 but from 160 mg of 5-methoxy-<br>
1H-pyrrolo [2,3-b]pyridine-3-carbaldehyde in 4 cm3 of<br>
ethanol, 110 mg of 2-thioxoimidazolidin-4-one and<br>
0.09 cm3 of piperidine. After refluxing for 2.5 hours,<br>
220 mg of (5Z)-5-[(5-methoxy-1H-pyrrolo[2,3-b]pyridin-<br>
3-yl)methylene]-2-thioxoimidazolidin-4-one is obtained<br>
in the form of orange powder with the following<br>
characteristics:<br>
1H-NMR spectrum at 400 MHz: 3.87 (s, 3H) ; 6.86 (s, 1H) ;<br>
7.95 (d, J = 2.5 Hz, 1H) ; 8.03 (d, J = 2.. 5 Hz, 1H) ;<br>
8.50 (s, 1H); 11.84 (s broad, 1H); 12.30 (s broad, 1H).<br>
LC-MS (1): retention time 2.60 min, LC-MS-DAD-ELSD:<br>
273 (-) = (M-H) (-) ; 275 (+) = (M+H)(+).<br>
b) 5-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde<br>
can be prepared as described in D. Mazeas et al. :<br>
Heterocycles. 1999, 50(2); 1065-1080.<br>
Example 16<br>
(5Z)-5-[(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one<br><br>
a)	(5Z) -5-[(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)raethylidene]-2-thioxoimidazolidin-4-one can be<br>
prepared as in Example 1 but from 13 5 mg of 5-phenyl-<br>
lH-pyrrolo[2,3-b]pyridine-3-carbaldehyde in 3 cm3 of<br>
ethanol, 70 mg of 2-thioxoimidazolidin-4-one and<br>
0.06 cm3 of piperidine. After refluxing for 2.5 hours,<br>
180 mg of (5Z) -5-[(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one is obtained in<br>
the form of orange powder with the following physical<br>
characteristics:<br>
Melting point: 265-270C<br>
1H-NMR spectrum at 400 MHz: 6.84 (s, 1H); 7.38 (t, J =<br>
7.5 Hz, 1H); 7.49 (t, J = 7.5 Hz, 2H); 7.82 (d, J = 7.5<br>
Hz, 2H) ; 8.52 (s, 1H) ; 8.61 (d, J = 2.0 Hz, 1H) ; 8.68<br>
(d, J = 2.0 Hz, 1H); from 10.0 to 11.5 (m very broad,<br>
3H) .<br>
LC-MS (1): retention time 3.49 min; LC-MS-DAD-ELSD:<br>
319(-) = (M-H) (-); 321(+) = (M+H) (+).<br>
b) 5-phenyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde<br>
can be prepared as follows:<br>
Put 500 mg of 5-bromo-1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde, 13 cm3 of dioxan, 3.7 cm3 of water, 2.9 g<br>
of caesium carbonate, 340 mg of phenylboronic acid, and<br>
160 mg of 1,1'-bis(diphenylphosphino)ferrocene-<br>
dichloropalladium(II) in a microwave tube. Irradiate<br>
the reaction mixture with microwaves for thirty minutes<br>
at 140C. After cooling, pour the reaction mixture into<br>
50 cm3 of water. Extract the mixture obtained with two<br>
times 50 cm3 of ethyl acetate. Dry the combined organic<br>
phases over sodium sulphate, then reduce to dryness<br>
under vacuum. The residue obtained is purified by flash<br><br>
chromatography on a silica column with a<br>
dichloromethane/ethyl	acetate	eluent<br>
(dichloromethane/ethyl acetate gradient of 90/10 to<br>
50/50 by volume) to give 377 mg of 5-phenyl-1H-<br>
pyrrolo[2,3-b]pyridine-3-carbaldehyde with the<br>
following physical characteristics:<br>
1H-H-NMR spectrum at 400 MHz: 7.41 (tt, J = 1 and 7.4 Hz,<br>
1H); 7.52 (t, J = 7.4 Hz, 2H); 7.73(d, J = 7.4 Hz, 2H);<br>
8.51(S, 1H); 8.59 (d, J = 2.3 Hz, 1H); 8.66 (d, J = 2.3<br>
Hz); 9.97 (s, 1H); 12.77 (sb, 1H).<br>
LC-MS (1): retention time 3.38 min; LC-MS-DAD-ELSD: 221<br>
(-) = (M-H)(-); 225(+) = (M+H)(+).<br>
Example 17<br>
(5Z)-5-[(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-thioxoimidazolidin-4-one<br>
a) (5Z)-5-[(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-thioxoimidazolidin-4-one can be<br>
prepared as in Example 1 but from 500 mg of raw 5-<br>
methyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde<br>
titrated at 65%, 362 mg of 2-thioxoimidazolidin-4-one<br>
and 106 mg of piperidine in 15 cm3 of ethanol. Heat the<br>
mixture under ethanol reflux for four hours under<br>
argon, then cool to 0C on an ice bath for ten minutes.<br>
Filter the suspension and concentrate the filtrate at<br>
reduced pressure to obtain 685 mg of (5Z)-5-[(5-methyl-<br>
1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-2-<br>
thioxoimidazolidin-4-one in the form of a yellow powder<br>
with the following characteristics:<br>
LC-MS: retention time: 2.83 min, 259(+)= (M+H)(+).<br><br>
1H-NMR spectrum at 400 Hz.: 2.42 (s: 3H) ; 6.73 (sb:<br>
1H);'8.10 (d, J = 2Hz: 1H); 8.15 (d, J = 2Hz: 1H); 8.49<br>
(s: 1H) ; 11.5-12.1 (massive: 2H) ; 12.26 (se, 1H) .<br>
b) 5-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde<br>
can be prepared as follows:<br>
Add	1.6 g	of	1,3,5,7-<br>
tetraazatricyclo[3.3.1.1-3,7~]decane to a suspension of<br>
1 g of 5-methyl-1H-pyrrolo[2,3-b]pyridine in a mixture<br>
of 10 cm3 of water and 5 cm3 of acid acetic. Reflux the<br>
mixture under argon for four hours and thirty minutes,<br>
then add 3 0 cm3 of water to the hot mixture and leave<br>
to return to room temperature while stirring overnight.<br>
Then extract the mixture with three times 50 cm3 of<br>
ethyl acetate. Then combine the organic phases and wash<br>
with 3 times 50 cm3 of water, dry over magnesium<br>
sulphate and concentrate to dryness at reduced pressure<br>
to obtain 610 mg of a mixture containing 65% (by NMR)<br>
of 5-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde in<br>
the form of a yellow powder, for which the<br>
characteristics of the main product are as follows:<br>
LC-MS: retention time 3.79 min, 161(+)= (M+H)(+).<br>
1H-NMR spectrum at 400 Hz: 2.41 (s: 3H); 8.21 (d, J =<br>
2Hz: 1H); 8.22 (d, J = 2Hz: 1H) ; 8.40 (s: 1H) ; 9.90 (s:<br>
1H); 12.5-12.7 (se: 1H).<br>
c) 5-methyl-1H-pyrrolo[2,3-b]pyridine can be prepared<br>
as follows:<br>
Add 7 g of potassium tert-butanolate to a suspension of<br>
7.5 g of 5-methyl-3-[(trimethylsilyl)ethynyl]pyridin-2-<br>
amine in 17 0 cm3 of NMP. Reflux the reaction mixture<br>
for six hours thirty minutes under argon then allow to<br>
return to room temperature overnight. Then pour the<br><br>
reaction mixture slowly into 74 0 cm3 of a saturated<br>
aqueous solution of ammonium chloride and filter the<br>
insoluble matter on celite. Extract the filtrate with<br>
three times 500 cm3 of ethyl acetate then wash the<br>
combined organic phases with water, dry over magnesium<br>
sulphate and concentrate to dryness at reduced<br>
pressure. Then take up the residue in ethyl acetate.<br>
The solution obtained is washed with water, then dried<br>
over magnesium sulphate and concentrated to dryness at<br>
reduced pressure to obtain 2.6 g of 5-methyl-1H-<br>
pyrrolo [2,3-b]pyridine in the form of a brown solid<br>
with the following characteristics:<br>
LC-MS: retention time 0.85 min, 133(+)= (M+H)(+).<br>
1H-NMR spectrum at 400 Hz: 2.38(s: 3H) ; 6.35(dd, J =<br>
1.5, 3Hz: 1H) ; 7.38 (dd, J = 2.5, 3Hz: 1H) , 7.73 (db, J<br>
= 1Hz: 1H); 8.2 (d, J = 2Hz: 1H); 11.42 (se, 1H).<br>
d) 5-methyl-3-[(trimethylsilyl)ethynyl]pyridin-2-amine<br>
can be prepared as follows:<br>
A suspension of 1 g of 2-amino-3-bromo-5-methylpyridine<br>
with 204 mg of CuI and 250 mg of lithium chloride in<br>
3 0 cm3 of dimethylformamide is placed under argon and<br>
stirred. 3.7 cm3 of triethylamine, 195 mg of [1,1'-<br>
bis(diphenylphosphino)ferrocene]dichloropalladium(II)<br>
and 800 mg of trimethylsilylacetylene are then added<br>
successively. The mixture is heated at 4 8C for twenty-<br>
two hours. The reaction mixture is then concentrated to<br>
dryness at reduced pressure, and the residue is taken<br>
up in a mixture of 30 cm3 of ethyl acetate and 30 cm3 of<br>
water. Brown insoluble matter is filtered on celite.<br>
The phases are separated and the organic phase is<br>
washed with two times 30 cm3 of water. The aqueous<br>
phase is extracted with 30 cm3 of ethyl acetate, then<br><br>
all the organic phases are combined, dried over<br>
magnesium sulphate and concentrated to dryness at<br>
reduced pressure. The residue is purified by flash<br>
chromatography on a silica column [eluent: n-<br>
hexane/ethyl acetate (gradient from 5/95 to 40/60 by<br>
volume)], to give 353 mg of 5-methyl-3-<br>
t(trimethylsilyl)ethynyl]pyridin-2-amine in the form of<br>
a beige solid with the following characteristics:<br>
LC-MS: retention time 3.28 min, 205(+)= (M+H)(+).<br>
1H-NMR spectrum at 400 Hz: 0.20 (m: 9H) ; 2.10 (s: 3H);<br>
5.90 (se: 2H); 7.40 (s: 1H); 7.85 (se: 1H).<br>
Example 18<br>
(5Z)-2-thioxo-5-{[5-(trifluoromethyl)-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl]methylidene}imidazolidin-4-one<br>
a)	(5Z)-2-thioxo-5-{[5-(trifluoromethyl)-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl]methylidene}imidazolidin-4-<br>
one can be prepared as in Example 1, but from 174 mg of<br>
5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde in 6 cm3 of ethanol, 94 mg of 2-<br>
thioxoimidazolidin-4-one and 0.03 cm3 of piperidine.<br>
After refluxing for two hours and thirty minutes,<br>
148 mg of a mixture containing 80% of (5Z)-2-thioxo-5-<br>
{[5-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl]methylidene}imidazolidin-4-one is obtained in the<br>
form of orange powder, for which the characteristics of<br>
the main compound are as follows:<br>
LC-MS: retention time 3.28 min; 313(+)= (M+H)(+).<br>
1H-NMR spectrum at 400 MHz: 6.98 (s, 1H) ; 8.52 (d, J =<br>
2 Hz, 1H) ; 8.66 (d, J = 2Hz, 1H) ; 9.07 (s, 1H) ; 12.00<br>
(s broad, 1H).<br><br>
b) 5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde can be prepared as follows:<br>
Add	92 6 mg	of	1,3,5,7-<br>
tetraazatricyclo[3.3.1.1~3,7~]decane to a mixture of<br>
820 mg of 5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridine<br>
in 6 cm3 of water and 3 cm3 of acid acetic. Reflux the<br>
reaction mixture for two hours and thirty minutes. Then<br>
add 6 cm3 of water to the hot mixture. On returning to<br>
a temperature close to 2 5C, the mixture is extracted<br>
with ethyl acetate (40 cm3). The organic phase is<br>
washed with a saturated solution of sodium chloride,<br>
dried over magnesium sulphate and concentrated under<br>
vacuum. The residue is purified by chromatography on<br>
silica (elution with a 20-100% gradient of ethyl<br>
acetate in heptane) to obtain 123 mg of 5-<br>
trifluoromethyl-1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde in the form of a beige powder with the<br>
following characteristics:<br>
LC-MS: retention time 3.14 min; 215(+)= (M+H)(+).<br>
1H-NMR spectrum at 400 MHz: 8.67 (d, J = 2.4 Hz, 1H) ;<br>
8.75 (d, J = 2.4 Hz, 1H) ; 8.69 (s, 1H) ; 10.00 (s, 1H) ;<br>
13.17 (s broad, 1H).<br>
c) 5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridine can be<br>
prepared as follows:<br>
A solution of 3.4 g of 5-trifluoromethyl-3-<br>
[(trimethylsilyl)ethynyl]pyridin-2-amine and 2.96 g of<br>
potassium tert-butylate in 55 cm3 of N-<br>
methylpyrrolidinone is heated at 90C for three hours.<br>
The mixture is cooled to room temperature then poured<br>
slowly into 250 cm3 of water saturated with ammonium<br>
chloride. The mixture is diluted with ethyl acetate,<br><br>
filtered and the phases are separated into their<br>
isomers and the aqueous phase is extracted with ethyl<br>
acetate (2x100 cm3) . The organic phases are combined,<br>
dried over magnesium sulphate and concentrated under<br>
vacuum. The residue is taken up slowly in water and the<br>
resultant suspension is filtered. The solid is dried<br>
under vacuum to obtain 1.58 g of 5-trifluoromethyl-1H-<br>
pyrrolo [2 , 3-b]pyridine in the form of a brown powder<br>
with the following characteristics:<br>
LC-MS: retention time 3.55 min; 187(+)= (M+H)(+).<br>
1H-NMR spectrum at 400 MHz: 6.63 (dd, J = 1.7 and 3.5<br>
Hz, 1H) ; 7.69 (dd, J = 2.2 and 3 5 Hz, 1H) ; 8.38 (d, J<br>
= 1.7 Hz, 1H) ; 8.55 (d, J = 2.2 Hz, 1H) ; 12.16 (s<br>
broad, 1H).<br>
d)	5-trifluoromethyl-3-<br>
[(trimethylsilyl)ethynyl]pyridin-2-amine can be<br>
prepared as follows:<br>
A mixture of 6.68 g of 2-amino-3-iodo-5-<br>
trifluoromethyl-pyridine, 11.7 g of lithium, chloride,<br>
0.88 g of copper iodide, 11.7 g of triethylamine,<br>
0.85 g of [1,1'-bis(diphenylphosphino)ferrocene]-<br>
dichloropallaidium(II) and 3.4 g of<br>
trimethylsilylacetylene in 160 cm3 of dimethylformamide<br>
is heated at 48C for twenty-three hours. The mixture<br>
is cooled to room temperature then concentrated under<br>
vacuum. The residue is taken up in 200 cm3 of water and<br>
200 cm3 of ethyl acetate. The insoluble matter is<br>
filtered and the organic phase is washed with water,<br>
dried over magnesium sulphate and concentrated under<br>
vacuum. The residue is purified by chromatography on a<br>
silica column [eluent: ethyl acetate/heptane (gradient<br>
from 0/100 to 30/70 by volume)], to obtain 3.42 g of 5-<br><br>
trifluoromethyl-3-[(trimethylsilyl)ethynyl]pyridin-2-<br>
amine in the form of beige powder with the following<br>
characteristics:<br>
LC-MS: retention time: 4.94 min; LC-MS-DAD-ELSD:<br>
259(+) = (M+H) (+) .<br>
e) 2-amino~3-iodo-5-trifluoromethyl-pyridine can be<br>
prepared as follows:<br>
A mixture of 4.0 g of 2-amino-5-trifluoromethyl-<br>
pyridine and 6.2 g of N-iodo succinimide in 110 cm3 of<br>
acid acetic is heated at 70C for three hours, then<br>
cooled to room temperature and concentrated under<br>
vacuum. The residue is taken up slowly in 60 cm3 of<br>
water saturated with sodium bicarbonate, then 60 cm3 of<br>
water. The solid which precipitates is filtered and<br>
then dried under vacuum to obtain 6.68 g of 2-amino-3-<br>
iodo-5-trifluoromethyl-pyridine in the form of a beige<br>
solid with the following characteristics:<br>
LC-MS: retention time: 3.72 min; LC-MS-DAD-ELSD: 289(+)<br>
= (M+H)(+).<br>
Example 19<br>
(5Z)-5-[(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-thioxoimidazolidin-4-one<br>
a)	(5Z)-5-[(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-thioxoimidazolidin-4-one can be<br>
prepared as in Example 1, but from 265 mg of 5-fluoro-<br>
lH-pyrrolo[2,3-b]pyridine-3-carbaldehyde, 13 cm3 of<br>
ethanol, 190 mg of 2-thioxoimidazolidin-4-one and<br>
0.16 cm3 of piperidine. After refluxing for 2.5 hours,<br>
327 mg of (5Z) -5-[(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one is obtained in<br><br>
the form of orange powder with the following physical<br>
characteristics:<br>
1H-NMR spectrum at 400 MHz: 6.81 (s, 1H) ; 8.30 (m, 2H) ;<br>
8.60 (s, 1H); 11.93 (s broad, 1H); 12.57 (s broad, 1H).<br>
LC-MS (1): retention time 2.91 min; LC-MS-DAD-ELSD: 261<br>
(-) = (M-H)(-); 263 (+) = (M+H)(+).<br>
b)	5-fluoro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde<br>
can be prepared as in Example 2 but from 54 5 mg of 5-<br>
fluoro-1H-pyrrolo[2,3-b]pyridine, in a mixture of<br>
3.4 cm3 of water and 1.6 cm3 of acid acetic, and 54 5 mg<br>
of 1,3,5,7-tetraazatricyclo[3.3.1.1~3,7~]-decane.<br>
265 mg of 5-fluoro-1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde is obtained in the form of a beige solid<br>
with the following physical characteristics:<br>
1H-NMR spectrum at 400 MHz: 8.15 (dd, J = 3 and 9 Hz,<br>
1H);.8.36 (dd, 1.8 and 3 Hz, 1H) ; 8.53 (s, 1H) ; 9.90<br>
(s, 1H) ; 12.79 (s broad, 1H) .<br>
LC-MS (1): retention time: 2.59 min; LC-MS-DAD-ELSD 163<br>
(-) = (M-H)(-); 165(+) = (M+H)(+).<br>
c)	5-fluoro-1H-pyrrolo[2,3-b]pyridine can be prepared<br>
as described in WO2005/103050.<br>
Example 20<br>
3-[(Z)-(5-oxo-2-thioxoimidazolidin-4-ylidene)methyl]-<br>
1H-pyrrolo[2,3-b]pyridine-5-carbonitrile<br>
a)	3-[(Z)-(5-oxo-2-thioxoimidazolidin-4-<br>
ylidene)methyl]-1H-pyrrolo[2,3-b]pyridine-5-<br>
carbonitrile can be prepared as in Example 1, but from<br>
173 mg of 3-formyl-1H-pyrrolo[2,3]pyridine-5-<br>
carbonitrile, in 7.4 cm3 of ethanol, 122 mg of 2-<br>
thioxoimidazolidin-4-one, and 0.05 cm3 of piperidine.<br><br>
After refluxing for three hours, 200 mg of 3-[5-oxo-2-<br>
thioxo-imidazolidin-(4Z)-ylidenemethyl]-1H-<br>
pyrrolo{[2,3-b]pyridine-5-carbonitrile is obtained in<br>
the form of orange powder, with the following physical<br>
characteristics:<br>
LC-MS (1): retention time 2.86; LC-MS-DAD-ELSD: 270(+)<br>
= (M+H)(+).<br>
1H-NMR spectrum at 400 MHz: 6.84 (s, 1H) ; 8.66 (s, 1H) ;<br>
8.69 (s, 1H); 8.99 (s, 1H); 12.17 (s broad, 1H).<br>
b)	3-formyl-1H-pyrrolo[2,3]pyridine-5-carbonitrile can<br>
be prepared as in Example 2, but from 860 mg of 1H-<br>
pyrrolo[2.3]pyridine-5-carbonitrile in a mixture of<br>
15 cm3 of water and 4.8 cm3 of acid acetic, and 1.2 6 g<br>
of tetraazatricyclo[3.3.1.1~3,7~]decane. 275 mg of 3-<br>
formyl-1H-pyrrolo[2,3]pyridine-5-carbonitrile is<br>
obtained in the form of beige powder with the following<br>
physical characteristics:<br>
1H-NMR spectrum at 400 MHz: 8.66 (s, 1H) ; 8.77 (m, 2H) ;<br>
9.98 (s, 1H).<br>
LC-MS (1): retention time 2.39 min; LC-MS-DAD-ELSD:<br>
170 (-) = (M-H)(-); 172 (+) = (M+H) (+) .<br>
c)	lH-pyrrolo[2,3-b]pyridine-5-carbonitrile can be<br>
prepared as described in WO2004/078756.<br>
Example 21<br>
(5Z)-5-[(5-phenylamino-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one<br>
a) (5Z)-5-[(5-phenylamino-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one can be<br>
prepared as in Example 1, but from 63 mg of 5-<br>
phenylamino-1H-pyrrolo [2,3-b]pyridine-3-carbaldehyde in<br><br>
2 cm3 of ethanol, 32 mg of 2-thioxoimidazolidin-4-one<br>
and 0.03 cmJ of piperidine. After refluxing for 2.5<br>
hours, 70 mg of (5Z)-5-[(5-phenylamino-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one is<br>
obtained in. the form of orange powder with the<br>
following physical characteristics:<br>
1H-NMR spectrum at 400 MHz: 6.71 (s, 1H) ; 6.76 (t, J =<br>
7.6 Hz, 1H); 7.01 (d, J = 7.6 Hz, 2H); 7.21 (t, J = 7.6<br>
Hz, 2H) ; 7.98 (d, J = 2.4 Hz, 1H) ; 8.06 (s, 1H) ; 8.12<br>
(d, J = 2.4 Hz, 1H); 8.47 (s, 1H); 11.70 (s broad, 3H);<br>
12.29 (s broad, 1H).<br>
LC-MS (1): retention time 3.55 min; LC-MS-DAD-ELSD 334<br>
(-) = (M-H)(-); 336 (+) = (M+H)(+).<br>
b)	5-phenylamino-1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde can be prepared as in Example 14 but from<br>
1.6 g of aluminium chloride in suspension in 25 cm3 of<br>
dichloromethane, 0.5 g of N-phenyl-1H-pyrrolo [2,3-<br>
b]pyridin-5-amine, and 1.1 cm3 of<br>
dichloro(methoxy)methane. After one hour thirty minutes<br>
of reaction and hydrolysis of the reaction mixture,<br>
180 mg of a raw product is obtained, which is then<br>
purified by flash chromatography on a silica column<br>
with dichloromethane/ethyl acetate eluent (gradient<br>
from 80/20 to 50/50 by volume). 70 mg of 5-phenyl-1H-<br>
pyrrolo[2,3-b]pyridine-3-carbaldehyde is obtained in<br>
the form of ochre powder with the following physical<br>
characteristics:<br>
1H-NMR spectrum at 400 MHz: 6.80 (t, J = 7.4 Hz, 1H);<br>
7.02 (d, J = 7.4 Hz, 2H) ; 7.24 (t, J = 7.4 Hz, 2H) ;<br>
8.17 (m, 3H) ; 8.36 (s, 1H) ; 9.86 (s, 1H) , 12.56 (s<br>
broad, 1H).<br><br>
LC-MS-DAD-ELSD: 236 (-)=(M-H)(-); 237 (+) = (M+H)(+).<br>
c) 5-phenylamino-1H-pyrrolo[2,3-b]pyridine can be<br>
prepared as in Example 5, but by reacting 1.34 g of 1-<br>
[(4-methylphenyl)sulphonyl]-N-phenyl-1H-pyrrolo[2,3-<br>
b]pyridin-5-amine in 3 0 cm3 of methanol, and 4.15 g of<br>
potassium hydroxide for three hours at room<br>
temperature. After treatment of the reaction mixture,<br>
0.63 g of 5-phenylamino-1H-pyrrolo[2,3-b]pyridine is<br>
obtained in the form of beige powder with the following<br>
physical characteristics:<br>
1H-NMR spectrum at 400 MHz: 6.3 5 (d, J = 3.5Hz, 1H) ;<br>
6.69 (t, J = 7.5Hz, 1H); 6.89 (d, J = 7.5 Hz, 2H); 7.15<br>
(t, J = 7.5 Hz, 2H) ; 7.40 (s broad, 1H) ; 7.70 (d, J =<br>
2.6 Hz, 1H) 7.83 (s, 1H) ; 8.04 (d, J = 2.6 Hz, 1H),<br>
11.45 (s broad, 1H).<br>
LC/MS retention time 3.22 min; LC-MS-DAD-ELSD208(-) =<br>
(M-H)(-); 210(+) =(M+H)(+).<br>
d)	1-[(4-methylphenyl)sulphonyl]-N-phenyl-1H-<br>
pyrrolo[2,3-b]pyridin-5-amine can be prepared as<br>
follows:<br>
Put 750 mg of 5-bromo-1-[(4-methylphenyl)sulphonyl]-1H-<br>
pyrrolo [2,3-b]pyridine in 19 cm3 of toluene, 54 mg of<br>
9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene, 970 mg<br>
of caesium carbonate, 280 mg of aniline and 40 mg of<br>
tri(dibenzylideneacetone)dipalladium(0) in a microwave<br>
oven reactor. Irradiate the reactor in a microwave oven<br>
for forty-five minutes at 150C. After cooling, filter<br>
the reaction mixture, then reduce to dryness under<br>
vacuum in a rotary evaporator. Combine the brown<br>
residue with another two residues obtained similarly,<br>
then purify by flash chromatography on a silica column<br><br>
with dichloromethane eluent to give 1.34 g of 1-[ (4-<br>
methy1phenyl)sulphonyl]-N-phenyl-1H-pyrrolo[2,3-<br>
b]pyridin-5-amine in the form of a beige powder with<br>
the following physical characteristics:<br>
LC/MS retention time 4.58 min; LC-MS-DAD-ELSD; 364 (+) =<br>
(M+H)(+).<br>
e)	5-bromo-1-[(4-methylphenyl)sulphonyl]-1H-<br>
pyrrolo[2,3-b]pyridine can be prepared as follows:<br>
Add 1.63 g of 5-bromo-1H-pyrrolo [2, 3-b]pyridine, 30 mg<br>
of tetrabutyl ammonium hydrogen sulphate, 1.81 g of<br>
tosyl chloride and 4.3 g of sodium hydroxide pellets in<br>
solution in 40 cm3 of water to 41 cm3 of toluene. After<br>
stirring for four hours at room temperature, pour the<br>
reaction mixture into 50 cm3 of water. Extract the<br>
mixture obtained with 50 cm3 of ethyl acetate. The<br>
organic phase is decanted, dried over magnesium<br>
sulphate, filtered and then evaporated to dryness under<br>
vacuum in a rotary evaporator. 2.4 g of 5-bromo-1-[(4-<br>
methylphenyl)sulphonyl]-1H-pyrrolo[2,3-b]pyridine is<br>
obtained in the form of white powder with the following<br>
physical characteristics:<br>
LC/MS retention time 4.70 min; LC-MS-DAD-ELSD 353(+) =<br>
(M+H)(+) (1 bromine atom Br present).<br>
Example 22<br>
(5Z)-5-[(5-morpholin-4-yl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-thioxoimidazolidin-4-one<br>
a) (5Z)-5-[(5-morpholin-4-yl-1H-pyrrolo[2,3-b]pyridin-<br>
3-yl)methylidene]-2-thioxoimidazolidin-4-one can be<br>
prepared as in Example 1, but from 14 0 mg of 5-<br>
morpholin-4-yl-1H-pyrrolo[2,3-b]pyridine-3 -carbaldehyde<br>
in 4.5 cm3 of ethanol, 75 mg of 2-thioxoimidazolidin-4-<br><br>
one and 0.03 cm3 of piperidine. After refluxing for 2.5<br>
hours, 160 mg of(5Z)-5-[(5-morpholin-4-yl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-<br>
thioxoimidazolidin-4-one is obtained in the form of<br>
orange powder with the following physical<br>
characteristics:<br>
LC-MS(1): retention time 2.68 min; LC-MS-DAD-ELSD<br>
328(-) =(M-H)(-); 230(+) =(M+H)(+).<br>
1H-NMR spectrum at 400 MHz: 3.16(m, 4H) ; 3.78(m, 4H) ;<br>
6.88(s, 1H) ; 7.86(d, J = 2.3 Hz, 1H) ; 8.15(d, J =<br>
2.3 Hz, 1H) ; 8.48(s, 1H) ; 11.78(s broad, 1H) ; 12.09(s broad, 1H); 12.23(s broad, 1H).<br>
b)	5-morpholin-4-yl-1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde can be prepared as in Example 14 but from<br>
2 g of aluminium chloride in suspension in 50 cm3 of<br>
dichloromethane, 0.59 g of 5-morpholin-4-yl-1H-<br>
pyrrolo[2,3-b]pyridine and 0.8 cm3 of<br>
dichloro(methoxy)methane. After one hour thirty minutes<br>
of reaction and hydrolysis of the reaction mixture,<br>
140 mg of 5-morpholin-4-yl-1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde is obtained in the form of a beige powder<br>
with the following physical characteristics:<br>
LC/MS retention time 2.3 5 min; LC-MS-DAD-ELSD 230(-) =<br>
(M-H)(-) ; 232(+)=(M+H)(+).<br>
1H-NMR spectrum at 400 MHz: 3.12(m, 4H); 3.78(m, 4H);<br>
7.88(d, J = 2.8 Hz, 1H) ; 8.22(d, J = 2.8 Hz, 1H) ;<br>
8.34(s, 1H); 9.87(s, 1H); 12.48(s broad, 1H).<br>
c)	5-morpholin-4-yl-1H-pyrrolo[2,3-b]pyridine can be<br>
prepared as in Example 5, but from 1.18 g of l-[(4-<br>
methylphenyl)sulphonyl]-5-morpholin-4-yl-1H-<br>
pyrrolo [2,3-b]pyridine in 33 cm3 of methanol and 3.7 g<br><br>
of potassium, hydroxide pellets. After treatment of the<br>
reaction mixture, 0.59 g of 5-morpholin-4-yl-1H-<br>
pyrrolo[2,3-b]pyridine is obtained in the form of beige<br>
powder with the following physical characteristics:<br>
1H-NMR spectrum at 400 MHz: 3.05(m, 4H); 3.77(m, 4H) ;<br>
6.32(dd, J = 2 and 3.2 Hz, 1H) ; 7.36(dd, J = 2 and<br>
3.2 Hz, 1H); 7.48(d, J = 2.7 Hz, 1H); 8.06(d, J = 2.7<br>
Hz, 1H); 11.35(s broad, 1H).<br>
LC/MS retention time 1.27 min; LC-MS-DAD-ELSD:204(+) =(M+H)(+).<br>
d) 1-[(4-methylphenyl)sulphonyl]-5-morpholin-4-yl-1H-<br>
pyrrolo[2,3-b]pyridine can be prepared as in Example 21<br>
but from 62 cm3 of toluene, 2.6 g of 5-bromo-1-[(4-<br>
methylphenyl)sulphonyl]-1H-pyrrolo[2,3-b]pyridine,<br>
3.35 g of caesium carbonate, 170 mg of 9,9-dimethyl-<br>
4,5-bis(diphenylphosphino)xanthene, 0.9 g of morpholine<br>
and 130 mg of tri(dibenzylideneacetone)dipalladium(0).<br>
The reactor is irradiated in a microwave oven, for one<br>
hour at 150C. After cooling, the reaction mixture is<br>
filtered, and evaporated to dryness under vacuum in a<br>
rotary evaporator. The brown residue obtained is<br>
purified by flash chromatography on a silica column<br>
with dichloromethane/ethyl acetate eluent(gradient<br>
from 100 to 90/10 by volume) to give 1.18 g of l-[(4-<br>
methylphenyl)sulphonyl]-5-morpholin-4-yl-1H-<br>
pyrrolo[2,3-b]pyridine in the form of beige powder with<br>
the following physical characteristics:<br>
LC/MS retention time 3.96 min; LC-MS-DAD-ELSD: 358(+) =(M+H)(+) .<br>
Example 23<br><br>
(5Z)-5-[(5-benzyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-thioxoimidazolidin-4-one<br>
a)	(5Z)-5-[(5-benzyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-thioxoimidazolidin-4-one can be<br>
prepared as in Example 1, but from 55 mg of 5-benzyl-4-<br>
yl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde in 1.8 cm3<br>
of ethanol, 27 mg of 2-thioxoimidazolidin-4-one and<br>
0.023 cm3 of piperidine. After refluxing for 2.5 hours,<br>
60 mg of(5Z)-5-[(5- morpholin-4-yl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one is<br>
obtained in the form of orange powder with the<br>
following physical characteristics:<br>
1H-NMR spectrum at 400 MHz: 4.06(s, 2H) ; 6.69(s,	1H) ;<br>
7.17(t, J = 6.9 Hz, 1H) ; 7.29(m, 4H) ; 8.17(d,	J =<br>
1.8 Hz, 1H) ; 8.23(d, J = 1.8 Hz, 1H) ; 8.49(s,	1H) ;<br>
11.35(s broad, 1H); 12.26(s broad, 1H).<br>
LC-MS(1): retention time 3.66 min; LC-MS-DAD-ELSD:<br>
333(-) =(M-H)(-) ; 335(+) =(M+H)(+) .<br>
b) 5-benzyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde<br>
can be prepared as in Example 16, but from 260 mg of 5-<br>
bromo-1-[(4-methylphenyl)sulphonyl]-1H-pyrrolo[2,3-<br>
b]pyridine 3-carbaldehyde, in 4.7 cm3 of<br>
tetrahydrofuran and 2.5 cm3 of water, 680 mg of caesium<br>
carbonate and 55 mg of 1,1'-<br>
bis(diphenylphosphino)ferrocenedichloropalladium(II).<br>
After forty-five minutes of irradiation at 150C, pour<br>
the reaction mixture into a water/ethyl acetate<br>
mixture. Dry the organic phase over sodium sulphate and<br>
extract the aqueous phase again with 2 times 5 0 cm3 of<br>
a dichloromethane/methanol 90/10 mixture by volume. Dry<br>
the dichloromethane phase over sodium sulphate then<br>
combine with the preceding organic phases before<br><br>
concentrating under vacuum in a rotary evaporator. The<br>
brown residue is purified by flash chromatography on a<br>
silica column with a dichloromethane/ethyl acetate<br>
eluent(gradient dichloromethane/ethyl acetate from<br>
90/10 to 50/50 by volume) to give 55 mg of 5-benzyl-1H-<br>
pyrrolo[2,3-b]pyridine-3-carbaldehyde in the form of<br>
beige powder with the following physical<br>
characteristics:<br>
1H-NMR spectrum at 400 MHz: 4.09(s, 2H); 7.19(m, 1H);<br>
7.28(m, 4H) ; 8.22(d, J = 2.1 Hz, 1H) ; 8.31(d, J =<br>
2.1 Hz, 1H) ; 8.42(s, 1H) ; 9.87 (s, 1H) ; 12.61(s<br>
broad, 1H).<br>
LC-MS(1): retention time 3.61 min; LC-MS-DAD-ELSD: 235<br>
(-) =(M-H)(-); 237(+) =(M+H)(+).<br>
c)	5-bromo-1-[(4-methylphenyl)sulphonyl]-1H-<br>
pyrrolo[2,3-b]pyridine-3-carbaldehyde can be prepared<br>
as follows:<br>
Add, at 0C, 1 g of 5-bromo-1H-pyrrolo [2,3-b]pyridine-<br>
3-carbaldehyde, then 0.27 g of sodium hydride to 10 cm3<br>
of anhydrous tetrahydrofuran. Stir the reaction mixture<br>
for fifteen minutes at 0C before adding 1.87 g of<br>
tosyl chloride in solution in 1.7 cm3 of<br>
tetrahydrofuran. Continue stirring the reaction mixture<br>
for two hours, allowing it to return to room<br>
temperature. Pour the reaction mixture into 100 cm3 of<br>
iced water. Extract the mixture obtained with two times<br>
100 cm3 of ethyl acetate. Dry the organic phases over<br>
magnesium sulphate and then evaporate to dryness under<br>
vacuum in a rotary evaporator. 1.32 g of 5-bromo-1-[(4-<br>
methylphenyl)sulphonyl]-1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde is obtained in the form of a beige powder<br>
with the following physical characteristics:<br><br>
LC-MS-DAD-ELSD: 381(+) =(M+H)(+)(1 bromine atom Br<br>
present).<br>
Example 24<br>
(5E/Z)-3-phenyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-2-thioxoimidazolidin-4-one<br>
(5E/Z)-3-phenyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-2-thioxoimidazolidin-4-one can be<br>
prepared as in Example 1, but from 75 mg of 1H-<br>
pyrrolo[2,3-b]pyridine-3-carbaldehyde in 3.5 cm3 of<br>
ethanol, 98 mg of 2-thioxoimidazolidin-3-phenyl-4-one<br>
(SIGMA) and 0.02 cm3 of piperidine. After refluxing for<br>
five hours, 151 mg of a 50/50 mixture of(5Z/E) -3-<br>
phenyl-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)-2-<br>
thioxoimidazolidin-4-one is obtained in the form of a<br>
yellow powder with the following characteristics:<br>
1H-NMR spectrum at 400 MHz: 7.01(s, 0.5H); 7.11(s,<br>
0.5H); 7.21(dd, J = 5.0 and 8.0 Hz, 0.5H); 7.28(dd, J<br>
= 5.0 and 8.0 Hz, 0. 5H) ; 7.39(m, 2H) ; from 7.42 to<br>
7.58(m, 3H); 8.13(dd, J = 1.5 and 8.0 Hz, 0.5H); 8.33<br>
(m, 1.5H); 8.67(d, J = 2.0 Hz, 0.5H); 8.99(d, J = 2.0<br>
Hz, 0.5H); from 12.2 to 12.6(m, 2H).<br>
HPLC-MS-DAD-ELSD: 321(+) =(M+H)(+) ; 319(-) =(M-H)(-)<br>
(50/50 mixture of isomers).<br>
Example 25<br>
(5Z)-2-azepan-1-yl-5-[(5-chloro-1H-pyrrolo [2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one<br>
(5Z)-2-azepan-1-yl-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 7, but from 278 mg of<br>
(5Z)-5- [(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br><br>
yl)methylene]-2-thioxoimidazolidin-4-one(Example 3),<br>
2.5 cm3 of ethanol and 992 mg of azepane. After one<br>
hour at a temperature of 160C under microwave<br>
irradiation and filtration of the solid, 92 mg of(5Z)-<br>
2-azepan-1-yl-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3,5-dihydro-4H-imidazol-4-one is<br>
obtained in the form of a yellow powder with the<br>
following characteristics:<br>
Melting point: 310-320C.<br>
1H-NMR spectrum at 400 MHz: 1.53(m, 4H); 1.78(m<br>
broad, 4H); 3.63(m spread out, 4H); 6.58(s, 1H); 8.13<br>
(s, 1H); 8.21(d, J = 3.0 Hz, 1H); 9.21(s broad, 1H);<br>
11.0(m spread out, 1H); 12.15(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 344(+) =(M+H)(+) ; 342(-) =(M-H)(-).<br>
Example 26<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-(4-phenylpiperazin-1-yl)-3,5-dihydro-<br>
4H-imidazol-4-one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2 ,3-b]pyridin-3-<br>
yl)methylidene]-2-(4-phenylpiperazin-1-yl)-3,5-dihydro-<br>
4H-imidazol-4-one can be prepared as in Example 7, but<br>
from 167 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one<br>
(Example 3), 2cm3 of ethanol and 973 mg of 4-<br>
phenylpiperazine. After one hour at a temperature of<br>
160C under microwave irradiation, then filtration of<br>
the solid, 182 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-2-(4-phenylpiperazin-1-yl)-<br>
3,5-dihydro-4H-imidazol-4-one is obtained in the form<br>
of orange powder with the following characteristics:<br>
Melting point: 340-350C.<br><br>
1H-NMR spectrum at 400 MHz: 3.29(m partially masked,<br>
4H) ; 3.75(m, 4H); 6.70(s, 1H); 6.82(J = 7.5 Hz, 1H);<br>
7.02(d, J = 7.5 Hz, 2H) ; 7.24(t, J = 7.5 Hz, 2H) ;<br>
8.24(d, J = 3.0 Hz, 1H) ; 8.28(s, 1H) ; 8.98(d, J =<br>
3.0 Hz, 1H); 11.2(s broad, 1H); 12.2(s broad, 1H).<br>
UPLC-MS-DAD-ELSD: 407(+)/...=(M+H)(+)/...(1 chlorine atom<br>
Cl present).<br>
Example 27<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-pyrrolidin-1-yl-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-pyrrolidin-1-yl-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 223 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one<br>
(Example 3), 2.5 cm3 of ethanol and 569 mg of<br>
pyrrolidine. After thirty minutes at a temperature of<br>
160C under microwave irradiation, then filtration of<br>
the solid, 186 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-2-pyrrolidin-1-yl-3,5-<br>
dihydro-4H-imidazol-4-one is obtained in the form of a<br>
yellow powder with the following characteristics:<br>
Melting point: 350-360C.<br>
1H-NMR spectrum at 400 MHz: 1.94(m, 4H) ; 3.52(m<br>
broad, 4H); 6.59(s, 1H) ; 8.19(s, 1H) ; 8.21(d, J =<br>
3.0 Hz, 1H); 9.15(m spread out, 1H) ; 11.1(m spread<br>
out, 1H) ; 12.15(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 316(+)/...=(M+H)(+)/...; 314(-)/...=(M-H)( -<br>
)/...<br><br>
Example 28<br>
(5Z)-5-t(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yDmethylidene]-2-morpholin-4-yl-3, 5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-morpholin-4-yl-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 139 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one<br>
(Example 3), 2.5 cm3 of ethanol and 436 mg of<br>
morpholine. After two hours at a temperature of 160C<br>
under microwave irradiation, then filtration of the<br>
solid, 92 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-2-morpholin-4-yl-3,5-<br>
dihydro-4H-imidazol-4-one is obtained in the form of a<br>
yellow powder with the following characteristics:<br>
1H-NMR spectrum at 400 MHz: 3.59(m, 4H) ; 3.70(m, 4H);<br>
6.70(s, 1H) ; 8.22(m, 2H) ; 8.94(m spread out, 1H) ;<br>
11.15(m spread out, 1H); 12.2(m spread out, 1H).<br>
Example 29<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(2-methylpropyl)amino]-3,5-dihydro-<br>
4H-imidazol-4-one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(2-methylpropyl)amino]-3,5-dihydro-<br>
4H-imidazol-4-one can be prepared as in Example 7 but<br>
from 200 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one<br>
(Example 3), 4 cm3 of ethanol and 525 mg of 2-<br>
methylpropylamine. After forty-five minutes at a<br>
temperature of 16 0C under microwave irradiation, then<br>
filtration of the solid, 89 mg of(5Z)-5-[(5-chloro-1H-<br><br>
pyrrolo [2,3-b]pyridin-3-yl)methylidene]-2-[(2-<br>
methylpropyl)amino]-3,5-dihydro-4H-imidazol-4-one is<br>
obtained in the form of a yellow powder with the<br>
following characteristics:<br>
Melting point: 325-330C.<br>
1H-NMR spectrum at 400 MHz: 0.95(d, J = 6.5 Hz, 6H) ;<br>
1.93(m, 1H) ; 3.19(t, J = 6 Hz, 2H) ; 6.57(s, 1H) ;<br>
7.21(s broad 1H) ; 8.11(s, 1H) ; 8.21(s broad, 1H) ;<br>
9.25(m spread out, 1H); 10.4(m spread out, 1H); 12.15(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 318(+)/...=(M+H)(+)/...; 316(-)/...=(M-H)(-<br>
) /...(1 Cl present).<br>
Example 30<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-piperidin-1-yl-3 , 5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-piperidin-1-yl-3 , 5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 195 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one<br>
(Example 3), 2.5 cm3 of ethanol and 596 mg of<br>
piperidine. After thirty minutes at a temperature of<br>
160C under microwave irradiation, then filtration of<br>
the solid, 152 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-2-piperidin-1-yl-3,5-<br>
dihydro-4H-imidazol-4-one is obtained in the form of<br>
orange powder with the following characteristics:<br>
Melting point: 315-320C.<br><br>
1H-NMR spectrum at 400 MHz: Of 1.51 to 1.70(m, 6H) ;<br>
3.59(m, 4H) ; 6.61(s, 1H) ; 8.19(s, 1H) ; 8.22(d, J =<br>
3.0 Hz, 1H) ; 9.01(m spread out, 1H) ; 11.0(m spread<br>
out, 1H); 12.1(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 330(+)/...=(M+H)(+)/...; 328(-)/...=(M-H)(-<br>
) /...(1 Cl present).<br>
Example 31<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[methyl(2-methylpropyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[methyl(2-methylpropyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one can be prepared as in Example<br>
7, but from 63 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one<br>
(Example 3) , 1 cm3 of ethanol and 187 mg of N-methyl-<br>
(2-methyl)propylamine. After fifteen minutes at a<br>
temperature of 160C, thirty minutes at 170C, and one<br>
hour thirty minutes at 180C under microwave<br>
irradiation, the mixture is concentrated under vacuum.<br>
The residue is taken up in methylene chloride and the<br>
solid is filtered to obtain 30 mg of(5Z)-5-[(5-chloro-<br>
lH-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-2-[methyl(2-<br>
methylpropyl)amino]-3,5-dihydro-4H-imidazol-4-one in<br>
the form of a yellow powder with the following<br>
characteristics:<br>
1H-NMR spectrum at 400 MHz: 0.91(d, J = 6.5 Hz, 6H) ;<br>
2.04(m, 1H) ; 3.09(s, 3H) ; 3.30(m masked, 2H) ; 6.59<br>
(s, 1H) ; 8.13(s broad, 1H); 8.21(d, J = 2.0 Hz, 1H) ;<br>
9.20(m spread out, 1H) ; 11.1(m spread out, 1H) ; 12.15<br>
(m spread out, 1H).<br><br>
HPLC-MS-DAD-ELSD: 332(+)/...=(M+H)(+) /...; 330(-)/...=(M-H)(-<br>
)/...(1 chlorine atom Cl present).<br>
Example 32<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-(dimethylamino)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-(dimethylamino)-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 279 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one<br>
(Example 3), 1.5 cm3 of ethanol and 2 cm3 of solution of<br>
dimethylamine at 33% in ethanol. After thirty minutes<br>
at a temperature of 160C under microwave irradiation,<br>
then filtration of the solid, 220 mg of(5Z)-5-[(5-<br>
chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-2-<br>
(dimethylamino)-3,5-dihydro-4H-imidazol-4-one is<br>
obtained in the form of a yellow powder with the<br>
following characteristics:<br>
Melting point: 350C.<br>
1H-NMR spectrum at 400 MHz: 3.10(s, 6H); 6.60(s, 1H) ;<br>
8.19(s, 1H); 8.22(d, J = 2.0 Hz, 1H); 9.09(m spread<br>
out, 1H); 11.1(m spread out, 1H); 12.15(m spread out,<br>
1H).<br>
HPLC-MS-DAD-ELSD: 290(+)/...=(M+H)(+)/...(1 chlorine atom<br>
Cl present).<br>
Example 33<br>
(5Z)-5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(cyclopropylmethyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one<br><br>
(5Z)-5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(cyclopropylmethyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one can be prepared as in Example<br>
7, but from 860 mg of(5Z)-5-[(5-bromo-1H-pyrrolo[2,3 -<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one<br>
(Example 14), 8 cm3 of ethanol and 1.89 g of 1-<br>
cyclopropylmethanamine. After thirty minutes at a<br>
temperature of 160C under microwave irradiation, then<br>
filtration of the solid, 500 mg of(5Z)-5-[(5-bromo-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-2-<br>
[(cyclopropylmethyl)amino]-3,5-dihydro-4H-imidazol-4-<br>
one is obtained in the form of a pale yellow powder<br>
with the following characteristics:<br>
1H-NMR spectrum at 400 MHz: 0.30(m, 2H) ; 0.49(m, 2H) ;<br>
1.17(m, 1H) ; 3.38(m partially masked, 2H) ; 6.59(s,<br>
1H); 7.23(m broad, 1H); 8.11(s, 1H); 8.28(d, J = 2.0<br>
Hz, 1H) ; 9.32(m broad, 1H) ; 10.4(m spread out, 1H);<br>
12.15(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 360(+) =(M+H)(+) ; 358(-) =(M-H)(-)<br>
(1 bromine atom Br present).<br>
Example 34<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-methoxy-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-methoxy-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 200 mg of(5Z)-5-[(5-methoxy-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-2-thioxoimidazolidin-4-one<br>
(Example 15), 3 cm3 of ethanol and 519 mg of 1-<br>
cyclopropylmethanamine. After forty minutes at a<br>
temperature of 13 0C and ten minutes at 14 0C under<br><br>
microwave irradiation, the mixture is concentrated<br>
under vacuum. The residue is purified by preparative<br>
LC-MS [Column Xterra RP18 30x100; 5u; with<br>
water buffered with 10 mM of ammonium hydrogen<br>
carbonate adjusted to pH 9 with ammonia / acetonitrile<br>
with gradient from 70/30 to 0/100 in 8 min], to obtain<br>
58 mg of(5Z)-2-[(cyc1opropylmethyl)amino]-5-[(5-<br>
methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-<br>
dihydro-4H-imidazol-4-one in the form of a yellow<br>
lyophilizate with the following characteristics:<br>
Melting point: 280-286C.<br>
1H-NMR spectrum at 400 MHz: 0.28(m, 2H) ; 0.48(m, 2H) ;<br>
1.13(m, 1H) ; from 3.15 to 3.40(m partially masked,<br>
2H) ; 3.88(s, 3H) ; 6.62(s, 1H) ; 7.14(m, 1H) ; 7.98(m,<br>
1H) ; 8.11(m, 1H) ; 8.40(m, 1H) ; 10.35(m spread out,<br>
1H); 11.8(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 312(+) =(M+H)(+) ; 310(-) =(M-H)(-).<br>
Example 35<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-fluoro-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-fluoro-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 250 mg of(5Z)-5-[(5-fluoro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-2-thioxoimidazolidin-4-one<br>
(Example 19), 4 cm3 of ethanol and 678 mg of 1-<br>
cyclopropylmethanamine. After thirty minutes at a<br>
temperature of 160C under microwave irradiation, then<br>
filtration of the solid, 73 mg of(5Z) -2-<br>
[(cyclopropylmethyl)amino]-5-[(5-fluoro-1H-pyrrolo[2,3-<br><br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one is obtained in the form of a yellow powder with the<br>
following characteristics:<br>
Melting point: 312C.<br>
1H-NMR spectrum at 400 MHz: 0.29(m, 2H); 0.48(m, 2H) ;<br>
1.13(m, 1H) ; 3.22(t, J = 6.0 Hz, 1H) ; 6.59(s, 1H) ;<br>
7.27(m spread out, 1H); 8.22(m, 2H); 8.76(d broad, J<br>
= 9.0 Hz, 1H) ; 10.45(m spread out, 1H) ; 12.05(m<br>
spread out, 1H).<br>
UPLC-MS-DAD-ELSD: 300(+) =(M+H)(+) .<br>
Example 36<br>
(5Z)-2-azepan-1-yl-5-[(5-fluoro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one<br>
(5Z)-2-azepan-1-yl-5-[(5-fluoro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 7, but from 60 mg of<br>
(5Z)-5-[(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-thioxoimidazolidin-4-one(Example<br>
19), 0.6 cm3 of ethanol and 227 mg of azepane. After<br>
thirty minutes at a temperature of 160C under<br>
microwave irradiation, then filtration of the solid,<br>
22 mg of(5Z)-2-azepan-1-yl-5-[(5-fluoro-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one is obtained in the form of a yellow<br>
powder with the following characteristics:<br>
Melting point: 299C.<br>
1H-NMR spectirum at 400 MHz: from 1.44 to 1.87(m, 8H) ;<br>
3.62(m spread out, 4H) ; 6.59(s, 1H) ; 8.21(s broad,<br><br>
2H); 8.77(m spread out, 1H); 11.0(m very broad, 1H);<br>
12.05(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 328(+) =(M+H)(+).<br>
Example 37<br>
3-[(Z)-{2-[(cyclopropylmethyl)amino]-5-oxo-1,5-dihydro-<br>
4H-imidazol-4-ylidene}methyl]-1H-pyrrolo[2,3-<br>
b]pyridine-5-carbonitrile<br>
3-[(Z)-{2-[(cyclopropylmethyl)amino]-5-oxo-1,5-dihydro-<br>
4H-imidazol-4-ylidene}methyl]-1H-pyrrolo[2,3-<br>
b]pyridine-5-carbonitrile can be prepared as in Example<br>
7, but from 200 mg of 3-[(Z) -(5-oxo-2-<br>
thioxoimidazolidin-4-ylidene)methyl]-1H-pyrrolo[2,3-<br>
b]pyridine-5-carbonitrile(Example 20), 2 cm3 of<br>
ethanol and 52 8 mg of 1-cyclopropylmethanamine. After<br>
thirty minutes at a temperature of 140C under<br>
microwave irradiation, then filtration of the solid,<br>
58 mg of 3-[(Z)-{2-[(cyclopropylmethyl)amino]-5-oxo-<br>
1,5-dihydro-4H-imidazol-4-ylidene}methyl]-1H-<br>
pyrrolo[2,3-b]pyridine-5-carbonitrile is obtained in<br>
the form of a yellow powder with the following<br>
characteristics:<br>
Melting point: 335C.<br>
1H-NMR spectrum at 400 MHz: 0.30(m, 2H) ; 0.49(m,	2H) ;<br>
1.13(m, 1H) ; from 3.15 to 3.40(m masked, 2H) ;	6.60<br>
(s, 1H) ; 7.40(s broad, 1H) ; 8.25(s broad, 1H) ;	8.60<br>
(s, 1H) ; 9.53(s broad, 1H) ; 10.7(m spread out,	1H) ;<br>
12.2(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 307(+) =(M+H)(+); 305(-) =(M-H)(-).<br><br>
Example 38<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-phenyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-phenyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 140 mg of(5Z)-5-[(5-phenyl-1H-pyrrolo[2,3 -<br>
b]pyridin-3-yl)methylidene]-2-thioxoimidazolidin-4-one<br>
(Example 16) , 3 cm3 of ethanol and 311 mg of 1-<br>
cyclopropylmethanamine. After forty-five minutes at a<br>
temperature of 140C and thirty minutes at 150C under<br>
microwave irradiation, the solid is filtered, and then<br>
purified by preparative LC-MS [Column Xterra RP18<br>
30x100; 5u; with water buffered with 10 mM of ammonium<br>
hydrogen carbonate adjusted to pH 9 with ammonia /<br>
acetonitrile with gradient from 70/30 to 0/100 in 8<br>
min], to obtain 11 mg of(5Z) -2-<br>
[(cyclopropylmethyl)amino]-5-[(5-phenyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one in the form of a yellow powder with the following<br>
characteristics:<br>
1H-NMR spectrum at 400 MHz: 0.22(m, 2H) ; 0.43(m, 2H) ;<br>
1.11(m, 1H) ; 3.26(m partially masked, 2H) ; 6.70(s,<br>
1H); 7.15(m broad, 1H); 7.38(t, J = 7.5 Hz, 1H); 7.49<br>
(t, J = 7.5 Hz, 2H) ; 7.77(d broad, J = 7.5 Hz, 2H) ;<br>
8.17(s broad, 1H) ; 8.53(s broad, 1H) ; 9.17(m spread<br>
out, 1H); 10.4(m spread out, 1H); 12.0(m spread out,<br>
1H).<br>
HPLC-MS-DAD-ELSD: 358(+) =(M+H)(+); 356(-) =(M-H)(-).<br>
Example 39<br><br>
(5Z)-2-morpholin-4-yl-5-[(5-phenyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one<br>
(5Z)-2-morpholin-4-yl-5-[(5-phenyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 7, but from 200 mg of<br>
(5Z)-5-[(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one(Example 16),<br>
2 cm3 of ethanol and 544 mg of morpholine. After thirty<br>
minutes at a temperature of 160C under microwave<br>
irradiation, then filtration of the solid, 160 mg of<br>
(5Z)-2-morpholin-4-yl-5-[(5-phenyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one is obtained in the form of a yellow powder with the<br>
following characteristics:<br>
Melting point: 3 61C.<br>
1H-NMR spectrum at 400 MHz: from 3.50 to 3.75(m, 8H) ;<br>
6.80(s, 1H) ; 7.38(t, J = 7.5 Hz, 1H) ; 7.49(t, J =<br>
7.5 Hz, 2H) ; 7.76(d, J = 7.5 Hz, 2H) ; 8.21(s, 1H) ;<br>
8.57(d, J = 2.0 Hz, 1H); 9.12(s broad, 1H); 11.15(m<br>
spread out, 1H); 12.1(s broad, 1H).<br>
HPLC-MS-DAD-ELSD: 374(+) =(M+H)(+) ; 372(-) =(M-H)(-).<br>
Example 40<br>
(5Z)-5-[(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-piperidin-1-yl-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-5-[(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-piperidin-1-yl-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 200 mg of(5Z)-5-[(5-phenyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one<br><br>
(Example 16) , 2 cm3 of ethanol and 531 mg of<br>
piperidine. After thirty minutes at a temperature of<br>
160C under microwave irradiation, then filtration of<br>
the solid, 137 mg of(5Z)-5-[(5-phenyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-2-piperidin-1-yl-3,5-<br>
dihydro-4H-imidazol-4-one is obtained in the form of a<br>
yellow powder with the following characteristics:<br>
Melting point: 307C.<br>
1H-NMR spectrum at 400 MHz: from 1.50 to 1.69(m, 6H) ;<br>
3.59(m, 4H) ; 6.71(s, 1H) ; 7.38(t, J = 7.5 Hz, 1H) ;<br>
7.49(t, J = 7.5 Hz, 2H) ; 7.75(d, J = 7.5 Hz, 2H) ;<br>
8.15(s, 1H) ; 8.55(d, J = 2.0 Hz, 1H) ; 9.2 0(s broad,<br>
1H); 11.0(m spread out, 1H); 12.05(s broad, 1H).<br>
HPLC-MS-DAD-ELSD: 372(+) =(M+H)(+); 370(-) =(M-H)(-).<br>
Example 41<br>
(5Z)-2-(4-methylpiperazin-1-yl)-5-[(5-phenyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-2-(4-methylpiperazin-1-yl)-5-[(5-phenyl-1H-<br>
pyrrolo [2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 200 mg of(5Z)-5-[(5-phenyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one<br>
(Example 16) , 2 cm3 of ethanol and 625 mg of 4-<br>
methylpiperatzine. After forty minutes at a temperature<br>
of 160C under microwave irradiation, then filtration<br>
of the solid, 140 mg of(5Z)-2-(4-methylpiperazin-1-<br>
yl) -5-[(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3,5-dihydro-4H-imidazol-4-one is<br>
obtained in the form of a yellow powder with the<br>
following characteristics:<br><br>
Melting point: 304C.<br>
1H-NMR spectrum at 400 MHz: 2.23(s, 3H) ; 2.40(m, 4H) ;<br>
3.59(m, 4H) ; 6.78(s, 1H) ; 7.3 8(t, J = 7.5 Hz, 1H) ;<br>
7.49(t, J = 7.5 Hz, 2H) ; 7.76(d, J = 7.5 Hz, 2H) ;<br>
8.19(s, 1H); 8.55(d, J = 2.0 Hz, 1H); 9.15(s broad,<br>
1H) ; 11.1(mi spread out, 1H) ; 12.1(s broad, 1H) .<br>
HPLC-MS-DAD-ELSD: 387(+) =(M+H)(+); 385(-) = (M-H)(-).<br>
Example 4 2<br>
(5Z)-2-azepan-1-yl-5-[(5-phenyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one<br>
(5Z)-2-azepan-1-yl-5-[(5-phenyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 7, but from 200 mg of<br>
(5Z)-5-[(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one(Example 16),<br>
2 cm3 of ethanol and 619 mg of azepane. After forty<br>
minutes at a temperature of 160C under microwave<br>
irradiation, then filtration of the solid, 90 mg of<br>
(5Z)-2-azepan-1-yl-5-[(5-phenyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one is obtained in the form of a yellow powder with the<br>
following characteristics:<br>
Melting point: 302C.<br>
1H-NMR spectrum at 400 MHz: from 1.47 to 1.78(m, 8H) ;<br>
from 3.53 to 3.78(m spread out, 4H) ; 6.69(s, 1H) ;<br>
7.38(t, J = 7.5 Hz, 1H) ; 7.49(t, J = 7.5 Hz, 2H) ;<br>
7.73(d, J = 7.5 Hz, 2H) ; 8.14(s, 1H) ; 8.53(s broad,<br>
1H) ; 9.18(s broad, 1H); 11.0(m spread out, 1H); 12.0(s broad, 1H).<br><br>
HPLC-MS-DAD-ELSD: 386(+) =(M+H)(+); 384(-)=(M-H)(-).<br>
Example 43<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-methyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-methyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 240 mg of(5Z)-5-[(5-methyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-2-thioxoimidazolidin-4-one<br>
(Example 17), 4cm3 of ethanol and 661 mg of 1-<br>
cyclopropylmethanamine. After thirty-five minutes at a<br>
temperature of 160C under microwave irradiation, then<br>
filtration of the solid, 61 mg of(5Z) -2-<br>
[(cyclopropylmethyl)amino]-5-[(5-methyl-1H-pyrrolo [2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one is obtained in the form of a yellow powder with the<br>
following characteristics:<br>
Melting point: 319-320C.<br>
1H-NMR spectrum at 400 MHz: 0.29(m, 2H) ; 0.48(m,	2H);<br>
1.16(m, 1H) ; 2.40(s, 3H) ; 3.23(t, J = 6.0 Hz,	2H) ;<br>
6.59(s, 1H) ; 7.19(m spread out, 1H) ; 8.09(s,	1H) ;<br>
8.12(s, 1H) ; 8.49(s, 1H) ; 10.25(m spread out,	1H) ;<br>
11.8(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 296(+) =(M+H)(+); 294(-) =(M-H)(-).<br>
Example 44<br>
(5Z)-2-[(2-methylpropyl)amino]-5-[(5-methyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br><br>
(5Z)-2-[(2-methylpropyl)amino]-5-[(5-methyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 240 rag of(5Z)-5-[(5-methyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-2-thioxoimidazolidin-4-one<br>
(Example 17) , 4 cm3 of ethanol and 680 mg of 2-<br>
methylpropylamine. After thirty-five minutes at a<br>
temperature of 160C under microwave irradiation, then<br>
filtration of the solid, 95 mg of(5Z)-2-[(2-<br>
methylpropyl)amino]-5-[(5-methyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one is obtained in the form of a yellow powder with the<br>
following characteristics:<br>
Melting point: 338-339C.<br>
1H-NMR spectrum at 400 MHz: 0.93(d, J = 7.0 Hz, 6H) ;<br>
1.94(m, 1H); 2.40(s, 3H); 3.19(t broad, J = 6.0 Hz,<br>
2H) ; 6.58(s, 1H) ; 7.15(m spread out, 1H) ; 8.09(s,<br>
1H) ; 8.11(s, 1H) ; 8.51(s broad, 1H) ; 11.1(m spread<br>
out, 1H) ; 11.75(s broad, 1H).<br>
HPLC-MS-DAD-ELSD: 298(+) =(M+H)(+) ; 296(-) =(M-H)(-).<br>
Example 45<br>
(5Z)-5-[(5-methyl-1H-pyrrolo[2,3~b]pyridin-3-<br>
yl)methylidene]-2-piperidin-1-yl-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-5-[(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-piperidin-1-yl-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 240 mg of(5Z)-5-[(5-methyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-2-thioxoimidazolidin-4-one<br>
(Example 17) , 4 cm3 of ethanol and 791 mg of<br>
piperidine. After forty minutes at a temperature of<br><br>
160C under microwave irradiation, then filtration of<br>
the solid, 138 mg of(5Z)-5-[(5-methyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-2-piperidin-1-yl-3,5-<br>
dihydro-4H-imidazol-4-one is obtained in the form of a<br>
yellow powder with the following characteristics:<br>
Melting point: 320-321C.<br>
1H-NMR spectrum at 400 MHz: from 1.53 to	1.69	(m, 6H) ;<br>
2.39(s, 3H); 3.58(m, 4H); 6.61(s, 1H);	8.09	(s, 1H);<br>
8.14(s broad, 1H) ; 8.3 9(m spread out,	1H) ;	11.0(m<br>
very broad, 1H); 11.8(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 310(+) =(M+H)(+); 308(-) =(M-H)(-).<br>
Example 46<br>
(5Z)-5-[(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-(4-phenylpiperazin-1-yl)-3,5-dihydro-<br>
4H-imidazol-4-one<br>
(5Z)-5-[(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-(4-phenylpiperazin-1-yl)-3,5-dihydro-<br>
4H-imidazol-4-one can be prepared as in Example 7, but<br>
from 240 mg of(5Z)-5-[(5-methyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-2-thioxoimidazolidin-4-one<br>
(Example 17), 4 cm3 of ethanol and 1.51 g of 4-<br>
phenylpiperazine. After thirty minutes at a temperature<br>
of 160C under microwave irradiation, the solid is<br>
filtered then taken up in 50 cm3 of ethanol, filtered<br>
and dried under vacuum to obtain 166 mg of(5Z)-5-[(5-<br>
methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-2-(4-<br>
phenylpiperazin-1-yl)-3,5-dihydro-4H-imidazol-4-one in<br>
the form of a yellow powder with the following<br>
characteristics:<br>
Melting point: 331-332C.<br><br>
1H-NMR spectrum at 400 MHz: 2.41(s, 3H); 3.27(m, 4H) ;<br>
3.73(m, 4H) ; 6.69(s, 1H) ; 6.82(t, J = 7.5 Hz, 1H) ;<br>
7.01(d, J = 7.5 Hz, 2H) ; 7.25(t, J = 7.5 Hz, 2H) ;<br>
8.10(s, 1H); 8.21(s, 1H); 8.39(s, 1H); 11.15(m very<br>
broad, 1H) ; 11.9(s, 1H) .<br>
HPLC-MS-DAD-ELSD: 387(+) =(M+H)(+); 385(-) =(M-H)(-).<br>
Example 4 7<br>
(5Z)-2-azepan-1-yl-5-[(5-methyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one<br>
(5Z)-2-azepan-1-yl-5-[(5-methyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 7 but from 240 mg of<br>
(5Z)-5-[(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-thioxoimidazolidin-4-one(Example<br>
17) , 4 cm3 of ethanol and 922 mg of azepane. After<br>
thirty minutes at a temperature of 160C under<br>
microwave irradiation, then filtration of the solid,<br>
34 mg of(5Z)-2-azepan-1-yl-5-[(5-methyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one is obtained in the form of a brown<br>
powder with the following characteristics:<br>
Melting point: 324-326C.<br>
1H-NMR spectrum at 400 MHz: 1.54(m, 4H); 1.76(s<br>
broad, 4H); 2.39(s, 3H); 3.62(s broad, 4H); 6.57(s,<br>
1H); 8.10(m, 2H); 8.51(s broad, 1H); 10.72(s broad,<br>
1H); 11.77(s broad, 1H).<br>
Example 48<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-{[5-<br>
(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl]methylidene}-3,5-dihydro-4H-imidazol-4-one<br><br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-{[5-<br>
(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl]methylidene}-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as in Example 7, but from 70 mg of(5Z)-2-<br>
thioxo-5-{[5-(trifluoromethyl)-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl]methylidene}imidazolidin-4-one(Example<br>
18), 3 cm3 of ethanol and 159 mg of 1-<br>
cyclopropylmethanamine. After thirty minutes at a<br>
temperature of 160C under microwave irradiation, then<br>
filtration of the solid, 32 mg of(5Z)-2-<br>
[(cyclopropylmethyl)amino]-5-{[5-(trifluoromethyl)-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl]methylidene}-3,5-dihydro-4H-<br>
imidazol-4-one is obtained in the form of a yellow<br>
powder with the following characteristics:<br>
Melting point: 350C.<br>
1H-NMR spectrum at 400 MHz: 0.27(m, 2H) ; 0.48(m, 2H) ;<br>
1.13(m, 1H) ; 3.25(t, J = 6.0 Hz, 2H) ; 6.62(s, 1H) ;<br>
7.33(m spread out, 1H) ; 8.19(s, 1H) ; 8.57(s broad,<br>
1H); 9.71(m spread out, 1H); 10.6(m spread out, 1H);<br>
12.4(m spread out, 1H) .<br>
HPLC-MS-DAD-ELSD: 350(+) =(M+H)(+) .<br>
Example 49<br>
(5Z)-2-azepan-1-yl-5-{ [5-(trifluoromethyl)-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl]methylidene}-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-2-azepan-1-yl-5-{[5-(trifluoromethyl)-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl]methylidene}-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 70 mg of(5Z)-2-thioxo-5-{[5-(trifluoromethyl)-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl]methylidene}imidazolidin-4-<br>
one(Example 18) , 3 cm3 of ethanol and 222 mg of<br><br>
azepane. After fifty minutes at a temperature of 160C<br>
under microwave irradiation, then filtration of the<br>
solid, 22 mg of(5Z)-2-azepan-1-yl-5-{[5-<br>
(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl]methylidene}-3,5-dihydro-4H-imidazol-4-one is<br>
obtained in the form of a yellow powder with the<br>
following characteristics:<br>
Melting point: 340C.<br>
1H-NMR spectrum at 400 MHz: 1.53(m, 4H} ; 1.74(m<br>
broad, 4H) ; from 3.40 to 3.90(m spread out, 4H) ; 6.61<br>
(s, 1H); 8.18(s, 1H) ; 8.56(s broad, 1H) ; 9.77(m<br>
spread out, 1H); 11.1(m spread out, 1H) ; 12.4(m<br>
spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 378(+) =(M+H)(+); 376(-) =(M-H)(-).<br>
Example 50<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-{[5-(phenylamino)-<br>
lH-pyrrolo[2,3-b]pyridin-3-yl]methylidene}-3,5-dihydro-<br>
4H-imidazol-4-one<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-{[5-(phenylamino)-<br>
lH-pyrrolo[2,3-b]pyridin-3-yl]methylidene}-3,5-dihydro-<br>
4H-imidazol-4-one can be prepared as in Example 7, but<br>
from 70 mg of(5Z)-5-[(5-phenylamino-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one<br>
(Example 21), 1 cm3 of ethanol and 148 mg of 1-<br>
cyclopropylmethanamine. After thirty minutes at a<br>
temperature of 160C under microwave irradiation, the<br>
yellow solid precipitated in the reaction mixture is<br>
filtered to obtain 18 mg of(5Z)-5-[(5-phenylamino-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-<br>
thioxoimidazolidin-4-one in the form of orange powder<br>
with the following physical characteristics:<br><br>
1H-NMR spectrum at 400 MHz: 0.16(m, 2H); 0.39(m,	2H);<br>
1.01(m, 1H) ; 3.08(t, J = 6.0 Hz, 2H) ; 6.54(s,	1H) ;<br>
6.71(t, J.= 7.5 Hz, 1H) ; 6.93(d, J = 7.5 Hz,	2H) ;<br>
7.03(m spread out, 1H); 7.18(t, J = 7.5 Hz, 2H);	7.91<br>
(S, 1H); 8.05(s, 1H); 8.11(s, 1H); 8.50(s, 1H);	10.3<br>
(m spread out, 1H); 11.8(m spread out, 1H).<br>
LC-MS(1): retention time 3.55 min; HPLC-MS-DAD-ELSD:<br>
371(+) =(M+H)(+); 373(-) =(M-H)(-).<br>
Example 51<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-morpholin-4-yl-<br>
1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-<br>
4H-imidazol-4-one<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-morpholin-4-yl-<br>
1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-<br>
4H-imidazol-4-one can be prepared as in Example 7, but<br>
from 160 mg of(5Z)-5-[(5-morpholin-4-yl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-2-<br>
thioxoimidazolidin-4-one(Example 22), 2 cm3 of ethanol<br>
and 345 mg of 1-cyclopropylmethanamine. After one hour<br>
at a temperature of 160C under microwave irradiation,<br>
the yellow solid precipitated in the reaction mixture<br>
is filtered to obtain 100 mg of(5Z)-2-<br>
[(cyclopropylmethyl)amino]-5-[(5-morpholin-4-yl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one in the form of a yellow powder with the<br>
following physical characteristics:<br>
Melting point: 331C.<br>
1H-NMR spectrum at 400 MHz: 0.29(m, 2H); 0.48(m, 2H) ;<br>
1.12(m, 1H) ; 3.13(m, 4H) ; 3.22(t, J = 6.0 Hz, 2H) ;<br>
3.79(m, 4H) ; 6.61(s 1H) ,- 7.11(m broad, 1H) ; 8.08(m,<br><br>
2H); 8.38(s broad, 1H); 10.3(m spread out, 1H); 11.7(s broad, 1H).<br>
HPLC-MS-DAD-ELSD: 367=(M+H)(+); 365(-) =(M-H)(-).<br>
Example 52<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-thiophen-3-yl-<br>
1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-<br>
4H-imidazol-4-one<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-thiophen-3-yl-<br>
1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-<br>
4H-imidazol-4-one can be prepared as follows:<br>
A microwave oven reactor is charged with 150 mg of<br>
(5Z)-5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-[(cyclopropylmethyl)amino]-3,5-dihydro-<br>
4H-imidazol-4-one(Example 33), 4.8 cm3 of dioxan,<br>
1.2 cm3 of water, 80 mg of thiophene-3-boronic acid,<br>
54 0 mg of caesium carbonate and 15 mg of 1,1'-<br>
bis(diphenylphosphino)-ferrocenedichloropalladium(II).<br>
The reactor is sealed and irradiated for 2 x thirty<br>
minutes at 145C. After adding 80 mg of thiophene-3-<br>
boronic acid and 14 mg of catalyst, the reaction<br>
mixture is irradiated again for 30 minutes at 150C.<br>
The reaction mixture is concentrated under vacuum,<br>
taken up in 20 cm3 of water and 20 cm3 of ethyl acetate.<br>
85 mg of insoluble matter is filtered. The filtrate is<br>
decanted and re-extracted with ethyl acetate. The<br>
organic phases are dried over magnesium sulphate, then<br>
concentrated under vacuum to give 92 mg of a brown<br>
solid. The two solid residues isolated, containing the<br>
expected product, are combined and then purified by<br>
preparative LC-MS [Column Xterra RP18 30x100; 5u; with<br>
water buffered with 10 mM of ammonium hydrogen<br>
carbonate adjusted to pH 9 with ammonia / acetonitrile<br><br>
with gradient from 70/30 to 0/100 in 8 min]to obtain<br>
25 mg of(5Z)-(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-<br>
thiophen-3-yl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3,5-dihydro-4H-imidazol-4-one in the<br>
form of brown powder with the following physical<br>
characteristics:<br>
1H-NMR spectrum at 400 MHz: 0.29(m, 2H) ; 0.49(m, 2H) ;<br>
1.16(m, 1H) ; 3.27(m partially masked, 2H) ; 6.71(s,<br>
1H) ; 7.19(m broad, 1H) ; 7.69(m, 2H) ; 7.91(s broad,<br>
1H); 8.19(s broad, 1H); 8.64(d, J = 2.0 Hz, 1H); 9.07<br>
(s broad, 1H); 10.4(m spread out, 1H); 11.95(m spread<br>
out, 1H).<br>
HPLC-MS-DAD-ELSD: 358(+) =(M+H)(+); 356(-) =(M-H)(-).<br>
Example 53<br>
(5Z)-2-[(cyclopropylmethyl)amino]-5-{[5-(4-piperazin-1-<br>
ylphenyl)-1H-pyrrolo [2,3-b]pyridin-3-yl]methylidene}-<br>
3,5-dihydro-4H-imidazol-4-one<br>
a)	(5Z)-2-[(cyclopropylmethyl)amino]-5-{ [5-(4-<br>
piperazin-1-ylphenyl)-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl]methylidene}-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as follows:<br>
Stir 140 mg of 1,1-dimethylethyl 4-(4-{3-[(Z)-{2-<br>
[(cyclopropylmethyl)amino]-5-oxo-1,5-dihydro-4H-<br>
imidazol-4-ylidene}methyl]-1H-pyrrolo[2,3-b]pyridin-5-<br>
yl}phenyl)piperazine-1-carboxylate in 3 cm3 of a 4M<br>
solution of hydrochloric acid in dioxan for two hours<br>
at room temperature. The resultant precipitate is<br>
filtered, then purified on 5 g of column SCX with<br>
elution with methanol then with a 2M solution of<br>
ammonia in methanol, to obtain 22 mg of(5Z)-2-<br>
[(cyclopropylmethyl)amino]-5-{[5-(4-piperazin-1-<br><br>
ylphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]methylidene}-<br>
3,5-dihydro-4H-imidazol-4-one in the form of a yellow<br>
powder with the following physical characteristics:<br>
1H-NMR spectrum at 400 MHz: 0.25(m, 2H); 0.45(m, 2H);<br>
1.12(m, 1H) ; 2.91(m, 4H) ; 3.13(m, 4H) ; from 3.20 to<br>
3.40(m partially masked, 2H) ; 6.69(s, 1H) ; 7.01(d, J<br>
= 8.5 Hz, 2H) ; 7.15(m spread out, 1H) ; 7.61(d, J =<br>
8.5 Hz, 2H) ; 8.13(s, 1H) ; 8.48(d, J = 1.5 Hz, 1H) ;<br>
9.05(s broad, 1H) ; 10.35(m spread out,lH); 11.95(s<br>
broad, 1H).<br>
HPLC-MS-DAD-ELSD: 442(+) =(M+H)(+).<br>
b)	1,1-dimethylethyl	4-(4-{3-[(Z)-{2-<br>
[(cyclopropylmethyl)amino]-5-oxo-1,5-dihydro-4H-<br>
imidazol-4-ylidene}methyl]-1H-pyrrolo[2,3-b]pyridin-5-<br>
yl}phenyl)piperazine-1-carboxylate can be prepared as<br>
in Example 52, but from 80 mg of(5Z)-5-[(5-bromo-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-<br>
[(cyclopropylmethyl)amino]-3,5-dihydro-4H-imidazol-4-<br>
one(Example 33) in 2.4 cm3 of dioxan and 0.8 cm3 of<br>
water,	100 mg	of	(4-{4-[(1,1-<br>
dimethylethoxy)carbonyl]piperazin-1-yl}phenyl)boronic<br>
acid, 2 80 mg of caesium carbonate and 15 mg of 1,1'-<br>
bis(diphenylphosphino)ferrocenedichloropalladium(II).<br>
110 mg of 1,1-dimethylethyl 4-(4-{3-[(Z)-{2-<br>
[(cyclopropylmethyl)amino]-5-oxo-l,5-dihydro-4H-<br>
imidazol-4-ylidene}methyl]-1H-pyrrolo[2,3-b]pyridin-5-<br>
yl}phenyl)piperazine-1-carboxylate is obtained in the<br>
form of powder with the following physical<br>
characteristics:<br>
1H-NMR spectrum at 400 MHz: 0.25(s broad, 2H) ; 0.44(s<br>
broad, 2H); 1.12(s broad, 1H); 1.45(s, 9H); 3.17(m,<br>
4H) ; 3.27(partially masked, 2H) ; 3.49(m, 4H) ; 6.68<br><br>
(s, 1H); 7.06(d broad, J = 7.8 Hz, 2H); 7.17(s broad,<br>
1H) ; 7.64(d broad, J = 7.8 Hz, 2H) ; 8.14(s, 1H) ; 8.49<br>
(s, 1H); 9.05(s broad, 1H); 10.40(s broad, 1H); 11.94(s broad, 1H).<br>
Rf: 0.24(dichloromethane/ethyl acetate eluent 90/10) .<br>
LC-MS-DAD-ELSD: 540(-) =(M-H)(-); 542(+) =(M+H)(+) .<br>
Example 54<br>
(5Z)-5-[(5-benzyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(cyclopropylmethyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one<br>
(5Z)-5-[(5-benzyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yDmethylidene]-2-[(cyclopropylmethyl) amino]-3,5-<br>
dihydro-4H-imidazol-4-one can be prepared as in Example<br>
7, but from 60 mg of(5Z)-5-[(5-benzyl-1H-pyrrolo [2,3-<br>
b]pyridin-3-yl)methylidene]-2-thioxoimidazolidin-4-one<br>
(Example 23) , 1 cm3 of ethanol and 13 mg of 1-<br>
cyclopropylinethanamine. After thirty minutes at a<br>
temperature of 160C under microwave irradiation, then<br>
filtration of the solid, 31 mg of(5Z)-5-[(5-benzyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-2-<br>
[(cyclopropylmethyl)amino]-3,5-dihydro-4H-imidazol-4-<br>
one is obtained in the form of a yellow powder with the<br>
following characteristics:<br>
Melting point: 315-318C.<br>
1H-NMR spectrum at 400 MHz: 0.28(m, 2H); 0.47(m, 2H);<br>
1.14(m, 1H); 3.21(m, 2H); 4.03(s, 2H); 6.56(s, 1H);<br>
from 7.11 to 7.33(m, 5H) ; 8.11(s, 1H) ; 8.18(s, 1H) ;<br>
8.58(s, 1H); 10.1(m spread out, 1H); 11.85(m spread<br>
out, 1H).<br>
UPLC-MS-DAD-ELSD: 372(+) =(M+H)(+) ; 370(-) =(M-H)(-).<br><br>
Example 55<br>
(5Z)-2-amino-3-[3-(dimethylamino)propyl]-5-(1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-2-amino-3-[3-(dimethylamino)propyl]-5-(1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 351 mg of(5Z)-5-[(1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one(Example 1),<br>
2.5 cm3 of ethanol and 1.47 g of 3-dimethylamino-<br>
propylamine. After thirty minutes at a temperature of<br>
150C under microwave irradiation, then concentrating<br>
under vacuum and taking up the residue in methylene<br>
chloride, filtration of the solid gives 8 mg of(5Z)-2-<br>
amino-3-[3-(dimethylamino)propyl]-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one in the form of a yellow powder with the following<br>
characteristics:<br>
XH-NMR spectrum at 400 MHz: 1.67(m, 2H); 2.12(s, 6H) ;<br>
2.20(t, J = 7.0 Hz, 2H) ; 3.56(t, J = 7.0 Hz, 2H) ;<br>
6.71(s, 1H) ; 7.11(dd, J = 5.0 and 8.0 Hz, 1H) ; 7.33<br>
(s broad, 2H); 8.24(m, 2H); 8.59(dd, J = 1.5 and 8.0<br>
Hz, 1H) ; 12.0(s broad, 1H).<br>
UPLC-MS-DAD-ELSD: 313(+) =(M+H)(+); 311(-) =(M-H)(-).<br>
Example 56<br>
(5Z)-2-amino-3-(3-morpholin-4-ylpropyl)-5-(1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-2-amino-3-(3-morpholin-4-ylpropyl)-5-(1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br><br>
from 310 mg of(5Z)-5-[(1H-pyrrolo[2,3-b]pyridin-3-<br>
yl) methylene]-2-thioxoimidazolidin-4-one(Example 1),<br>
2.5 cm3 of ethanol and 310 mg of 3-<br>
morpholinopropylamine. After fifty minutes at a<br>
temperature of 160C under microwave irradiation, then<br>
filtration of the solid, 86 mg of(5Z)-2-amino-3-(3 -<br>
morpholin-4-ylpropyl)-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one	is<br>
obtained in the form of a yellow powder with the<br>
following characteristics:<br>
1H-NMR spectrum at 400 MHz: 1.67(m, 2H) ; 2.2-2.4(m,<br>
6H) ; 3.6(m, 6H) ; 6.7(s, 1H) ; 7.15(dd, J = 5.0 and<br>
8.0 Hz, 1H) ; 7.35(s broad, 2H) ; 8.25(m, 2H) ; 8.6(dd,<br>
J = 1.5 and 8.0 Hz, 1H); 12.0(s broad, 1H).<br>
HPLC-MS-DAD-ELSD: 355(+) =(M+H)(+).<br>
Example 57<br>
(5Z)-2-amino-3-(3-ethoxypropyl)-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one<br>
(5Z)-2-amino-3-(3-ethoxypropyl)-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 7, but from 350 mg of<br>
(5Z)-5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-<br>
thioxoimidazolidin-4-one(Example 1), 2.5 cm3 of<br>
ethanol and 3 50 mg of 3-ethoxypropyl amine. After fifty<br>
minutes at a temperature of 160C under microwave<br>
irradiation, then filtration of the solid, 28 mg of<br>
(5Z)-2-amino-3-(3-ethoxypropyl)-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one is obtained in the form of a yellow powder with the<br>
following characteristics:<br><br>
1H-NMR spectrum at 400 MHz: 1.12(t, J = 7 Hz, 3H) ;<br>
1.67'(m, 2H) ; 3.3-3.5(m, 4H) ; 3.65(t, J = 7 Hz, 2H) ;<br>
6.72(s, 1H) ; 7.15(dd, J = 5.0 and 8.0 Hz, 1H) ; 7.25<br>
(s broad, 2H); 8.25(s broad, 2H); 8.6(dd, J = 1.5 and<br>
8.0 Hz, 1H); 12.0(s broad, 1H).<br>
HPLC-MS-DAD-ELSD: 314(+) =(M+H)(+); 312(-) =(M-H)(-).<br>
Example 5 8<br>
(5Z)-2-amino-3-(3-pyrrolidin-1-ylpropyl)-5-(1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-2-amino-3-(3-pyrrolidin-1-ylpropyl)-5-(1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 366 mg of(5Z)-5-[(1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one(Example 1),<br>
2.5 cm3 of ethanol and 1.92 g of 3-(1-<br>
pyrrolidyl)propylamine. After fifty minutes at a<br>
temperature of 160C under microwave irradiation, then<br>
filtration of the solid, 58 mg of(5Z)-2-amino-3-(3-<br>
pyrrolidin-1-ylpropyl)-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one	is<br>
obtained in the form of a yellow powder with the<br>
following characteristics:<br>
1H-NMR spectrum at 400 MHz: 1.69(m, 6H) ; 2.39(t, J =<br>
6.5 Hz, 2H) ; 2.42(m, 4H) ; 3.59(t, J = 6. 5 Hz, 2H) ;<br>
6.71(s, 1H) ; 7.11(dd, J = 5.0 and 8.0 Hz, 1H) ; 7.40<br>
(s broad, 2H); 8.23(m, 2H); 8.59(d broad, J = 8.0 Hz,<br>
1H); 12.0(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 339(+) =(M+H)(+); 337(-) =(M-H)(-).<br>
Example 59<br><br>
(5Z)-2-[(cyclopropylmethyl)amino]-3-phenyl-5-(1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-2-[(cyclopropylmethyl)amino]-3-phenyl-5-(1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 128 mg of(5Z/E)-3-phenyl-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-2-thioxoimidazolidin-4-one<br>
(Example 24), 3.5 cm3 of ethanol and 284 mg of 1-<br>
cyclopropylmethanamine. After thirty minutes at a<br>
temperature of 160C under microwave irradiation and<br>
purification by preparative LC-MS [Column Xterra RP18<br>
30x100; 5u; with water buffered with 10 mM of ammonium<br>
hydrogen carbonate adjusted to pH 9 with ammonia /<br>
acetonitrile with gradient from 70/30 to 0/100 in 8<br>
min], 34 mg of(5Z)-2-[(cyclopropylmethyl)amino]-3-<br>
phenyl-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)-<br>
3,5-dihydro-4H-imidazol-4-one is obtained in the form<br>
of yellow lyophilizate with the following<br>
characteristics:<br>
1H-NMR spectrum at 400 MHz: 0.31(m, 2H) ; 0.47(m, 2H) ;<br>
1.23(m, 1H) ; 3.30(m partially masked, 2H) ; 6.84(s,<br>
1H) ; 7.00(t, J = 6.0 Hz, 1H) ; 7.13(dd, J = 5.0 and<br>
8.0 Hz, 1H); 7.35(d, J = 7.5 Hz, 2H) ; 7.50(t, J = 7.5<br>
Hz, 1H) ; 7.58(t, J = 7.5 Hz, 2H) ; 8.27(dd, J = 1.5<br>
and 5.0 Hz, 1H) ; 8.31(d, J = 2.0 Hz, 1H) ; 8.67(d<br>
broad, J = 8.0 Hz, 1H); 12.0(s broad, 1H).<br>
HPLC-MS-DAD-ELSD: 358(+) =(M+H)(+); 356(-) =(M-H)(-).<br>
Example 60<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-(methylsulphanyl)-3,5-dihydro-4H-<br>
imidazol-4-one<br><br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-(methylsulphanyl)-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as follows:<br>
Slowly add 0.86 cm3 of a molar solution of sodium<br>
hydroxide to a mixture of 200 mg of(5Z)-5-[(5-chloro-<br>
1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-<br>
thioxoimidazolidin-4-one(Example 3) and 122 mg of<br>
methyl iodide in 7 cm3 of methanol at 0C. Then stir<br>
the mixture at room temperature for two hours. The<br>
solid that forms is filtered, then dried under vacuum<br>
to obtain 175 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-2-(methylsulphanyl)-3,5-<br>
dihydro-4H-imidazol-4-one in the form of yellow powder<br>
with the following characteristics:<br>
Melting point: &gt;410C<br>
1H-NMR spectrum at 400 MHz: 2.71(s, 3H); 7.03(s, 1H);<br>
8.29(d, J = 2.0 Hz, 1H); 8.37(s, 1H); 9.31(s broad,<br>
1H); from 11.4 to 12.7(m very broad, 2H).<br>
HPLC-MS-DAD-ELSD: 293(+)/...=(M+H)(+) /...; 291(-)/...=(M-H)( -<br>
) /...(1 chlorine atom Cl present).<br>
Example 61<br>
(5Z)-2-(benzylsulphanyl)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one<br>
(5Z)-2-(benzylsulphanyl)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 60, but from 400 mg<br>
of	(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one(Example 3),<br>
270 mg of benzyl bromide, 14 cm3 of methanol at 0C and<br>
of 1.8 cm3 of a molar solution of sodium hydroxide.<br><br>
After two hours at room temperature, the solid formed<br>
is filtered to obtain 452 mg of(5Z)-2-(benzylsulphanyl)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one in the form of yellow powder with the following<br>
characteristics:<br>
Melting point: 313-315C.<br>
1H-NMR spectrum at 400 MHz: 4.63(s, 2H); 7.10(s, 1H);<br>
from 7.23 to 7.40(m, 3H); 7.51(d broad, J = 7.5 Hz,<br>
2H); 8.29(d, J = 2.5 Hz, 1H); 8.43(s, 1H); 9.20(d, J<br>
= 2.5 Hz, 1H); from 11.6 to 12.7(m very broad, 2H).<br>
HPLC-MS-DAD-ELSD: 3 69(+)/...=(M+H)(+)/...(1 chlorine atom<br>
Cl present).<br>
Example 62<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-(propylsulphanyl)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-(propylsulphanyl)-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 60, but<br>
from 200 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one<br>
(Example 3) , 146 mg of iodo-1-propane, 7 cm3 of<br>
methanol at 0C and 0.86 cm3 of a molar solution of<br>
sodium hydroxide. After stirring at room temperature<br>
overnight, the solid formed is filtered to obtain<br>
172 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-(propylsulphanyl)-3,5-dihydro-4H-<br>
imidazol-4-one in the form of yellow powder with the<br>
following characteristics:<br>
Melting point: 316-318C.<br><br>
1H-NMR spectrum at 400 MHz: 1.05(t, J = 7.6 Hz,	3H);<br>
1.83(sext, J = 7.6 Hz, 2H) ; 3.33(masked, 2H) ;	7.03<br>
(s, 1H) ; 8.2 9(d, J = 2.4 Hz, 1H) ; 8.3 3(s, 1H) ;	9.28<br>
(d, J = 2.4 Hz, 1H); 12.10(s broad, 1H).<br>
Example 63<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-((1-methyl)ethylsulphanyl)-3,5-<br>
dihydro-4H-imidazol-4-one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-((1-methyl)ethylsulphanyl)-3,5-<br>
dihydro-4H-imidazol-4-one can be prepared as in Example<br>
60, but from 200 mg of(5Z)-5-[(5-chloro-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-<br>
thioxoimidazolidin-4-one(Example 3), 146 mg of iodo-2-<br>
propane, 7 cm3 of methanol at 0C and 0.86 cm3 of a<br>
molar solution of sodium hydroxide. The mixture is<br>
stirred at 50 C overnight then at 70 C for an extra<br>
day. The solid formed is then filtered to obtain 90 mg<br>
of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-((1-methyl)ethylsulphanyl)-3,5-<br>
dihydro-4H-imidazol-4-one in the form of yellow powder<br>
with the following characteristics:<br>
Melting point: 291-293C.<br>
1H-NMR spectrum at 400 MHz: 1.52(d, J = 6.9 Hz, 6H) ;<br>
4.13(m, 1H) ; 7.03(s, 1H) ; 8.29(d, J = 2.4 Hz, 1H) ;<br>
8.32(s, 1H); 9.33(d, J = 2.4 Hz, 1H); 12.05(s broad,<br>
1H).<br>
Example 64<br>
(5Z)-2-butyl-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3,5-dihydro-4H-imidazol-4-one<br><br>
(5Z)-2-butyl-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as in Example 13, but from 131 mg of raw 2-<br>
butyl-imidazolidin-4-one and 135 mg of 5-chloro-1H-<br>
pyrrolo[2,3-b]pyridine-3-carbaldehyde to give 164 mg of<br>
(5Z)-2-butyl-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3,5-dihydro-4H-imidazol-4-one in the<br>
form of a yellow powder with the following<br>
characteristics:<br>
Melting point: 288-290C.<br>
1H-NMR spectrum at 400 MHz: 0.97(t, J = 7.5 Hz, 3H) ;<br>
1.42(m, 2H) ; 1.78(m, 2H) ; 2.57(t, J = 7.5 Hz, 2H) ;<br>
7.13(s, 1H) ; 8.29(d, J = 2.5 Hz, 1H) ; 8.33(s, 1H) ;<br>
9.38(d, J = 2.5 Hz, 1H) ; 11.1(s broad, 1H) ; 12.5(m<br>
spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 303(+) =(M+H)(+).<br>
Example 65<br>
(5Z)-2-butyl-5-[(6-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3,5-dihydro-4H-imidazol-4-one<br>
(5Z)-2-butyl-5-[(6-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as in Example 13, but from 87 mg of raw 2-<br>
butyl-imidazolidin-4-one and 90 mg of 6-chloro-1H-<br>
pyrrolo[2,3-b]pyridine-3-carbaldehyde to give 85 mg of<br>
(5Z)-2-butyl-5-[(6-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3,5-dihydro-4H-imidazol-4-one in the<br>
form of a yellow powder with the following<br>
characteristics:<br>
Melting point: 318-321C.<br><br>
1H-NMR spectrum at 400 MHz: 0.94(t, J = 7.5 Hz, 3H);<br>
1.40(m, 2H) ; 1.71(m, 2H) ; 2.54(t, J = 7.5 Hz, 2H) ;<br>
7.13(s, 1H) ; 7.24(d, J = 8.0 Hz, 1H) ; 8.31(s, 1H) ;<br>
9.07(d, J = 8.0 Hz, 1H) ; 11.1(s broad, 1H) ; 12.5(m<br>
spread out, 1H).<br>
SM-EI: 302(+.) =(M)(+.); 260(+) =(M-C3H6)(+).<br>
Example 66<br>
(5Z)-2-butyl-3-methyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one<br>
a)(5Z)-2-butyl-3-methyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as in Example 13, but from 0.63 g of 2-butyl-<br>
3-methyl-3,5-dihydro-4H-imidazol-4-one, 200 mg of 1H-<br>
pyrrolo[2,3-b]pyridine-3-carbaldehyde and 0.14 cm3 of<br>
piperidine in 10 cm3 of ethanol. After one hour under<br>
reflux, the mixture is cooled to room temperature and<br>
the yellow solid is filtered, washed with a little<br>
ethanol then dried under vacuum to give 323 mg of(5Z)-<br>
2-butyl-3-methyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one in the<br>
form of a yellow powder with the following<br>
characteristics:<br>
Melting point: 220-222C.<br>
1H-NMR spectrum at 400 MHz: 0.99(t, J = .7.0 Hz, 3H) ;<br>
1.50(m, 2H) ; 1.80(m, 2H) ; 2.68(t, J = 7.0 Hz, 2H) ;<br>
3.10(s, 3H) ; 7.19(dd, J = 5.0 and 8.0 Hz, 1H) ; 7.29<br>
(s, 1H) ; 8.2 9(dd, J = 1.5 and 5.0 Hz, 1H) ; 8.3 8(s,<br>
1H) ; 9.01(d broad, J = 8.0 Hz, 1H) ; 12.4(m spread<br>
out, 1H) .<br>
HPLC-MS-DAD-ELSD: 283(+) =(M+H)(+) ; 281(-) =(M-H)(-).<br><br>
b)	2-butyl-3-methyl-3,5-dihydro-4H-imidazol-4-one can<br>
be prepared as follows:<br>
Slowly add a 2M solution of methylamine in THF(12 cm3)<br>
to a solution of 1.99 g of N-(1-<br>
methoxypentylidene)methylglycinate in 20 cm3 of<br>
methanol. Stir the mixture at room temperature for<br>
three hours, then concentrate under vacuum to obtain<br>
1.63 g of raw 2-butyl-3-methyl-3,5-dihydro-4H-imidazol-<br>
4-one, which is used as such in the next stage.<br>
c)	N-(1-methoxypentylidene)methylglycinate can be<br>
prepared as follows:<br>
Stir a suspension of 2 g of methyl pentanimidoate<br>
hydrochloride and 1.67 g of methyl glycinate<br>
hydrochloride in 2 0 cm3 of methylene chloride at 0C<br>
for five hours, then add 1.8 cm3 of triethylamine. Stir<br>
the resultant mixture at room temperature for one hour,<br>
dilute with 10 cm3 of phosphate buffer pH 7, then<br>
extract with methylene chloride(3x2 0 cm3) . The<br>
combined organic phases are dried over magnesium<br>
sulphate and concentrated under vacuum to obtain 1.99 g<br>
of N-(1-methoxypentylidene)methylglycinate.<br>
Example 67<br>
(5Z)-2-(2-Phenylethyl)-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one<br>
a)(5Z)-2-(2-phenylethyl)-5-(1H-pyrrolo[2,3-b]pyridin-<br>
3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as in Example 13, but from 1 g of raw 2-(2-<br>
phenylethyl)-3,5-dihydro-4H-imidazol-4-one and 0.2 g of<br>
lH-pyrrolo [2,3-b]pyridine-3-carbaldehyde to give 244 mg<br>
of(5Z)-2-(2-phenylethyl)-5-(1H-pyrrolo[2,3-b]pyridin-<br>
3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-one in the<br><br>
form of a yellow powder with the following<br>
characteristics:<br>
Melting point: 270-272C.<br>
1H-NMR spectrum at 400 MHz: 2.88(t, J = 7.5 Hz, 2H) ;<br>
3.09(t, J = 7.5 Hz, 2H) ; 7.18(s, 1H) ; 7.20(m, 2H) ;<br>
7.31(m, 4H); 8.29(dd, J = 1.5 and 5.0 Hz, 1H); 8.35<br>
(s, 1H); 8.89(d broad, J = 8.0 Hz, 1H); 11.2(m spread<br>
out, 1H); 12.4(m very broad, 1H).<br>
HPLC-MS-DAD-ELSD: 317(+) =(M+H)(+); 315(-) =(M-H)(-).<br>
b)	2-(2-phenylethyl)-3,5-dihydro-4H-imidazol-4-one can<br>
be prepared as in Example 13, but from 2 g of methyl 3-<br>
phenylpropanimidoate hydrochloride to obtain 2.85 g of<br>
raw 2-(2-phenylethyl)-3,5-dihydro-4H-imidazol-4-one.<br>
c)	Methyl 3-phenylpropanimidoate hydrochloride can be<br>
prepared as in Example 13, but from 5 cm3 of 2-<br>
phenylethyl carbonitrile, 1.7 cm3 of methanol and 4 cm3<br>
of ether. 7.5 g of methyl 3-phenylpropanimidoate<br>
hydrochloride is obtained in the form of a white solid.<br>
Example 68<br>
(5Z)-2-(3-methylbutyl)-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one<br>
a)(5Z)-2-(3-methylbutyl)-5-(1H-pyrrolo[2,3-b]pyridin-<br>
3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as in Example 13, but from 105 mg of raw 2-(3-<br>
methylbutyl)-3,5-dihydro-4H-imidazol-4-one and 0.2 g of<br>
lH-pyrrolo[2,3-b]pyridine-3-carbaldehyde to give 64 mg<br>
of(5Z)-2-(3-methylbutyl)-5-(1H-pyrrolo[2,3-b]pyridin-<br>
3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-one in the<br>
form of a yellow powder with the following<br>
characteristics:<br><br>
Melting point: 274C.<br>
1H-NMR spectrum at 400 MHz: 0.93(d, J = 7.5 Hz, 6H) ;<br>
1.63(m, 3H) ; 2.54(t, J = 7.5 Hz, 2H) ; 7.15(s, 1H) ;<br>
7.19(dd, J = 5.0 and 8.0 Hz, 1H) ; 8.29(dd, J = 1.5<br>
and 5.0 Hz, 1H) ; 8.33(s, 1H) ; 8.91(d broad, J = 8.0<br>
Hz, 1H); 11.05(s broad, 1H); 12.3(s broad, 1H).<br>
HPLC-MS-DAD-ELSD: 283(+) =(M+H)(+); 281(-) =(M-H)(-).<br>
b)	2-(3-Methylbutyl)-3,5-dihydro-4H-imidazol-4-one can<br>
be prepared as in Example 13, but from 3 g of methyl 4-<br>
methyl pentemimidoate hydrochloride to obtain 2.0 g of<br>
raw 2-(3-methylbutyl)-3,5-dihydro-4H-imidazol-4-one.<br>
c)	Methyl 4-methyl pentanimidoate hydrochloride can be<br>
prepared as in Example 13, but from 12.5 cm3 of 3-<br>
methylbutyl carbonitrile, 4.6 cm3 of methanol and 5 cm3<br>
of ether. 2 0.7 g of methyl 4-methyl pentanimidoate<br>
hydrochloride is obtained in the form of a white solid.<br>
Example 69<br>
(5Z)-2-cyclohexyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one<br>
a)(5Z)-2-cyclohexyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as in Example 13, but from 2 96 mg of raw 2-<br>
cyclohexyl-3,5-dihydro-4H-imidazol-4-one and 0.13 g of<br>
lH-pyrrolo[2,3-b]pyridine-3-carbaldehyde to give 135 mg<br>
of 5Z)-2-cyclohexyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one in the<br>
form of a yellow powder with the following<br>
characteristics:<br>
Melting point: 322C.<br><br>
1H-NMR spectrum at 400 MHz: from 1.20 to 1.42(m, 3H);<br>
1.53(m, 2H); 1.69(m, 1H); 1.80(m, 2H); 1.99(m, 2H);<br>
2.54(m partially masked, 1H) ; 7.18(s, 1H) ; 7.20(dd,<br>
J = 5.0 and 8.0 Hz, 1H) ; 8.29(dd, J = 1.5 and 5.0 Hz,<br>
1H); 8.34(s, 1H); 8.93(d broad, J = 8.0 Hz, 1H); 11.1<br>
(m spread out, 1H); 12.3(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 364(+) =(M+H)(+); 362(-) =(M-H)(-).<br>
b)	2-Cyclohexyl-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as in Example 13, but from 704 mg of methyl<br>
cyclohexanecarboximidoate hydrochloride to obtain 1.2 g<br>
of raw 2-cyclohexyl-3,5-dihydro-4H-imidazol-4-one.<br>
c)	Methyl cyclohexanecarboximidoate hydrochloride is<br>
prepared according to Synlett 2001, 11, 1707-1710.<br>
Gaseous hydrogen chloride is bubbled for 12 0 min in a<br>
solution of 10 cm3 of cyclohexane carbonitrile in<br>
5.4 cm3 of methanol and 3 0 cm3 of heptane cooled to 0C.<br>
The mixture is stirred for one hour at 0C then put in<br>
the freezer. After forty-eight hours, the white solid<br>
formed is filtered, washed with heptane, then dried<br>
under vacuum to obtain 12.0 g of methyl<br>
cyclohexanecarboximidoate hydrochloride in the form of<br>
a white solid.<br>
Example 70<br>
(5Z)-2-cyclohexyl-3-methyl-5-(1H-pyrrolo[2,3-b]pyridin-<br>
3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-one<br>
a)	(5Z) -2-cyclohexyl-3-methyl-5-(1H-pyrrolo [2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 13, but from 493 mg<br>
of raw 2-cyclohexyl-3-methyl-3,5-dihydro-4H-imidazol-4-<br>
one and- 0.16 g of lH-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde to give 144 mg of(5Z)-2-cyclohexyl-3-<br><br>
methyl-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)-<br>
3,5-dihydro-4H-imidazol-4-one in the form of a yellow<br>
powder with the following characteristics:<br>
Melting point: 261-262C.<br>
1H-NMR spectrum at 400 MHz: from 1.22 to 1.49(m, 3H) ;<br>
1.58(m, 2H); 1.72(m, 1H); 1.83(m, 2H); 1.99(m, 2H) ;<br>
2.71(tt, J = 3.5 and 11.0 Hz, 1H) ; 3.13(s, 3H) ; 7.21<br>
(dd, J = 5.0 and 8.0 Hz, 1H); 7.30(s, 1H); 8.30(dd, J<br>
= 1.5 and 5.0 Hz, 1H) ; 8.3 9(s, 1H) ; 8.99(d broad, J =<br>
8.0 Hz, 1H); 12.4(m spread out, 1H).<br>
UPLC-MS-DAD-ELSD: 309(+) =(M+H)(+) .<br>
b)	2-cyclohexyl-3-methyl-3,5-dihydro-4H-imidazol-4-one<br>
can be prepared as in Example 66, but from 1 g of N-<br>
[cyclohexyl(methoxy)methylidene]methylglycinate to<br>
obtain 1.07 g of 2-cyclohexyl-3-methyl-3,5-dihydro-4H-<br>
imidazol-4-one.<br>
c)	N-[cyclohexyl(methoxy)methylidene]methylglycinate<br>
can be prepared as in Example 66, but from 1 g of<br>
methyl cyclohexanecarboximidoate hydrochloride and<br>
0.71 g of methyl glycinate hydrochloride to obtain<br>
1.09 g of N-<br>
[cyclohexyl(methoxy)methylidene]methylglycinate.<br>
Example 71<br>
(5Z)-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)-2-<br>
(tetrahydro-2H-pyran-4-yl)-3, 5-dihydro-4H-imidazol-4-<br>
one<br>
a)(5Z)-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)-2-<br>
(tetrahydro-2H-pyran-4-yl)-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 13, but from 690 mg<br>
of raw 2-(tetrahydro-2H-pyran-4-yl)-3,5-dihydro-4H-<br><br>
imidazol-4-one and 0.2g of 1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde to give 283 mg of(5Z)-5-(1H-pyrrolo [2,3-<br>
b]pyridin-3-ylmethylidene)-2-(tetrahydro-2H-pyran-4-<br>
yl)-3,5-dihydro-4H-imidazol-4-one in the form of a<br>
yellow powder with the following characteristics:<br>
Melting point: 317-319C.<br>
1H-NMR spectrum at 400 MHz: 1.79(m, 2H) ; 1.91(m, 2H) ;<br>
2.82(tt, J = 3.5 and 11.0 Hz, 1H); 3.45(m, 2H); 3.94<br>
(m, 2H) ; 7.20(m, 2H) ; 8.29(dd, J = 1.5 and 5.0 Hz,<br>
1H); 8.36(s, 1H); 8.95(d broad, J = 8.0 Hz, 1H); 11.2<br>
(s broad, 1H); 12.4(s broad, 1H).<br>
HPLC-MS-DAD-ELSD: 297(+) =(M+H)(+); 295(-) =(M-H)(-).<br>
b)	2-(tetrahydro-2H-pyran-4-yl)-3, 5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 13, but<br>
from 2 g of methyl tetrahydro-2H-pyran-4-carboximidoate<br>
hydrochloride to obtain 3.2 g of raw 2-(tetrahydro-2H-<br>
pyran-4-yl)-3,5-dihydro-4H-imidazol-4-one.<br>
c)	Methyl tetrahydro-2H-pyran-4-carboximidoate can be<br>
prepared as in Example 13, but from 3 g of<br>
tetrahydropyran-4-carbonitrile, 1.2 cm3 of methanol and<br>
6 cm3 of ether. 4.4 g of methyl tetrahydro-2H-pyran-4-<br>
carboximidoate hydrochloride is obtained in the form of<br>
a white solid.<br>
d)	Tetrahydropyran-4-carbonitrile can be prepared as<br>
follows:<br>
Slowly add 10 cm3 of thionyl chloride to 3 g of<br>
tetrahydropyran-4-carboxamide cooled on an ice bath.<br>
Heat the mixture at 80 C for two hours, then<br>
concentrate under vacuum. Take up the residue in 20 cm3<br>
of water and adjust the pH of the solution to pH 7 with<br><br>
potassium hydroxide. Extract the aqueous phase with<br>
ethyl acetate(4x5 0 cm3). The combined organic phases<br>
are washed with water(2x50 cm3), dried over magnesium<br>
sulphate, and then concentrated under vacuum to obtain<br>
2.47 g of tetrahydropyran-4-carbonitrile.<br>
e) Tetrahydropyran-4-carboxamide is prepared according<br>
to J. Chem. Soc. 1930, 2525-2530.<br>
Example 72<br>
(5Z)-5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3-<br>
methyl-2-(tetrahydro-2H-pyran-4-yl)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
a)	(5Z)-5-[(1H-pyrrolo [2,3-b]pyridin-3-yl)methylidene]-<br>
3-methyl-2-(tetrahydro-2H-pyran-4-yl)-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 13, but<br>
from 748 mg of raw 2-(tetrahydro-2H-pyran-4-yl)-3-<br>
methyl-imidazolidin-4-one and 0.2 g of 1H-pyrrolo[2,3-<br>
b]	pyridine-3-carbaldehyde, to give 193 mg of(5Z)-5-<br>
[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3-methyl-<br>
2-(tetrahydro-2H-pyran-4-yl)-3,5-dihydro-4H-imidazol-4-<br>
one in the form of a yellow powder with the following<br>
characteristics:<br>
Melting point: 283-285C.<br>
1H-NMR spectrum at 400 MHz: from 1.53 to 1.93(m, 4H) ;<br>
3.03(m, 1H); 3.16(s, 3H); 3.51(m, 2H); 3.99(m, 2H);<br>
7.21(dd, J = 5.0 and 8.0 Hz, 1H) ; 7.32(s, 1H) ; 8.29<br>
(dd, J = 1.5 and 5.0 Hz, 1H) ; 8.39(s, 1H) ; 9.01(d<br>
broad, J = 8.0 Hz, 1H); 12, 3(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 311(+) =(M+H)(+); 309(-) =(M-H)(-).<br>
b) 2-(tetrahydro-2H-pyran-4-yl)-3-methyl-imidazolidin-<br>
4-one can be prepared as in Example 66, but from 2.55 g<br><br>
of	N-[methoxy(tetrahydro-2H-pyran-4-<br>
yl)methylidene]methylglycinate, to obtain 2.03 g of 2-<br>
(tetrahydro-2H-pyran-4-yl)-3-methyl-imidazolidin-4-one.<br>
c)	N-[methoxy(tetrahydro-2H-pyran-4-<br>
yl)methylidene]methylglycinate can be prepared as in<br>
Example 66, but from 2 g of methyl tetrahydro-2H-pyran-<br>
4-carboximidoate hydrochloride and 1.41 g of methyl<br>
glycinate hydrochloride, to obtain 2.55 g of N-<br>
[methoxy(tetrahydro-2H-pyran-4-<br>
yl) methylidene]methylglycinate.<br>
Example 73<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-<br>
3,5-dihydro-4H-imidazol-4-one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-<br>
3,5-dihydro-4H-imidazol-4-one can be prepared as in<br>
Example 13, but from 303 mg of raw 2-(tetrahydro-2H-<br>
pyran-4-yl)-3-methyl-imidazolidin-4-one(Example 72)<br>
and 0.1 g of 5-chloro-1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde to give 130 mg of(5Z)-5-[(5-chloro-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3-methyl-2-<br>
(tetrahydro-2H-pyran-4-yl)-3,5-dihydro-4H-imidazol-4-<br>
one in the form of a yellow powder with the following<br>
characteristics:<br>
Melting point: 338C.<br>
1H-NMR spectrum at 400 MHz: from 1.75 to 1.97	(m, 4H) ;<br>
3.06(m, 1H); 3.17(s, 3H); 3.52(m, 2H); 3.99	(m,	2H);<br>
7.31(s, 1H) ; 8.29(d, J = 2.0 Hz, 1H) ; 8.39	(s,	1H) ;<br>
9.48(s broad, 1H); 12.65(m spread out, 1H).<br><br>
HPLC-MS-DAD-ELSD: 345(+)/...=(M+H)(+) /...; 343(-)/...=(M-H)( -<br>
)/...(1 chlorine atom Cl present).<br>
Example 74<br>
(5Z)- 2 -(2-methylpropyl)-5-(1H-pyrrolo[2,3-b]pyridin-3 -<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one<br>
a)	(5Z)-2-(2-methylpropyl)-5-(1H-pyrrolo[2,3-b]pyridin-<br>
3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as in Example 13, but from 575 mg of raw 2-(2-<br>
methylpropyl)-3,5-dihydro-4H-imidazol-4-one and 0.2 g<br>
of lH-pyrrolo[2,3-b]pyridine-3-carbaldehyde to give<br>
99 mg of(5Z)-2-(2-methylpropyl)-5-(1H-pyrrolo [2,3 -<br>
b]	pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one in the form of a yellow powder with the following<br>
characteristics:<br>
Melting point: 292-293C.<br>
1H-NMR spectrum at 400 MHz: 1.00(d, J = 7.0 Hz, 6H) ;<br>
2.18	 (m, 1H) ; 2.41(d, J = 7.0 Hz, 2H) ; 7.17(s, 1H) ;<br>
7.18	 (dd, J = 5.0 and 8.0 Hz, 1H) ; 8.29(dd, J = 1.5<br>
and 5.0 Hz, 1H) ; 8.34(s, 1H) ; 8.89(d broad, J = 8.0<br>
Hz, 1H); 11.1(s broad, 1H); 12.35(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 269(+) =(M+H)(+); 267(-) =(M-H)(-).<br>
b)	2-(2-methylpropyl)-3,5-dihydro-4H-imidazol-4-one can<br>
be prepared as in Example 13, but from 2 g of methyl 3-<br>
methylbutanimidoate hydrochloride to obtain 1.5 g of<br>
raw 2-(2-methylpropyl)-3,5-dihydro-4H-imidazol-4-one.<br>
c)	Methyl 3-methylbutanimidoate hydrochloride can be<br>
prepared as in Example 13, but from 3.1 cm3 of 2-<br>
methyl-propyl carbonitrile, 1.3 cm3 of methanol and<br>
4 cm3 of ether. 4.0 g of methyl 3-methylbutanimidoate<br>
hydrochloride is obtained in the form of a white solid.<br><br>
Example 75<br>
(5Z)-3-methyl-2-(2-methylpropyl)-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one<br>
a)(5Z)-3-methyl-2-(2-methylpropyl)-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 13, but from 466 mg<br>
of raw 3-methyl-2-(2-methylpropyl)-3,5-dihydro-4H-<br>
imidazol-4-one and 0.17 g of lH-pyrrolo[2,3-b]pyridine-<br>
3-carbaldehyde, to give 82 mg of(5Z) -3-methyl-2-(2-<br>
methylpropyl)-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one in the<br>
form of a yellow powder with the following<br>
characteristics:<br>
Melting point: 201C.<br>
1H-NMR spectrum at 400 MHz: 1.07(d, J = 7.5 Hz, 6H) ;<br>
2.27(m, 1H) ; 2.56(d, J = 7.5 Hz, 2H) ; 3.10(s, 3H) ;<br>
7.19(dd, J = 5.0 and 8.0 Hz, 1H) ; 7.29(s, 1H) ; 8.29<br>
(dd, J = 1.5 and 5.0 Hz, 1H) ; 8.38(s, 1H) ; 8.98(d<br>
broad, J = 8.0 Hz, 1H); 12.4(m spread out, 1H).<br>
UPLC-MS-DAD-ELSD: 283(+) =(M+H)(+); 281(-) =(M-H)(-).<br>
b)	3-methyl-2-(2-methylpropyl)-3,5-dihydro-4H-imidazol-<br>
4-one can be prepared as in Example 66, but from 1.16 g<br>
of N-(1-methoxy-3-methylbutylidene)methylglycinate, to<br>
obtain 901 mg of 3-methyl-2-(2-methylpropyl)-3,5-<br>
dihydro-4H-imidazol-4-one.<br>
c)	N-(1-methoxy-3-methylbutylidene)methylglycinate can<br>
be prepared CLS in Example 66, but from 959 mg of methyl<br>
3-methylbutanimidoate hydrochloride and 8 02 mg of<br>
methyl glycinate hydrochloride to obtain 1.18 g of N-<br>
(1-methoxy-3-methylbutylidene)methylglycinate.<br><br>
Example 76<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-(2-methylpropyl)-3,5-<br>
dihydro-4H-imidazol-4-one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-(2-methylpropyl)-3,5-<br>
dihydro-4H-imidazol-4-one can be prepared as in Example<br>
13, but from 420 mg of raw 3-methyl-2-(2-methylpropyl)-<br>
3,5-dihydro-4H-imidazol-4-one(Example 75) and 0.2 g of<br>
5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde to<br>
give 220 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3-methyl-2-(2-<br>
methylpropyl)-3,5-dihydro-4H-imidazol-4-one in the form<br>
of a yellow powder with the following characteristics :<br>
Melting point: 282C.<br>
1H-NMR spectrum at 400 MHz: 1.11(d, J = 7.5 Hz,	6H) ;<br>
2.33(m, 1H) ; 2.59(d, J = 7.0 Hz, 2H) ; 3.10(s,	3H) ;<br>
7.29(s, 1H) ; 8.30(d, J = 2.0 Hz, 1H) ; 8.38(s,	1H) ;<br>
9.46(d broad, J = 2.0 Hz, 1H) ; 12.6(m spread	out,<br>
1H) .<br>
HPLC-MS-DAD-ELSD: 317(+)/...=(M+H)(+)/...; 315(-)/...=(M-H)( -<br>
)/...(1 chlorine atom Cl present) .<br>
Example 77<br>
(5Z)-2-(cyclopropylmethyl)-5-(1H-pyrrolo[2,3-b]pyridin-<br>
3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-one<br>
a)	(5Z)-2-(cyclopropylmethyl)-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 13, but from 354 mg<br>
of raw 2-(cyclopropylmethyl)-3,5-dihydro-4H-imidazol-4-<br>
one and 0.2 g of 1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde to give 142 mg of(5Z) -2-<br><br>
(cyclopropylmethyl)-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one in the<br>
form of a yellow powder with the following<br>
characteristics:<br>
Melting point: 289C.<br>
1H-NMR spectrum at 400 MHz: 0.29(m, 2H) ; 0.55(m, 2H) ;<br>
1.14(m, 1H) ; 2.45(d, J = 7.5 Hz, 2H) ; 7.19(m, 2H) ;<br>
8.29(dd; J = 1.5 and 5.5 Hz, 1H) ; 8.34(s, 1H) ; 8.98<br>
(dd, J = 1.5 and 8.0 Hz, 1H); 11.1(s broad, 1H); 12.35<br>
(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 267(+) =(M+H)(+); 265(-) =(M-H)(-).<br>
b)	2-(cyclopropylmethyl)-3,5-dihydro-4H-imidazol-4-one<br>
can be prepared as in Example 13, but from 2 g of<br>
methyl 2-cyclopropylethanimidoate hydrochloride to<br>
obtain 2.5 g of raw 2-(cyclopropylmethyl)-3,5-dihydro-<br>
4H-imidazol-4-one.<br>
c)	Methyl 2-cyclopropylethanimidoate hydrochloride can<br>
be prepared as in Example 13, but from 10 cm3 of<br>
cyclopropylmethyl carbonitrile, 4.7 cm3 of methanol and<br>
10 cm3 of ether. 18.2 g of methyl 2-<br>
cyclopropylethanimidoate hydrochloride is obtained in<br>
the form of a white solid.<br>
Example 78<br>
(5Z)-2-(cyclopropylmethyl)-5-(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one<br>
(5Z)-2-(cyclopropylmethyl)-5-(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 13, but from 144 mg<br>
of raw 2-(cyclopropylmethyl)-3,5-dihydro-4H-imidazol-4-<br><br>
one(Example 77) and 0.1 g of 5-chloro-1H-pyrrolo [2,3 -<br>
b]pyridine-3-carbaldehyde to give 47 mg of(5Z)-2-<br>
(cyclopropylmethyl)-5-(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one in the form of a yellow powder with the following<br>
characteristics:<br>
Melting point: 295-296C.<br>
1H-NMR spectrum at 400 MHz: 0.30(m, 2H) ; 0.60(m, 2H) ;<br>
1.17(m, 1H) ; 2.48(m partially masked, 2H) ; 7.17(s,<br>
1H) ; 8.29(d, J = 2.0 Hz, 1H) ; 8.35(s, 1H) ; 9.42(s<br>
broad, 1H) ; 11.15(s broad, 1H) ; 12.5(m spread out,<br>
1H) .<br>
HPLC-MS-DAD-ELSD: 301(+)/...=(M+H)(+)/...; 299(-)/...=(M-H)( -<br>
)/...(1 chlorine atom Cl present) .<br>
Example 79<br>
(5Z)-2-(1-methylethyl)-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one<br>
a)(5Z)-2-(1-methylethyl)-5-(1H-pyrrolo[2,3-b]pyridin-<br>
3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as in Example 13, but from 324 mg of raw 2-(1-<br>
methylethyl)-3,5-dihydro-4H-imidazol-4-one and 0.2 g of<br>
lH-pyrrolo[2,3-b]pyridine-3-carbaldehyde, to give<br>
140 mg of(5Z)-2-(1-methylethyl)-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one in the form of a yellow powder with the following<br>
characteristics:<br>
Melting point: 309-310C.<br>
1H-NMR spectrum at 400 MHz: 1.29(d, J = 7.0 Hz, 6H) ;<br>
2.81(m, 1H) ; 7.18(s, 1H) ; 7.20(dd, J = 5.0 and 8.0<br>
Hz, 1H) ; 8.29(dd, J = 1.5 and 5.0 Hz, 1H) ; 8.34(s,<br><br>
1H) ; 8.98(d broad, J = 8.0 Hz, 1H) ; 11.15(m spread<br>
out, 1H); 12.35(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 255(+) =(M+H)(+); 253(-) =(M-H)(-).<br>
b)	2-(1-methylethyl)-3,5-dihydro-4H-imidazol-4-one can<br>
be prepared as in Example 13, but from 2 g of methyl 2-<br>
methylpropanimidoate hydrochloride to obtain 1.5 g of<br>
raw 2-(1-methylethyl)-3,5-dihydro-4H-imidazol-4-one.<br>
c)	Methyl 2-methylpropanimidoate hydrochloride can be<br>
prepared as in Example 13, but from 10 cm3 of isopropyl<br>
carbonitrile, 5 cm3 of methanol and 10 cm3 of ether.<br>
17 g of methyl 2-methylpropanimidoate hydrochloride is<br>
obtained in the form of a white solid.<br>
Example 80<br>
(5Z)-2-(1-methylethyl)-5-(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one<br>
(5Z)-2-(1-methylethyl)-5-(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 13, but from 131 mg<br>
of raw 2-(1-methylethyl)-3,5-dihydro-4H-imidazol-4-one<br>
(Example 79) and 0.1 g of 5-chloro-1H-pyrrolo[2,3-<br>
b]pyridine-3-carbaldehyde to give 116 mg of(5Z)-2-(1-<br>
methylethyl)-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one in the<br>
form of a yellow powder with the following<br>
characteristics:<br>
Melting point: 277-280C.<br>
1H-NMR spectrum at 400 MHz: 1.30(d, J = 7.5 Hz, 6H) ;<br>
2.81(m, 1H) ; 7.15(s, 1H) ; 8.29(d, J = 2.0 Hz, 1H) ;<br><br>
8.32(s, 1H); 9.47(d broad, J = 2.0 Hz, 1H); 11.15(s<br>
broad, 1H); 12.55(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 289(+)/...=(M+H)(+)/...; 287(-)/...=(M-H)(-<br>
)/...(1 chlorine atom Cl present) .<br>
Example 81<br>
(5Z)-3-methyl-2-(1-methylethyl)-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one<br>
a)(5Z)-3-methyl-2-(1-methylethyl)-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 13, but from 437 mg<br>
of raw 3-methyl-2-(1-methylethyl)-3,5-dihydro-4H-<br>
imidazol-4-one and 0.19 g of lH-pyrrolo[2,3-b]pyridine-<br>
3-carbaldehyde to give 163 mg of(5Z)-3-methyl-2-(1-<br>
methylethyl)-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one in the<br>
form of a yellow powder with the following<br>
characteristics:<br>
Melting point: 222-224C.<br>
1H-NMR spectrum at 400 MHz: 1.31(d, J = 7.0 Hz, 6H) ;<br>
3.02(m, 1H) ; 3.15(s, 3H) ; 7.20(dd, J = 5.0 and 8.0<br>
Hz, 1H) ; 7.31(s, 1H) ; 8.2 9(dd, J = 1.5 and 5.0 Hz,<br>
1H) ; 8.3 9(s, 1H); 9.05(d broad, J = 8.0 Hz, 1H) ; 12.4<br>
(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 269(+) =(M+H)(+) ; 267(-) =(M-H)(-).<br>
b) 3-methyl-2-(1-methylethyl)-3,5-dihydro-4H-imidazol-<br>
4-one can be prepared as in Example 66, but from 1 g of<br>
N-(1-methoxy-2-methylpropylidene)methylglycinate, to<br>
obtain 789 mg of 3-methyl-2-(1-methylethyl)-3,5-<br>
dihydro-4H-imidazol-4-one.<br><br>
c) N-(1-methoxy-2-methylpropylidene)methylglycinate can<br>
be prepared as in Example 66, but from 870 mg of methyl<br>
2-methylpropanimidoate hydrochloride and 802 mg of<br>
methyl glycinate hydrochloride to obtain 1 g of N-(1-<br>
methoxy-2-methylpropylidene)methylglycinate.<br>
Example 82<br>
(5Z)-5-[(5-chloro-1H-pyrrolo [2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-(1-methylethyl)-3,5-dihydro-<br>
4H-imidazol-4-one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo [2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-(1-methylethyl)-3 , 5-dihydro-<br>
4H-imidazol-4-one can be prepared as in Example 13, but<br>
from 350 mg of raw 3-methyl-2-(1-methylethyl)-3,5-<br>
dihydro-4H-imidazol-4-one(Example 81) and 0.2 g of 5-<br>
chloro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde, to<br>
give 235 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3-methyl-2-(1-methylethyl)-<br>
3,5-dihydro-4H-imidazol-4-one in the form of a yellow<br>
powder with the following characteristics:<br>
Melting point: 282C.<br>
1H-NMR spectrum at 400 MHz: 1.32(d, J =	7.5 Hz, 6H) ;<br>
3.04(m, 1H); 3.15(s, 3H); 7.29(s, 1H);	8.30(d, J =<br>
2.0 Hz, 1H); 8.3 7(s, 1H); 9.55(s broad,	1H); 12.6(m<br>
spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 303(+)/...=(M+H)(+)/...; 301(-)/...=(M-H)( -<br>
) /...(1 CI present).<br>
Example 83<br>
(5Z)-2,3-dimethyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one<br><br>
a)(5Z)-2,3-dimethyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as follows:<br>
In a microwave oven reactor, mix together 0.8 cm3 of an<br>
8M solution of methylamine in ethanol and a suspension<br>
of 200 mg of(4Z) -4-[(1-acetyl-1H-pyrrolo [2, 3-<br>
b]pyridin-3-yl)methylidene]-2-methyl-1,3-oxazol-5(4H)-<br>
one in 4 cm3 of ethanol. Seal the reactor, then<br>
irradiate with microwave radiation for thirteen minutes<br>
at 170C. After filtration of the solid matter, 127 mg<br>
of(5Z)-2,3-dimethyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one	is<br>
obtained in the form of orange powder with the<br>
following characteristics:<br>
1H-NMR spectrum at 400 MHz: 2.3 7(s, 3H) ; 3.10(s, 3H) ;<br>
7.20(dd, J = 5.0 and 8.0 Hz, 1H) ; 7.29(s, 1H) ; 8.29<br>
(dd, J = 1.5 and 5.0 Hz, 1H) ; 8.3 9(s, 1H) ; 8.91(d<br>
broad, J = 8.0 Hz, 1H); 12.35(m spread out, 1H).<br>
HPLC-MS-DAD-ELSD: 241(+) =(M+H)(+) ; 239(-) =(M-H)(-).<br>
b)(4Z)-4- [(1-acetyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-methyl-l,3-oxazol-5(4H)-one can be<br>
prepared as follows:<br>
Put 1.92 g of N-acetylglycine and 1.23 g of sodium<br>
acetate in 25 cm3 of acetic anhydride in a three-necked<br>
flask, under argon. Heat the reaction mixture to 80C,<br>
stirring for one hour. Add 2 g of 1H-pyrrolo[2,3-<br>
b]pyridine-3-carbaldehyde and, after two hours at<br>
140C, cool the reaction mixture to 25C, then filter.<br>
Rinse the solid with water and then with ethanol before<br>
evaporating to dryness at reduced pressure. 1.68 g of<br>
(4Z)-2-methyl-4-(1H-pyrrolo[2,3-b]pyridin-3-<br><br>
ylmethylidene)-1,3-oxazol-5(4H)-one is obtained in the<br>
form of a. yellow powder with the following<br>
characteristics:<br>
LC/MS(1): Retention time: 3.3 min; 270(+) = [MH+].<br>
Example 84<br>
(5Z)-2-methyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene;) -3,5-dihydro-4H-imidazol-4-one<br>
(5Z)-2-methyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as in Example 83, but from 2.2 cm3 of 40%<br>
ammonia in ethanol and 200 mg of(4Z)-4-[(1-acetyl-1H-<br>
pyrrolo [2,3-b]pyridin-3-yl)methylidene]-2-methyl-1, 3-<br>
oxazol-5(4H)-one in 2 cm3 of ethanol. After eighteen<br>
minutes at 170C under microwave irradiation and<br>
filtration of the solid, 108 mg of(5Z)-2-methyl-5-(1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-<br>
imidazol-4-one is obtained in the form of orange powder<br>
with the following characteristics:<br>
Melting point: 277-281C.<br>
1H-NMR spectrum at 400 MHz: 2.25(s, 3H); 7.15(s, 1H) ;<br>
7.19(dd, J =5.0 and 8.0 Hz, 1H) ; 8.29(d broad, J =<br>
5.0 Hz, 1H); 8.35(s, 1H); 8.87(d broad, J = 8.0 Hz,<br>
1H); 11.1(m spread out, 1H); 12.35(m spread out, 1H).<br>
UPLC-MS-DAD-ELSD: 225(+) =(M+H)(+) ; 227(-) =(M-H)(-).<br>
Example 85<br>
(5Z)-2-methyl-3-(2-morpholin-4-ylethyl)-5-(1H-<br>
pyrrolo [2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
(5Z)-2-methyl-3-(2-morpholin-4-ylethyl)-5-(1H-<br>
pyrrolo [2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-<br><br>
imidazol-4-one can be prepared as in Example 83, but<br>
from 0.98 cm3 of 2-morpholin-4-ylethanamine and 200 mg<br>
of(4Z)-4-[(1-acetyl-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-methyl-1,3-oxazol-5(4H)-one in 2 cm3<br>
of ethanol. After eighteen minutes at 170C under<br>
microwave irradiation and filtration of the solid,<br>
105 mg of(5Z)-2-methyl-3-(2-morpholin-4-ylethyl)-5-<br>
(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-<br>
4H-imidazol-4-one is obtained in the form of orange<br>
powder with the following characteristics:<br>
Melting point: 235-240C.<br>
1H-NMR spectrum at 400 MHz: from 2.30 to 2.55(m<br>
partially masked, 9H) ; 3.55(m, 4H) ; 3.69(t, J = 6.0<br>
Hz, 2H) ; 7.21(dd, J = 5.0 and 8.0 Hz, 1H) ; 7.29(s,<br>
1H) ; 8.30(dd, J = 1.5 and 5.0 Hz, 1H) ; 8.39(s, 1H) ;<br>
8.92(d broad, J = 8.0 Hz, 1H) ; 10.0(m very broad,<br>
1H) .<br>
Example 86<br>
(5Z)-3-benzyl-2-methyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one<br>
(5Z)-3-benzyl-2-methyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as in Example 83, but from 0.8 cm3 of 1-<br>
phenylmethanamine and 200 mg of(4Z)-4-[(1-acetyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-2-methyl-1,3-<br>
oxazol-5(4H)-one in 2 cm3 of ethanol. After fifteen<br>
minutes at 170C under microwave irradiation and<br>
filtration of the solid, 105 mg of(5Z)-3-benzyl-2-<br>
methyl-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)-<br>
3,5-dihydro-4H-imidazol-4-one is obtained in the form<br>
of a yellow powder with the following characteristics:<br><br>
Melting point: 274-275C.<br>
1H-NMR spectrum at 400 MHz: 2.28(s, 3H); 4.83(s, 2H);<br>
7.20(dd, J == 5.0 and 8.0 Hz, 1H) ; 7.24(d, J = 7.5 Hz,<br>
2H) ; 7.30(t, J = 7.5 Hz, 1H) ; 7.38(m, 3H) ; 8.29(dd,<br>
J = 1.5 and 5.0 Hz, 1H); 8.41(s, 1H); 8.92(d broad, J<br>
= 8.0 Hz, 1H); 12.45(m spread out, 1H).<br>
Example 87<br>
(5Z)-2-methyl-3-propyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one<br>
(5Z)-2-methyl-3-propyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one can be<br>
prepared as in Example 83, but from 0.6 cm3 of propan-<br>
1-amine and 200 mg of(4Z) -4-[(1-acetyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-2-methyl-1,3-oxazol-5(4H)-<br>
one in 2 cm3 of ethanol. After sixteen minutes at 170C<br>
under microwave irradiation and filtration of the<br>
solid, 73 mg of(5Z)-2-methyl-3-propyl-5-(1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-<br>
imidazol-4-one is obtained in the form of yellow<br>
crystals with the following characteristics:<br>
Melting point: 206C.<br>
1H-NMR spectrum at 400 MHz: 0.88(t, J = 7.5 Hz,	3H) ;<br>
1.58(m, 2H) ; 2.38(s, 3H) ; 3.53(t, J = 7.5 Hz,	2H) ;<br>
7.19(m, 1H); 7.28(s, 1H); 8.29(m, 1H); 8.39(s,	1H);<br>
8.90(d broad, J = 8.0 Hz, 1H) ; 12.35(m spread	out,<br>
1H) .<br>
HPLC-MS-DAD-ELSD: 269(+) =(M+H)(+); 267(-) =(M-H)(-).<br>
Example 88<br><br>
(5Z)-2-methyl-3-(1-methylethyl)-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one<br>
(5Z)-2-methyl-3-(1-methylethyl)-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 83, but from 0.63 cm3<br>
of propan-2-amine and 200 mg of(4Z)-4-[(1-acetyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-2-methyl-1,3-<br>
oxazol-5(4H)-one in 2 cm3 of ethanol. After thirty-<br>
eight minutes at 170C under microwave irradiation and<br>
filtration of the solid, the filtrate is purified by<br>
preparative LC-MS [Column Xterra RP18 3 0x100; 5u; with<br>
water buffered with 10 mM of ammonium hydrogen<br>
carbonate adjusted to pH 9 with ammonia / acetonitrile<br>
with gradient from 70/30 to 0/100 in 8 min]. 39 mg of<br>
(5Z)-2-methyl-3-(1-methylethyl)-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one is obtained in the form of yellow lyophilizate with<br>
the following characteristics:<br>
Melting point: 207C.<br>
1H-NMR spectrum at 400 MHz: 1.41(d, J = 7.0 Hz, 6H) ;<br>
2.40(s, 3H); 4.21(m, 1H); 7.21(m, 2H); 8.29(dd, J =<br>
1.5 and 5.0 Hz, 1H) ; 8.37(s, 1H) ; 8.90(dd, J = 1.5<br>
and 8.0 Hz, 1H).<br>
Example 89<br>
(5Z)-2-butyl-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-3,5-dihydro-4H-imidazol-4-one<br>
a)(5Z)-2-butyl-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-<br>
3-yl)methylidene]-3-methyl-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 83, but from 0.14 cm3<br>
of 33% methylamine in ethanol and 67 mg of(4Z)-4-[(1-<br><br>
acetyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-butyl-1,3-oxazol-5(4H)-one in 4 cm3<br>
of ethanol. After fifteen minutes at 170C under<br>
microwave irradiation and filtration of the solid,<br>
26 mg of(5Z)-2-butyl-5-[(5-chloro-1H-pyrrolo [2,3-<br>
b]pyridin-3-yl)methylidene]-3-methyl-3,5-dihydro-4H-<br>
imidazol-4-one is obtained in the form of a yellow<br>
powder with the following characteristics:<br>
Melting point: 295-300C.<br>
1H-NMR spectrum at 400 MHz: 1.00(t, J = 7.5 Hz, 3H) ;<br>
1.50(m, 2H) ; 1.85(m, 2H) ; 2.69(t, J = 7.5 Hz, 2H) ;<br>
3.10(s, 3H) ; 7.27(s, 1H) ; 8.29(s broad, 1H) ; 8.35<br>
(s, 1H); 9.50(s broad, 1H); 12.55(m spread out, 1H).<br>
UPLC-MS-DAD-ELSD: 317(+)/...=(M+H)(+) /...; 315(-)/...=(M-H)( -<br>
)/...(1 chlorine atom Cl present) .<br>
b)(4Z)-4-[(1-acetyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-<br>
3-yl)methylidene]-2-butyl-l,3-oxazol-5(4H)-one can be<br>
prepared as in Example 83, but from 0.32 g of N-<br>
pentanoylglycine, 0.25 g of potassium acetate and 0.3 g<br>
of 5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde in<br>
1 cm3 of acetic anhydride. After four hours at 90 C,<br>
cool the reaction mixture to 25C and then dilute with<br>
water. The solid formed is filtered and purified by<br>
chromatography on silica(elution with methylene<br>
chloride) to obtain 69 mg of(4Z)-4-[(1-acetyl-5-<br>
chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-2-<br>
butyl-1,3-oxazol-5(4H)-one in the form of a yellow<br>
powder with the following characteristics:<br>
LC/MS retention time 5.75 min; LC-MS-DAD-ELSD: 346(+) =<br>
(M+H)(+).<br><br>
During the preceding purification, 88 mg of(4Z)-4-[(1-<br>
acetyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-methyl-1,3-oxazol-5(4H)-one is also<br>
isolated.<br>
Example 90<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2,3-dimethyl-3,5-dihydro-4H-imidazol-4-<br>
one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2,3-dimethyl-3,5-dihydro-4H-imidazol-4-<br>
one can be prepared as in Example 83, but from 0.21 cm3<br>
of 33% methylamine in ethanol and 85 mg of(4Z) -4-[(1-<br>
acetyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-methyl-1,3-oxazol-5(4H)-one(see<br>
Example 89) in 4 cm3 of ethanol. After fifteen minutes<br>
at 170C under microwave irradiation and filtration of<br>
the solid, 41 mg of(5Z)-2-methyl-5-[(5-chloro-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3-methyl-3,5-<br>
dihydro-4H-imidazol-4-one is obtained in the form of a<br>
yellow powder with the following characteristics:<br>
Melting point: 295-300C.<br>
1H-NMR spectrum at 400 MHz: 2.37(s, 3H); 3.11(s, 3H) ;<br>
7.29(s, 1H) ; 8.30(d, J = 2.0 Hz, 1H) ; 8.41(s, 1H) ;<br>
9.20(s broad, 1H); 12.6(m spread out, 1H).<br>
UPLC-MS-DAD-ELSD: 275(+)/...=(M+H)(+)/...; 274(-)/...=(M-H)( -<br>
)/...(1 chlorine atom Cl present).<br>
Example 91<br>
(5Z)-2-[methyl(2-methylpropyl)amino]-5-[(5-methyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br><br>
(5Z)-2-[methyl(2-methylpropyl)amino]-5-[(5-methyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 240 mg of(5Z)-5-[(5-methyl-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-2-thioxoimidazolidin-4-one<br>
(Example 17), 4 cm3 of ethanol and 68 0 mg of methyl-(2-<br>
methyl)propylamine. After twenty minutes at a<br>
temperature of 160C and one hour at 180C under<br>
microwave irradiation, then filtration of the solid,<br>
55 mg of(5Z)-2-[methyl(2-methylpropyl)amino]-5-[(5-<br>
methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-<br>
dihydro-4H-imidazol-4-one is obtained in the form of a<br>
brown powder with the following characteristics:<br>
Melting point: 287-289C.<br>
1H-NMR spectrum at 400 MHz: 0.90(d, J = 6.6 Hz, 6H) ;<br>
2.05(m, 1H) ; 2.40(s, 3H) ; 3.10(s, 3H) ; 3.30(m,<br>
masked, 2H); 6.58(s, 1H); 8.08(s broad, 1H); 8.13(s<br>
broad, 1H) ; 8.49(s broad, 1H) ; 11.00(s broad, 1H) ;<br>
11.80(s broad, 1H).<br>
Example 92<br>
(5Z)-5- [(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-phenyl-3,5-dihydro-4H-imidazol-4-one<br>
a)(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-phenyl-3,5-dihydro-4H-imidazol-4-one<br>
can be prepared as in Example 83, but from 2.7 cm3 of<br>
2M ammonia in ethanol and 96 mg of(4Z)-4-[(1-acetyl-5-<br>
chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methylidene]-2-<br>
phenyl-1,3-oxazol-5(4H)-one in 4 cm3 of ethanol. After<br>
four hours at 170C under microwave irradiation and<br>
filtration of the solid, 30 mg of(5Z)-5-[(5-chloro-1H-<br>
pyrrolo [2,3-b]pyridin-3-yl)methylidene]-2-phenyl-3,5-<br><br>
dihydro-4H-imidazol-4-one is obtained in the form of a<br>
yellow powder with the following characteristics:<br>
Melting point: 250C.<br>
1H-NMR spectrum at 400 MHz: 7.36(s, 1H); 7.61(m, 2H) ;<br>
8.16(m, 2H) ; 8.35(d, J = 2.4 Hz, 1H) ; 8.54(a, 1H) ;<br>
9.43(s, 1H); 11.93(s broad, 1H); 12.68(s broad, 1H).<br>
b)(4Z)-4-[(1-acetyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-<br>
3-yl)methylidene]-2-phenyl-1,3-oxazol-5(4H)-one can be<br>
prepared as in Example 83, but from 208 mg of hippuric<br>
acid, 98 mg of potassium acetate and 0.2 g of 5-chloro-<br>
1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde in 5 cm3 of<br>
acetic anhydride. After 4 hours at 100C, the reaction<br>
mixture is cooled to 25C and then diluted with water.<br>
The solid is filtered to obtain 222 mg of(4Z)-4-[(1-<br>
acetyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-phenyl-1,3-oxazol-5(4H)-one in the<br>
form of orange powder with the following<br>
characteristics:<br>
Melting point: 242C.<br>
Example 93<br>
(5Z)-2-[benzyl(methyl)amino]-5-[(5-chloro-1H-<br>
pyrrolo[2, 3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
5Z)-2-[benzyl(methyl)amino]-5-[(5-chloro-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 7, but<br>
from 100 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one<br>
(Example 3), 1.5 cm3 of ethanol and 435 mg of N-methyl-<br>
1-phenylmethanamine. After ninety minutes at a<br>
temperature of 180C under microwave irradiation, then<br><br>
filtration of the solid, 39 mg of(5Z) -2-<br>
[benzyl(methyl) amino]-5-[(5-chloro-1H-pyrrolo [2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one is obtained in the form of a yellow powder with the<br>
following characteristics:<br>
Melting point: 310C.<br>
1H-NMR spectrum at 400 MHz: 3.05(s, 3H); 4.73(br s,<br>
2H) ; 6.66(s, 1H) ; 7.20-7.47(m, 5H) ; 8.21(s, 2H) ;<br>
9.06(s, 1H); 11.22(br s, 1H); 12.17(b s, 1H).<br>
Mass spectrum: UPLC-MS-DAD-ELSD: 364(-) =(M-H)(-);<br>
366(+) =(M+H)(+).<br>
Example 94<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(furan-2-ylmethyl)(methyl)amino]-<br>
3,5-dihydro-4H-imidazol-4-one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(furan-2-ylmethyl)(methyl)amino]-<br>
3,5-dihydro-4H-imidazol-4-one can be prepared as in<br>
Example 7, but from 100 mg of(5Z)-5-[(5-chloro-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-<br>
thioxoimidazolidin-4-one(Example 3), 1.5 cm3 of<br>
ethanol and 399 mg of l-furan-2-yl-N-methylmethanamine.<br>
After one hour at a temperature of 180C under<br>
microwave irradiation, then filtration of the solid,<br>
49 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(furan-2-ylmethyl)(methyl)amino]-<br>
3,5-dihydro-4H-imidazol-4-one is obtained in the form<br>
of brown powder with the following characteristics:<br>
Melting point: 315C.<br><br>
1H-NMR spectrum at 400 MHz: 3.07(s, 3H) ; 4.71(b s,<br>
2H); 6.44(s, 2H); 6.67(s, 1H); 7.64(s, 1H); 8.23(s,<br>
2H); 9.09(b s, 1H); 11.11(b s, 1H), 12.15(b s, 1H).<br>
Mass spectrum: UPLC-MS-DAD-ELSD: 354(-) =(M-H)(-);<br>
356(+) =(M+H)(+).<br>
Example 95<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(2-methoxyethyl)(methyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(2-methoxyethyl)(methyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one can be prepared as in Example<br>
7, but from 100 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylene]-2-thioxoimidazolidin-4-one<br>
(Example 3), 1.5 cm3 of ethanol and 320 mg of 2-<br>
methoxy-N-methylethanamine. After fifteen minutes under<br>
microwave irradiation at each of the temperatures of<br>
160, 165, 170, 175 and 180C, then filtration of the<br>
solid, 50 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-2-[(2-<br>
methoxyethyl)(methyl)amino]-3,5-dihydro-4H-imidazol-4-<br>
one is obtained in the form of a yellow powder with the<br>
following characteristics:<br>
Melting point: 281C.<br>
1H-NMR spectrum at 400 MHz: 3.13(b s, 3H) ; 3.28-3.30<br>
(m, 2H) ; 3.58(b s, 3H) ; 3.65(b s, 2H) ; 6.61(s, 1H) ;<br>
8.18(s, 1H) ; 8.22(d, J = 2 Hz, 1H) ; 9.10(b s, 1H) ;<br>
11.07(b s, 1H); 12.18(b s, 1H).<br>
Mass spectrum: UPLC-MS-DAD-ELSD: 332(-) =(M-H)(-);<br>
334(+) =(M+H)(+).<br><br>
Example 96<br>
(5Z) -5-[(5-chloro-1H-pyrrolo [2, 3-b]pyridin-3-<br>
yl)methylidene]-2-[methyl(pyridin-2-ylmethyl)amino]-<br>
3,5-dihydro-4H-imidazol-4-one<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[methyl(pyridin-2-ylmethyl)amino]-<br>
3,5-dihydro-4H-imidazol-4-one can be prepared as in<br>
Example 7, but from 100 mg of(5Z) -5-[(5-chloro-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-<br>
thioxoimidazolidin-4-one(Example 3), 1.5 cm3 of<br>
ethanol and 439 mg of N-methyl-1-pyridin-2-<br>
ylmethanamine. After two hours at a temperature of<br>
180C under microwave irradiation, then filtration of<br>
the solid, 18 mg of(5Z)-5-[(5-chloro-1H-pyrrolo [2,3-<br>
b]pyridin-3-yl)methylidene]-2-[methyl(pyridin-2-<br>
ylmethyl)amino]-3,5-dihydro-4H-imidazol-4-one is<br>
obtained in the form of a yellow powder with the<br>
following characteristics:<br>
Melting point: 350C.<br>
1H-NMR spectrum at 400 MHz: 3.07(s, 3H) ; 4.78(s, 2H) ;<br>
6.68(s, 1H); 7.40(dd, J = 7.3, 4.9 Hz, 1H); 7.77(d,<br>
J = 8.3 Hz, 1H) ; 8.11-8.27(m, 2H) ; 8.51(d, J = 4.4<br>
Hz, 1H); 8.60(s, 1H); 9.05(b s, 1H); 11.25(b s, 1H) ;<br>
12.20(b s, 1H).<br>
Mass spectrum: UPLC-MS-DAD-ELSD: 365(-) =(M-H)(-);<br>
367(+) =(M+H)(+).<br>
Example 97<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl) methylidene]-2-phenoxy-3-phenyl-3,5-dihydro-4H-<br>
imidazol-4-one<br><br>
a)(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-phenoxy-3-phenyl-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 1, but<br>
from 42 mg of 5-chloro-1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde in 4 cm3 of ethanol, 59 mg of 2-phenoxy-3-<br>
phenyl-3,5-dihydro-4H-imidazol-4-one and 0.023 cm3 of<br>
piperidine. After refluxing for five hours, 60 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-phenoxy-3-phenyl- 3,5-dihydro-4H-<br>
imidazol-4-one is obtained in the form of a pale yellow<br>
solid with the following characteristics:<br>
Melting point: 287C.<br>
1H-NMR spectrum at 400 MHz: 6.96-7.77(m, 11H), 8.18(s, 1H), 8.20(s, 1H), 8.80(s, 1H) , 12.5(m spread<br>
out, 1H).<br>
Mass spectrum: m/z = 414(M+)<br>
b) 2-phenoxy-3-phenyl-3,5-dihydro-4H-imidazol-4-one can<br>
be prepared as follows: at a temperature close to 20C,<br>
add 0.1 g of phenol and 7 mg of potassium carbonate to<br>
0.2 g of N-[(phenylimino)methylidene]methylglycinate in<br>
solution in 5 cm3 of acetonitrile. After stirring for<br>
24 hours at a temperature close to 55C, the reaction<br>
mixture is concentrated to dryness at reduced pressure<br>
to give a residue, which is purified by flash<br>
chromatography on an SVL D26 Merck SI60 cartridge 25 g,<br>
15-40uM, flow rate 20ml/min, vf 4.3 ml [eluent: ethyl<br>
acetate / cyclohexane(1 / 3 by volume)]. After<br>
concentration of the fractions at reduced pressure, a<br>
yellow residue is obtained, which is stirred in 5 cm3<br>
of petroleum ether, then filtered and dried at reduced<br>
pressure to give 68 mg of 2-phenoxy-3-phenyl-3,5-<br><br>
dihydro-4H-imidazol-4-one, in the form of a pale yellow<br>
solid with the following mass spectrum: m/z = 252(M+).<br>
c) N-[(phenylimino)methylidene]methylglycinate can be<br>
prepared as follows: at a temperature close to 0C,<br>
under an argon atmosphere, add 9.64 g of dibromo-<br>
triphenylphosphine and 6.3 5 cm3 of triethylamine to<br>
3.17 g of N-(phenylcarbamoyl)methylglycinate in<br>
suspension in 100 cm3 of dichloromethane. Allow the<br>
temperature to return slowly to room temperature. After<br>
stirring for 20 hours at a temperature close to 20C,<br>
wash the reaction mixture successively with 50 cm3 of<br>
water and 5 0 cm3 of a saturated aqueous solution of<br>
potassium hydrogen carbonate, dry over anhydrous<br>
magnesium sulphate, filter and concentrate to dryness<br>
at reduced pressure, to give 9.5 g of a brown solid,<br>
which is purified by flash chromatography on an EVP D57<br>
Merck SI60 cartridge 200 g, 40-63uM, flow rate<br>
30ml/min, vf 17.5 ml [eluent: ethyl acetate /<br>
cyclohexane(1 / 7 by volume)]. After concentration of<br>
the fractions at reduced pressure, 1.47 g of N-<br>
[(phenylimino)methylidene]methylglycinate is obtained<br>
in the form of a pale yellow oil with the following<br>
mass spectrum: m/z = 190(M+) .<br>
d) N-(phenylcarbamoyl)methylglycinate can be prepared<br>
as follows: at a temperature close to 20C, under an<br>
argon atmosphere, add 2.3 9 cm3 of phenyl isocyanate and<br>
3.34 cm3 of triethylamine to 2.51 g of methylglycinate<br>
hydrochloride in suspension in 5 0 cm3 of<br>
dichloromethane. After stirring for 5 hours at a<br>
temperature close to 20C, the reaction mixture is<br>
washed with 50 cm3 of water. The aqueous phase is<br>
extracted with 2 x 50 cm3 of dichloromethane. The<br>
organic phases are combined, dried over anhydrous<br><br>
magnesium sulphate, filtered and concentrated to<br>
dryness at reduced pressure to give a residue, which is<br>
washed successively with 5 x 50 cm3 of petroleum ether<br>
and 3 x 100 cm3 of a petroleum ether / diisopropyl<br>
ether mixture(1/1 by volume). After drying at reduced<br>
pressure at a temperature close to 20C, 3.17 g of N-(phenylcarbamoyl)methylglycinate is obtained in the<br>
form of a white solid with the following mass spectrum:<br>
m/z = 208(M+).<br>
Example 98<br>
(5Z)-5-[1-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-<br>
methylidene]-2-methoxy-3-phenyl-3,5-dihydro-4H-<br>
imidazol-4-one<br>
a)(5Z)-5-[1-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-<br>
methylidene]-2-methoxy-3-phenyl-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 1, but<br>
from 34 mg of 5-chloro-1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde in 4 cm3 of ethanol, 36 mg of 2-phenoxy-3-<br>
phenyl-3,5-dihydro-4H-imidazol-4-one and 0.02 cm3 of<br>
piperidine. After refluxing for five hours, 4 3 mg of<br>
(5Z)-5- [1-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-<br>
methylidene]-2-methoxy-3-phenyl-3,5-dihydro-4H-<br>
imidazol-4-one is obtained in the form of a pale yellow<br>
solid with the following characteristics:<br>
Melting point: 227.5C.<br>
1H-NMR spectrum at 400 MHz:	4.18(s, 3H) , 7.29(s, 1H) ,<br>
7.42(m, 3H) , 7.52(t, J =	7.6 Hz, 2H), 8.31(s broad,<br>
1H), 8.41(s, 1H), 9.18(s	broad, 1H) , 12.55(m spread<br>
out, 1H).<br>
Mass spectrum: m/z = 352(M+)<br><br>
b) 2-methoxy-3-phenyl-3,5-dihydro-4H-imidazol-4-one can<br>
be prepared as follows: at a temperature close to 20C,<br>
add 9 mg of potassium carbonate to 0.2 g of N-<br>
[(phenylimino)methylidene]methylglycinate(prepared as<br>
described in Example 97) in solution in 5 cm3 of<br>
methanol. After stirring for six hours thirty minutes<br>
at a temperature close to 55C, the reaction mixture is<br>
concentrated to dryness at reduced pressure(2.7 kPa)<br>
to give a residue, which is purified by flash<br>
chromatography on an SVL D26 Merck SI60 cartridge 25 g,<br>
15-40uM, flow rate 20ml/min, vf 4.3 ml [eluent: ethyl<br>
acetate / cyclohexane(1 / 1 by volume)]. After<br>
concentration of the fractions at reduced pressure, a<br>
yellow residue is obtained, which is stirred in 5 cm3<br>
of petroleum ether, then filtered and dried at reduced<br>
pressure(2.7 kPa) to give 41 mg of 2-methoxy-3-phenyl-<br>
3,5-dihydro-4H-imidazol-4-one in the form of a pale<br>
yellow solid with the following mass spectrum: m/z =<br>
190(M+)<br>
Example 99<br>
(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-phenoxy-3,5-dihydro-4H-<br>
imidazol-4-one<br>
a)	(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-phenoxy-3,5-dihydro-4H-<br>
imidazol-4-one can be prepared as in Example 1, but<br>
from 74 mg of 5-chloro-1H-pyrrolo[2,3-b]pyridine-3-<br>
carbaldehyde in 7 cm3 of ethanol, 70 mg of 3-methyl-2-<br>
phenoxy-3,5-dihydro-4H-imidazol-4-one and 0.038 cm3 of<br>
piperidine. After refluxing for six hours, 48 mg of(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-phenoxy-3,5-dihydro-4H-<br><br>
imidazol-4-one is obtained in the form of a pale yellow<br>
solid with the following characteristics:<br>
1H-NMR spectrum at 400 MHz: 3.21(s, 3H) , 7.19(s, 1H) ,<br>
7.33-7.62(m, 5H), 8.12(s, 1H), 8.19(s, 1H), 8.79(s,<br>
1H) , 12.45(m spread out, 1H)<br>
Mass spectrum: m/z = 3 52(M+)<br>
b)	3-methyl-2-phenoxy-3,5-dihydro-4H-imidazol-4-one can<br>
be prepared as follows: at a temperature close to 20C,<br>
add 0.1 g of phenol and 12 mg of potassium carbonate to<br>
0.151 g of N-[(methylimino)methylidene]methylglycinate<br>
in solution in 5 cm3 of acetonitrile. After stirring<br>
for 6.5 hours at a temperature close to 55C, the<br>
reaction mixture is concentrated to dryness at reduced<br>
pressure(2.7 kPa) to give a residue, which is purified<br>
by flash chromatography on an SVL D26 Merck SI60<br>
cartridge 25 g, 15-40uM, flow rate 20ml/min, vf 4.3 ml<br>
[eluent: ethyl acetate / cyclohexane(1/1 by volume)].<br>
After concentration of the fractions at reduced<br>
pressure, a yellow residue is obtained, which is<br>
stirred in 5 cm3 of petroleum ether, then filtered and<br>
dried at reduced pressure(2.7 kPa) to give 149 mg of<br>
3-methyl-2-phenoxy-3,5-dihydro-4H-imidazol-4-one in the<br>
form of a white solid with the following mass spectrum:<br>
m/z = 190(M+).<br>
c)	N-[(methylimino)methylidene]methylglycinate can be<br>
prepared as follows: at a temperature close to 0C,<br>
under an argon atmosphere, add 5.42 g of dibromo-<br>
triphenylphosphine and 3.6 cm3(25.66 mmol) of<br>
triethylamine to 1.37 g of N-<br>
(methylcarbamoyl)methylglycinate in suspension in<br>
50 cm3 of dichloromethane. Allow the temperature to<br>
return slowly to room temperature. After stirring for<br><br>
24 hours at a temperature close to 20C, filter the<br>
reaction mixture several times on a No. 4 glass frit.<br>
The filtrate is taken up in 4 x 25 cm3 of petroleum<br>
ether, filtering each time to remove as much<br>
triphenylphosphine oxide as possible. The filtrate is<br>
concentrated to dryness at reduced pressure(2.7 kPa)<br>
to give 0.74 g of a yellow oil, which is purified by<br>
chromatography on 74 g of aluminium oxide(Fluka type<br>
507c neutral) activated with 4.4 cm3(6%) of water,<br>
Patm, vf 20 ml(eluent: dichloromethane). After<br>
concentration of the fractions at reduced pressure,<br>
0.48 g of N-[(methylimino)methylidene]methylglycinate<br>
is obtained in the form of a pale yellow oil with the<br>
following mass spectrum: m/z = 142(M+) .<br>
d) N-(methylcarbamoyl)methylglycinate can be prepared<br>
as follows: at a temperature close to 20C, under an<br>
argon atmosphere, add 3.9 cm3 of a 2M solution of<br>
methylamine in tetrahydrofuran to 1.0 g N-<br>
(oxomethylidene)methylglycinate in solution in 8 cm3 of<br>
tetrahydrofuran. After stirring for 4 hours at a<br>
temperature close to 20C, filter the reaction mixture<br>
on a No. 4 glass frit, then concentrate the filtrate to<br>
dryness at reduced pressure(2.7 kPa), to give a white<br>
residue, which is stirred with 3 x 25 cm3 of petroleum<br>
ether, then filtered and dried at reduced pressure(2.7<br>
kPa) to give 1.37 g of N-(methyl carbamoyl) methylglycinate in the form of a white<br>
solid with the following mass spectrum: m/z = 16 0(M+)<br>
Example 100: Pharmaceutical composition<br>
Tablets were prepared, corresponding to the following<br>
formula:<br><br><br>
(detailed excipients: lactose, talc, starch,<br>
magnesium stearate).<br>
Example 101: Pharmaceutical composition<br>
Tablets were prepared, corresponding to the following<br>
formula:	~<br><br>
(detailed excipients: lactose, talc, starch, magnesium<br>
stearate).<br>
Examples 1 and 10 are given as examples of a<br>
pharmaceutical preparation, which can be prepared if<br>
desired with other products shown as examples in the<br>
present application.<br><br>
Patent Claims<br>
1. Products of formula(I):<br><br>
in which:<br>
X-Y represents NH-C(S), N=C-NR7R8, N=C-SR, N=C-R<br>
or N=C-OR;<br>
R1 represents a hydrogen atom, a cycloalkyl radical or<br>
an alkyl, heterocycloalkyl, aryl or heteroaryl radical,<br>
all these radicals being optionally substituted;<br>
R, which may be identical to or different from Rl, is<br>
selected from the values of R1;<br>
R2 represents a hydrogen atom, a halogen atom or an<br>
alkyl radical;<br>
R3 represents a hydrogen atom, a halogen atom, a<br>
hydroxyl radical or an alkyl or alkoxy radical;<br>
R4 represents a hydrogen atom, a halogen atom or a<br>
cyano, CF3 or alkyl radical;<br>
R5 represents a hydrogen atom, a halogen atom, a<br>
hydroxyl, cyano, NR7R8, CONR7R8, NR11COR12 radical or a<br>
cycloalkyl, alkyl, alkoxy, heterocycloalkyl, aryl or<br><br>
heteroaryl radical, all these last-mentioned radicals<br>
being optionally substituted;<br>
R6 represents a hydrogen atom, a halogen atom or an<br>
NR7R8, alkyl or alkoxy radical;<br>
R7 and R8 are such that:<br>
either R7 and R8, which may be identical or different,<br>
are such that one of R7 and R8 represents a hydrogen<br>
atom or an alkyl radical, optionally substituted;<br>
and the other one of R7 and R8 represents a hydrogen<br>
atom or a cycloalkyl, alkyl, heterocycloalkyl,<br>
heteroaryl or aryl radical, all these radicals being<br>
optionally substituted;<br>
or R7 and R8 form, together with the nitrogen atom to<br>
which they are attached, a cyclic radical formed from 3<br>
to 7 ring members optionally containing one or more<br>
other heteroatoms selected from O, S or N, N being<br>
optionally substituted with R11, said cyclic radical<br>
itself being optionally substituted;<br>
all the alkyl, alkoxy, cycloalkyl, heterocycloalkyl,<br>
heteroaryl and aryl radicals, as well as the cyclic<br>
radical that. R7 and R8 can form together with the<br>
nitrogen atom to which they are attached, indicated as<br>
optionally substituted, thus being optionally<br>
substituted with one or more radicals, which may be<br>
identical or different, selected from the halogen atoms<br>
and the hydroxyl, cyano, nitro, CF3, NR9R10, NHCOR11,<br>
NHCO2R11, NHCONR9R10, NHSO2R13, COOH, COOalk, CONR9R10,<br>
SO2NR9R10, alkoxy, alkylthio, haloalkoxy,<br>
haloalkylthio, alkyl, fluoroalkyl, hydroxyalkyl,<br>
cycloalkyl, heterocycloalkyl, heteroaryl and phenyl<br>
radicals, these last-mentioned heteroaryl, aryl and<br><br>
phenyl radicals themselves being optionally substituted<br>
with one or more radicals, which may be identical or<br>
different, selected from the halogen atoms and the<br>
hydroxyl, NH2, NH(alk), N(alk)2, alkyl, hydroxyalkyl<br>
and alkoxy radicals;<br>
R9 and R10 are such that:<br>
either R9 and R10, which may be identical or different,<br>
are such that one of R9 and R10 represents a hydrogen<br>
atom or an alkyl radical optionally substituted with<br>
one or more radicals, which may be identical or<br>
different, selected from the halogen atoms and the<br>
hydroxyl and alkoxy radicals;<br>
and the other one of R9 and R10 represents a hydrogen<br>
atom or a cycloalkyl, alkyl, heterocycloalkyl,<br>
heteroaryl or aryl radical, all these radicals<br>
themselves being optionally substituted with one or<br>
more radicals, which may be identical or different,<br>
selected from the halogen atoms and the hydroxyl, NH2,<br>
NH(alk), N(alk)2, alkyl, hydroxyalkyl and alkoxy<br>
radicals;<br>
or R9 and R10 form, together with the nitrogen atom to<br>
which they are attached, a cyclic radical formed from 3<br>
to 7 ring members optionally containing one or more<br>
other heteroatoms selected from O, S or N, N being<br>
optionally substituted with R12, said cyclic radical<br>
itself being optionally substituted with one or more<br>
radicals, which may be identical or different, selected<br>
from the halogen atoms and the hydroxyl, NH2, NH(alk),<br>
N(alk)2, alkyl, hydroxyalkyl and alkoxy radicals;<br>
R11 and R12, which may be identical or different,<br>
represent a hydrogen atom or an alkyl or phenyl<br><br>
radical, optionally substituted with one or more<br>
radicals, which may be identical or different, selected<br>
from the halogen atoms and the hydroxyl and alkoxy<br>
radicals, the phenyl radical itself being optionally<br>
substituted with one or more alkyl radicals;<br>
R13 represents an alkyl or phenyl radical, optionally<br>
substituted with one or more radicals, which may be<br>
identical or different, selected from the halogen atoms<br>
and the hydroxyl and alkoxy radicals, the phenyl<br>
radical itself being optionally substituted with one or<br>
more alkyl radicals;<br>
all the above alkyl(alk) and alkoxy radicals being<br>
linear or branched and containing at most 12 carbon<br>
atoms;<br>
it being understood that the products of formula(I) in<br>
which all of the following conditions are fulfilled,<br>
are excluded:<br>
-	R2 represents hydrogen;<br>
-	R3 represents hydrogen or alkyl;<br>
-	X-Y represents N=C-NR7R8, N=C-SR or N=CR in which X<br>
represents N and Y represents =C-NR7R8, =C-SR or =CR<br>
and R represents aryl or heteroaryl<br>
-	R1 represents H or alk;<br>
-	and R4, R5 and R6 are such that two of them represent<br>
H and the other one represents hydrogen, NH2 or NHalk,<br>
said products of formula(I) being in all possible<br>
tautomeric and isomeric forms(racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br><br>
said products of formula(I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
2. Products of formula(I) as defined in Claim 1<br>
in which:<br>
Rl represents a hydrogen atom, or an alkyl radical, all<br>
these radicals being optionally substituted as stated<br>
in Claim 1 or in any one of the other claims;<br>
and R5 represents a halogen atom, a hydroxyl, cyano,<br>
NR7R8, CF3 radical or a cycloalkyl, alkyl, alkoxy,<br>
heterocycloalkyl, aryl or heteroaryl radical,<br>
all these last-mentioned radicals being optionally<br>
substituted as stated in Claim 1 or in any one of the<br>
other claims;<br>
the other substituent radicals R2, R3, R4, R6 and X-Y<br>
having the values defined in Claim 1 or in any one of<br>
the other claims,<br>
said products of formula(I) being in all possible<br>
tautomeric and isomeric forms(racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula(I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
3. Products of formula(I) as defined in Claim 1<br>
in which:<br>
R2 represents a hydrogen atom;<br>
and R5 represents a halogen atom, a hydroxyl, cyano,<br>
NR7R8, CF3 radical or a cycloalkyl, alkyl, alkoxy,<br>
heterocycloalkyl, aryl or heteroaryl radical, all these<br>
last-mentioned radicals being optionally substituted as<br>
stated in Claim 1 or in any one of the other claims;<br><br>
the other substituent radicals R1, R3, R4, R6 and X-Y<br>
having the values defined in Claim 1 or in any one of<br>
the other claims,<br>
said products of formula(I) being in all possible<br>
tautomeric and isomeric forms(racemates, enantiomers<br>
and diastereoisomers) , as well as salts of addition of<br>
said products of formula(I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
4. Products of formula(I) as defined in Claim 1<br>
in which:<br>
R3 represents a hydrogen atom;<br>
and R5 represents a halogen atom, a hydroxyl, cyano,<br>
CONR7R8 radical or a cycloalkyl, alkyl, alkoxy,<br>
heterocycloalkyl, aryl or heteroaryl radical, all these<br>
last-mentioned radicals being optionally substituted as<br>
stated in Claim 1 or in any one of the other claims;<br>
the other radicals R2, R3, R4, R6 and X-Y having the<br>
values defined in Claim 1 or in any one of the other<br>
claims,<br>
said products of formula(I) being in all possible<br>
tautomeric and isomeric forms(racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula(I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
5. Products of formula(I) as defined in Claim 1<br>
in which:<br>
X-Y represents NH-C(S), N=C-NR7R8 or N=C-R;<br>
Rl represents a hydrogen atom, a cycloalkyl radical or<br>
an alkyl, heterocycloalkyl, aryl or heteroaryl radical,<br><br>
all these radicals being optionally substituted as<br>
stated in Claim 1 or in any one of the other claims;<br>
R, which may be identical to or different from R1, is<br>
selected from the values of R1 as defined in Claim 1 as<br>
stated in Claim 1 or in any one of the other claims<br>
with the exception of aryl and heteroaryl;<br>
the other substituents R2, R3, R4, R5 and R6 having the<br>
values defined in Claim 1 or in any one of the other<br>
claims;<br>
said products of formula(I) being in all possible<br>
tautomeric and isomeric forms(racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula(I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
6. Products of formula(I) as defined in Claim 1<br>
in which:<br>
X-Y represents NH-C(S), N=C-NR7R8, N=C-SR, N=C-R or<br>
N=C-OR;<br>
R1 represents a hydrogen atom, a cycloalkyl radical or<br>
an alkyl, heterocycloalkyl, phenyl or heteroaryl<br>
radical, these last-mentioned radicals being optionally<br>
substituted;<br>
R, which may be identical to or different from R1, is<br>
selected from the values of Rl;<br>
R2 represents a hydrogen atom, a halogen atom or an<br>
alkyl radical;<br>
R3 represents a hydrogen atom, a halogen atom, a<br>
hydroxyl radical or an alkyl or alkoxy radical;<br><br>
R4 represents a hydrogen atom, a halogen atom or a<br>
cyano, CF3 or alkyl radical;<br>
R5 represents a hydrogen atom, a halogen atom, a<br>
hydroxyl, cyano, NR7R8, CONR7R8, NR11C0R12 radical or a<br>
cycloalkyl, alkyl, alkoxy, heterocycloalkyl, phenyl or<br>
heteroaryl radical, all these last-mentioned radicals<br>
being optionsilly substituted;<br>
R6 represents a hydrogen atom, a halogen atom or an<br>
NR7R8, alkyl or alkoxy radical;<br>
R7 and R8 are such that:<br>
either R7 and R8, which may be identical or different,<br>
are such that one of R7 and R8 represents a hydrogen<br>
atom or an alkyl radical optionally substituted with<br>
one or more radicals, which may be identical or<br>
different, selected from the halogen atoms and the<br>
hydroxyl and alkoxy radicals;<br>
and the other one of R7 and R8 represents a hydrogen<br>
atom or a cycloalkyl, alkyl, heterocycloalkyl,<br>
heteroaryl or phenyl radical, all these radicals being<br>
optionally substituted;<br>
or R7 and R8 form, together with the nitrogen atom to<br>
which they are attached, a cyclic radical formed from 3<br>
to 7 ring members optionally containing one or more<br>
other heteroatoms selected from O, S or N, N being<br>
optionally substituted with R11, said cyclic radical<br>
itself being optionally substituted;<br>
all the alkyl, alkoxy, cycloalkyl, heterocycloalkyl,<br>
heteroaryl and aryl radicals, as well as the cyclic<br>
radical that R7 and R8 can form together with the<br>
nitrogen atom to which they are attached, indicated as<br><br>
optionally substituted, thus being optionally-<br>
substituted with one or more radicals, which may be<br>
identical or different, selected from the halogen atoms<br>
and the hydroxyl, cyano, nitro, CF3, NR9R10, NHCOR11,<br>
NHSO2R13, COOH, COOalk, CONR9R10, SO2NR9R10, alkoxy,<br>
haloalkoxy, alkyl, fluoroalkyl, hydroxyalkyl,<br>
cycloalkyl, heterocycloalkyl, heteroaryl and phenyl<br>
radicals, these last-mentioned heteroaryl and phenyl<br>
radicals themselves being optionally substituted with<br>
one or more radicals, which may be identical or<br>
different, selected from the halogen atoms and the<br>
hydroxyl, NH2, NH(alk), N(alk)2, alkyl, hydroxyalkyl<br>
and alkoxy radicals;<br>
R9 and R10 are such that:<br>
either R9 and R10, which may be identical or different,<br>
are such that one of R9 and R10 represents a hydrogen<br>
atom or an alkyl radical and the other one of R9 and<br>
R10 represents a hydrogen atom or an alkyl, phenyl or<br>
phenylalkyl radical, themselves optionally substituted<br>
with one or more radicals, which may be identical or<br>
different, selected from the halogen atoms and the<br>
hydroxyl, NH2, NH(alk), N(alk)2, alkyl, hydroxyalkyl<br>
and alkoxy radicals;<br>
or R9 and R10 form, together with the nitrogen atom to<br>
which they are attached, a pyrrolidinyl, morpholine,<br>
piperidyl, azepinyl or piperazinyl radical optionally<br>
substituted with an alkyl or phenyl radical, itself<br>
optionally substituted with one or more radicals, which<br>
may be identical or different, selected from the<br>
halogen atoms and the alkyl, hydroxyl, NH2, NH(alk),<br>
N(alk)2, alkyl, hydroxyalkyl and alkoxy radicals;<br><br>
R11 and R12, which may be identical or different,<br>
represent a hydrogen atom or an alkyl or phenyl<br>
radical;<br>
R13 represents an alkyl or phenyl radical;<br>
all the above alkyl(alk) and alkoxy radicals being<br>
linear or branched and containing at most 6 carbon<br>
atoms;<br>
said products of formula(I) being in all possible<br>
tautomeric and isomeric forms(racemates, enantiomers<br>
and diastereoisomers) , as well as salts of addition of<br>
said products of formula(I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
7. Products of formula(I) as defined in any one<br>
of the other claims in which:<br>
X-Y represents NH-C(S), N=C-NR7R8, N=C-SR, N=C-R or<br>
N=C-OR;<br>
R1 represents a hydrogen atom or an alkyl or phenyl<br>
radical, optionally substituted;<br>
R represents a hydrogen atom; a cycloalkyl radical; an<br>
alkyl, heterocycloalkyl, phenyl, or heteroaryl radical,<br>
all these radicals being optionally substituted;<br>
R2 represents a hydrogen atom, a halogen atom or an<br>
alkyl radical;<br>
R3 represents a hydrogen atom, a halogen atom, a<br>
hydroxyl radical or an alkyl radical;<br>
R4 represents a hydrogen atom, a halogen atom or an<br>
alkyl radical;<br><br>
R5 represents a hydrogen atom; a halogen atom; a<br>
hydroxyl, cyano, NR7R8, alkyl, alkoxy,<br>
heterocycloalkyl, phenyl, or heteroaryl radical, these<br>
last-mentioned radicals as well as the phenyl residue<br>
in NHphenyl and NH(phenylalk) being optionally<br>
substituted;<br>
R6 represents a hydrogen atom, a halogen atom, or an<br>
NH2, NHalk, N(alk)2, alkyl or alkoxy radical;<br>
R7 and R8 are such that:<br>
either R7 and R8, which may be identical or different,<br>
are such that one of R7 and R8 represents a hydrogen<br>
atom or an alkyl radical;<br>
and the other one of R7 and R8 represents a hydrogen<br>
atom, or an alkyl or cycloalkyl radical, optionally<br>
substituted;<br>
or R7 and R8 form, together with the nitrogen atom to<br>
which they are attached, a cyclic radical selected from<br>
the azetidyl, piperidyl, azepanyl, morpholinyl,<br>
thiomorpholinyl, pyrrolidinyl, imidazolidinyl,<br>
piperazinyl radicals optionally substituted on its<br>
second nitrogen atom with an alkyl or phenyl radical,<br>
themselves optionally substituted; and homopiperazinyl,<br>
these radicals being optionally substituted;<br>
all the alkyl, alkoxy, heterocycloalkyl, heteroaryl and<br>
phenyl radicals, as well as the cyclic radical that R7<br>
and R8 can form together with the nitrogen atom to<br>
which they are attached, indicated as optionally<br>
substituted, thus being optionally substituted with one<br>
or more radicals, which may be identical or different,<br>
selected from the halogen atoms and the hydroxyl, NH2,<br>
NH(alk), N(alk)2, NHphenyl, NH(phenylalk), alkyl, CF3,<br><br>
alkoxy, OCF3, cycloalkyl, heterocycloalkyl, heteroaryl<br>
and phenyl radicals; these last-mentioned heteroaryl<br>
and phenyl radicals, as well as the phenyl residue in<br>
the NHphenyl and NH(phenylalk) radicals, themselves<br>
being optionally substituted with one or more radicals,<br>
which may be identical or different, selected from the<br>
halogen atoms and the hydroxyl, NH2, NHAlk, N(Alk)2,<br>
alkyl, hydroxyalkyl and alkoxy radicals;<br>
all the above alkyl(alk) and alkoxy radicals being<br>
linear or branched and containing at most 6 carbon<br>
atoms;<br>
said products of formula(I) being in all possible<br>
tautomeric and isomeric forms(racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula(I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
8. Products of formula(I) as defined in any one<br>
of the other claims in which:<br>
X-Y represents NH-C(S), N=C-NR7R8, N=C-SR, N=C-R or<br>
N=C-OR;<br>
R1 represents a hydrogen atom or an alkyl or phenyl<br>
radical, optionally substituted;<br>
R, which may be identical to or different from R1, is<br>
selected from the values of R1;<br>
R2 represents a hydrogen atom, a halogen atom or an<br>
alkyl radical;<br>
R3 represents a hydrogen atom, a halogen atom, a<br>
hydroxyl radical or an alkyl radical;<br><br>
R4 represents a hydrogen atom, a halogen atom or an<br>
alkyl radical;<br>
R5 represents a hydrogen atom, a halogen atom, a<br>
hydroxy1 radical, an NH2, NHalk, N(alk)2, NR7R8,<br>
NHphenyl, NH(phenylalk) radical or an alkyl,<br>
heterocycloalkyl, alkoxy, phenyl or heteroaryl radical,<br>
these last-mentioned radicals as well as the phenyl<br>
residue in NHphenyl and NH(phenylalk) being optionally<br>
substituted;<br>
R6 represents a hydrogen atom, a halogen atom, or an<br>
NH2, NHalk, N(alk)2, alkyl or alkoxy radical;<br>
R7 and R8 are such that:<br>
either R7 and R8, which may be identical or different,<br>
are such that one of R7 and R8 represents a hydrogen<br>
atom or an alkyl radical;<br>
and the other one of R7 and R8 represents a hydrogen<br>
atom, or an alkyl or cycloalkyl radical, optionally<br>
substituted;<br>
or R7 and R8 form, together with the nitrogen atom to<br>
which they are attached, a cyclic radical containing 4<br>
to 6 ring members selected from azetidyl; piperidyl;<br>
morpholinyl; thiomorpholinyl; pyrrolidinyl;<br>
imidazolidinyl; piperazinyl; and homopiperazinyl, these<br>
radicals being optionally substituted;<br>
all the alkyl, alkoxy, heteroaryl and phenyl radicals,<br>
as well as the cyclic radical that R7 and R8 can form<br>
together with the nitrogen atom to which they are<br>
attached, indicated as optionally substituted, thus<br>
being optionally substituted with one or more radicals,<br>
which may be identical or different, selected from the<br><br>
halogen atoms and the hydroxyl, NH2, NH(alk), N(alk)2,<br>
NHphenyl, NH(phenylalk), alkyl, CF3, alkoxy, 0CF3,<br>
cycloalkyl, heterocycloalkyl, heteroaryl and phenyl<br>
radicals; these last-mentioned heteroaryl and phenyl<br>
radicals, as well as the phenyl residue in the NHphenyl<br>
and NH(phenylalk) radicals, themselves being optionally<br>
substituted with one or more radicals, which may be<br>
identical or different, selected from the halogen atoms<br>
and the hydroxyl, NH2, NHAlk, N(Alk)2, alkyl,<br>
hydroxyalkyl and alkoxy radicals;<br>
all the above alkyl(alk) and alkoxy radicals being<br>
linear or branched and containing at most 6 carbon<br>
atoms;<br>
said products of formula(I) being in all possible<br>
tautomeric and isomeric forms(racemates, enantiomers<br>
and diastereoisomers) , as well as salts of addition of<br>
said products of formula(I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
9. Products of formula(I) as	defined in any one<br>
of the other claims, in which X-Y,	R2, R3, R4 and R6<br>
have the meanings stated in any	one of the other<br>
claims,<br>
R1 represents a hydrogen atom or an alkyl radical,<br>
optionally substituted;<br>
R5 represents a hydrogen atom, a halogen atom, a<br>
hydroxyl radical, CF3, NH2, NHalk, N(alk)2 or an alkyl,<br>
alkoxy or phenyl radical, optionally substituted;<br>
the alkyl radical that can be represented by R1 or the<br>
alkyl, alkoxy or phenyl radical that can be represented<br>
by R5, being optionally substituted with one or more<br>
radicals, which may be identical or different, selected<br><br>
from the halogen atoms and the hydroxyl, NHalk,<br>
N(alk)2, alkoxy, cycloalkyl, heterocycloalkyl,<br>
heteroaryl and phenyl radicals, these last-mentioned<br>
heteroaryl and phenyl radicals being optionally<br>
substituted with one or more radicals, which may be<br>
identical or different, selected from the halogen atoms<br>
and the hydroxyl, NH2, NHAlk, N(Alk)2, alkyl,<br>
hydroxyalkyl and alkoxy radicals;<br>
R7 and R8 are such that:<br>
either R7 and R8, which may be identical or different,<br>
are such that one of R7 and R8 represents a hydrogen<br>
atom or an alkyl radical,<br>
and the other one of R7 and R8 represents a hydrogen<br>
atom, an alkyl radical optionally substituted with one<br>
or more radicals, which may be identical or different,<br>
selected from the halogen atoms, the hydroxyl, NH2,<br>
NHalk, N(alk)2, NH(phenyl), NH(phenylalk) , alkoxy,<br>
OCF3, cycloalkyl radicals, and the pyrrolidinyl,<br>
piperazinyl, piperidyl, morpholinyl and phenyl<br>
radicals, all these last-mentioned cyclic radicals, as<br>
well as the phenyl residue in the phenylalkyl radical,<br>
themselves being optionally substituted with one or<br>
more radicals, which may be identical or different,<br>
selected from the halogen atoms and the hydroxyl, NH2,<br>
NHAlk, N(alk)2, alkoxy, alkyl and hydroxyalkyl<br>
radicals;<br>
or R7 and R8 form, together with the nitrogen atom to<br>
which they are attached, a radical preferably selected<br>
from the piperidyl, morpholinyl radicals, and the<br>
pyrrolidinyl, piperazinyl and homopiperazinyl radicals,<br>
optionally substituted with one or more radicals, which<br>
may be identical or different, selected from the alkyl<br><br>
and phenyl radicals, themselves optionally substituted<br>
with one or more radicals selected from the halogen<br>
atoms and the hydroxyl, NH2, NHAlk, N(Alk)2, alkoxy and<br>
cycloalkyl radicals;<br>
all the above alkyl(alk) and alkoxy radicals being<br>
linear or branched and containing at most 6 carbon<br>
atoms;<br>
said products of formula(I) being in all possible<br>
tautomeric and isomeric forms(racemates, enantiomers<br>
and diastereoisomers) , as well as salts of addition of<br>
said products of formula(I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
10.	Products of formula(I) as defined in any one<br>
of the other claims in which<br>
X-Y represents NH-C(S), N=C-NR7R8 or N=C-R,<br>
R7, R8 and R being selected from all the values defined<br>
in any one of the other claims for R7, R8 and R and the<br>
other substituents R1, R2, R3, R4, R5 and R6 of said<br>
products of formula(I) being selected from all the<br>
values defined in any one of the other claims<br>
respectively for R1, R2, R3, R4, R5 and R6,<br>
said products of formula(I) being in all possible<br>
tautomeric and isomeric forms(racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula(I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
11.	Products of formula(I) as defined in any one<br>
of the other claims in which<br>
X-Y represents NH-C(S), N=C-NR7R8 or N=C-R;<br><br>
R1 represents a hydrogen atom or an alkyl radical<br>
optionally substituted with one or more radicals, which<br>
may be identical or different, selected from the<br>
halogen atoms and the N(alk)2 and alkoxy radicals;<br>
R, which may be identical to or different from R1, is<br>
selected from the values of R1;<br>
R2 represents a hydrogen atom, a halogen atom or an<br>
alkyl radical;<br>
R3 represents a hydrogen atom or an alkyl radical;<br>
R4 represents a hydrogen atom or a halogen atom,<br>
R5 represents a hydrogen atom, a halogen atom or a<br>
hydroxyl, NH2, NHalk, N(alk)2, alkyl, alkoxy or phenyl<br>
radical, the alkyl radical being optionally substituted<br>
with an alkoxy, N(alk)2 or heterocycloalkyl radical and<br>
the phenyl radical being optionally substituted with<br>
one or more radicals, which may be identical or<br>
different, selected from the halogen atoms and the<br>
hydroxyl, NH2, NHalk, N(alk)2, alkyl and alkoxy<br>
radicals;<br>
R6 represents a hydrogen atom, a halogen atom or an<br>
alkyl radical;<br>
and R7 and R8 are such that:<br>
either R7 and R8, which may be identical or different,<br>
are such that one of R7 and R8 represents a hydrogen<br>
atom or an alkyl radical, and the other one of R7 and<br>
R8 represents an alkyl radical optionally substituted<br>
with a cycloalkyl radical;<br>
or R7 and R8 form, together with the nitrogen atom to<br>
which they are attached, a pyrrolidinyl, morpholine,<br><br>
piperidyl or piperazinyl radical optionally substituted<br>
with an alkyl radical;<br>
said products of formula(I) being in all possible<br>
tautomeric and isomeric forms(racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula(I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
12. Products of formula(I) as defined in any one<br>
of the preceding claims in which<br>
X-Y represents NH-C(S) or N=C-NR7R8;<br>
R1 and R2 which may be identical or different,<br>
represents a hydrogen atom or an alkyl radical;<br>
R3 represents a hydrogen atom;<br>
R4, R5 and R6, which may be identical or different,<br>
represent a hydrogen atom or a halogen atom;<br>
R7 and R8 represent the values defined in any one of<br>
Claims 1 to 4;<br>
all the above alkyl(alk) radicals being linear or<br>
branched and containing at most 6 carbon atoms;<br>
said products of formula(I) being in all possible<br>
tautomeric and isomeric forms(racemates, enantiomers<br>
and diastereoisomers), as well as salts of addition of<br>
said products of formula(I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
13. Products of formula(I) as defined in any one<br>
of the other claims, having the following names:<br>
-(5Z)-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-2-<br>
thioxoimidazolidin-4-one<br><br>
-	(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-thioxoimidazolidin-4-one<br>
-	(5Z)-2-[(cyclopropylmethyl)amino]-5-(1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylene)-3,5-dihydro-4H-imidazol-4-one<br>
-	(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-[(cyclopropylmethyl)amino]-3,5-dihydro-<br>
4H-imidazol-4-one<br>
-	(5Z)-5-[(6-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylene]-2-[(cyclopropylmethyl)amino]-3,5-dihydro-<br>
4H-imidazol-4-one<br>
-	(5Z)-2-[(cyclopropylmethyl)amino]-3-methyl-5-(1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylene)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
-	(5Z)-2-butyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylene)-3,5-dihydro-4H-imidazol-4-one<br>
-	(5Z)-2-azepan-1-yl-5-[(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one<br>
-	5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-piperidin-1-yl-3,5-dihydro-4H-<br>
imidazol-4-one<br>
-	5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[methyl(2-methylpropyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one<br>
-	(5Z)-5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(cyclopropylmethyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one<br><br>
-	(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-methoxy-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
-	(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-fluoro-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
-	(5Z)-2-azepan-1-yl-5-[(5-fluoro-1H-pyrrolo[2,3-<br>
b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-imidazol-4-<br>
one<br>
-	3-[(Z)-{2-[(cyclopropylmethyl)amino]-5-oxo-l,5-<br>
dihydro-4H-imidazol-4-ylidene}methyl]-1H-pyrrolo[2,3-<br>
b]pyridine-5-carbonitrile<br>
-	(5Z)-2-[(cyclopropylmethyl)amino]-5-[(5-phenyl-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
-	(5Z)-2-[(cyclopropylmethyl)amino]-5-{[5-<br>
(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl]methylidene}-3,5-dihydro-4H-imidazol-4-one<br>
-	(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-(methylsulphanyl)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
-	(5Z)-2-butyl-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3,5-dihydro-4H-imidazol-4-one<br>
-	(5Z) -2-(3-methylbutyl)-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one<br>
-	(5Z)-2-cyclohexyl-5-(1H-pyrrolo[2,3-b]pyridin-3-<br>
ylmethylidene)-3,5-dihydro-4H-imidazol-4-one<br><br>
-	(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-<br>
3,5-dihydro-4H-imidazol-4-one<br>
-	(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-3-methyl-2-(2-methylpropyl)-3,5-<br>
dihydro-4H-imidazol-4-one<br>
-	(5Z)-2-(cyclopropylmethyl)-5-(5-chloro-1H-<br>
pyrrolo[2,3-b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-<br>
imidazol-4-one<br>
-	(5Z)-2-(1-methylethyl)-5-(5-chloro-1H-pyrrolo[2,3-<br>
b]pyridin-3-ylmethylidene)-3,5-dihydro-4H-imidazol-4-<br>
one<br>
-	(5Z)-2-[benzyl(methyl)amino]-5-[(5-chloro-1H-<br>
pyrrolo[2,3-b]pyridin-3-yl)methylidene]-3,5-dihydro-4H-<br>
imidazol-4-one<br>
-	(5Z)-5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-<br>
yl)methylidene]-2-[(2-methoxyethyl)(methyl)amino]-3,5-<br>
dihydro-4H-imidazol-4-one<br>
said products of formula(I) being in all possible<br>
isomeric forms(racemates, enantiomers and<br>
diastereoisomers) , as well as salts of addition of said<br>
products of formula(I) with organic and inorganic<br>
acids or with organic and inorganic bases.<br>
14.	As medicinal products, the products of formula<br>
(I) as defined in any one of Claims 1 to 13, as well as<br>
salts of addition of said products of formula(I) with<br>
pharmaceutically acceptable inorganic and organic acids<br>
or inorganic and organic bases.<br>
15.	As medicinal products, the products of formula<br>
(I) as defined in Claim 13, as well as salts of<br><br>
addition of said products of formula(I) with<br>
pharmaceutically acceptable inorganic and organic acids<br>
or inorganic and organic bases.<br>
16.	Pharmaceutical compositions containing, as<br>
active principle, at least one of the products of<br>
formula(I) as defined in Claims 14 and 15 or a<br>
pharmaceutically acceptable salt of this product or a<br>
prodrug of this product and a pharmaceutically<br>
acceptable cairrier.<br>
17.	Use of product(s) of formula(I) as defined in<br>
any one of Claims 1 to 13, or of pharmaceutically<br>
acceptable salts of these products or alternatively of<br>
prodrugs for the preparation of a medicinal product<br>
intended to inhibit the activity of a protein kinase.<br>
18.	Use as defined in Claim 17 in which the protein<br>
kinase selected is Cdc7.<br>
19.	Use as defined in any one of the preceding<br>
claims in which the protein kinase is in a cell<br>
culture.<br>
20.	Use as defined in any one of the preceding<br>
claims in which the protein kinase is in a mammal.<br>
21.	Use of a product of formula(I) as defined in<br>
any one of Claims 1 to 13 for the preparation of a<br>
medicinal product intended for the treatment or<br>
prevention of a disease selected from the following<br>
group: disorders of proliferation of blood vessels,<br>
fibrotic disorders, disorders of proliferation of<br>
mesangial cells, metabolic disorders, allergies,<br>
asthmas, thromboses, diseases of the nervous system,<br>
retinopathy, psoriasis, rheumatoid arthritis, diabetes,<br>
muscular degeneration and cancers.<br><br>
22.	Use of a product of formula(I) as defined in<br>
any one of Claims 1 to 13 for the preparation of a<br>
medicinal product intended for the treatment or<br>
prevention of a disease selected from the following<br>
group: disorders of proliferation of mesangial cells,<br>
psoriasis, rheumatoid arthritis, diabetes, muscular<br>
degeneration and cancers.<br>
23.	Use of a product of formula(I) as defined in<br>
any one of Claims 1 to 13, for the preparation of a<br>
medicinal product intended for the treatment of<br>
cancers.<br>
24.	Use according to Claim 23, intended for the<br>
treatment of solid tumours.<br>
25.	Use according to Claim 23 or 24, intended for<br>
the treatment of cancers that are resistant to<br>
cytotoxic agents.<br>
26.	Use according to any one of Claims 23 to 25,<br>
intended for the treatment of cancers of the breast,<br>
stomach, ovaries, colon, lung, brain, larynx, lymphatic<br>
system, urogenital tract including bladder and<br>
prostate, and treatment of cancers of the bones and of<br>
the pancreas.<br>
27.	Use according to any one of Claims 23 to 25,<br>
intended for the treatment of cancers of the breast, of<br>
the colon or of the lung.<br>
28.	Use of a product of formula(I) as defined in<br>
any one of Claims 1 to 13, for the preparation of<br>
medicinal products intended for cancer chemotherapy.<br>
29.	Use of a product of formula(I) as defined in<br>
any one of Claims 1 to 13, for the preparation of<br><br>
medicinal products intended for cancer chemotherapy-<br>
alone or in combination.<br>
30. Products of formula(I) as defined in any one<br>
of Claims 1 to 13 as inhibitors of Cdc7.<br><br>
The invention relates to products of the formula(I) in which :<br>
X-Y is NH-C(S), N=C-NR7R8, N=C-SR, N=C-R or N=C-OR; R and R1 are H<br>
or optionally substituted cycloalkyl, alkyl, heterocycloalkyl, aryl or heteroaryl,;<br>
R2 is H, Hal or alkyl; R3 is H, Hal, OH, alkyl or alkoxy; R4 is H, Hal, CN or<br>
alkyl; R5 is essentially H, Hal, OH, NR7R8, cycloalkyl, alkyl, alkoxy, heterocycloalkyl,<br>
aryl or heteroaryl, optionally substituted; R6 is H, Hal, OH, NH2,<br>
NHalk, N(alk)2, alkyl or alkoxy; with R7 et R8 being such that one is H or optionally<br>
substituted alk, while the other is H or optionally substituted cycloalkyl,<br>
alkyl, heterocycloalkyl, heteroaryl or aryl; or with R7 and R8 forming together<br>
with N an optionally substituted cyclic radical optionally containing O, S or N.<br>
The invention also relates to isomers and salts thereof used as drugs and essentially<br>
as protein kinase inhibitors, in particular CDC7.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1LT0xOUC0yMDA5LSgwMS0wOS0yMDE0KS1DTEFJTVMucGRm" target="_blank" style="word-wrap:break-word;">1025-KOLNP-2009-(01-09-2014)-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1LT0xOUC0yMDA5LSgwMS0wOS0yMDE0KS1FWEFNSU5BVElPTiBSRVBPUlQgUkVQTFkgUkVDRUlWRUQucGRm" target="_blank" style="word-wrap:break-word;">1025-KOLNP-2009-(01-09-2014)-EXAMINATION REPORT REPLY RECEIVED.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1LT0xOUC0yMDA5LSgwMS0wOS0yMDE0KS1GT1JNLTIucGRm" target="_blank" style="word-wrap:break-word;">1025-KOLNP-2009-(01-09-2014)-FORM-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1LT0xOUC0yMDA5LSgwMS0wOS0yMDE0KS1GT1JNLTMucGRm" target="_blank" style="word-wrap:break-word;">1025-KOLNP-2009-(01-09-2014)-FORM-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1LT0xOUC0yMDA5LSgwMS0wOS0yMDE0KS1GT1JNLTUucGRm" target="_blank" style="word-wrap:break-word;">1025-KOLNP-2009-(01-09-2014)-FORM-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1LT0xOUC0yMDA5LSgwMS0wOS0yMDE0KS1PVEhFUlMucGRm" target="_blank" style="word-wrap:break-word;">1025-KOLNP-2009-(01-09-2014)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1LT0xOUC0yMDA5LSgwMS0wOS0yMDE0KS1QRVRJVElPTiBVTkRFUiBSVUxFIDEzNy0xLnBkZg==" target="_blank" style="word-wrap:break-word;">1025-KOLNP-2009-(01-09-2014)-PETITION UNDER RULE 137-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1LT0xOUC0yMDA5LSgwMS0wOS0yMDE0KS1QRVRJVElPTiBVTkRFUiBSVUxFIDEzNy5wZGY=" target="_blank" style="word-wrap:break-word;">1025-KOLNP-2009-(01-09-2014)-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1LT0xOUC0yMDA5LSgwOS0wOS0yMDE0KS1FWEFNSU5BVElPTiBSRVBPUlQgUkVQTFkgUkVDRUlWRUQucGRm" target="_blank" style="word-wrap:break-word;">1025-KOLNP-2009-(09-09-2014)-EXAMINATION REPORT REPLY RECEIVED.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1LT0xOUC0yMDA5LSgwOS0wOS0yMDE0KS1PVEhFUlMucGRm" target="_blank" style="word-wrap:break-word;">1025-KOLNP-2009-(09-09-2014)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1LT0xOUC0yMDA5LSgwOS0wOS0yMDE0KS1QRVRJVElPTiBVTkRFUiBSVUxFIDEzNy5wZGY=" target="_blank" style="word-wrap:break-word;">1025-KOLNP-2009-(09-09-2014)-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1rb2xucC0yMDA5LWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">1025-kolnp-2009-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1LT0xOUC0yMDA5LUFTU0lHTk1FTlQucGRm" target="_blank" style="word-wrap:break-word;">1025-KOLNP-2009-ASSIGNMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1rb2xucC0yMDA5LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">1025-kolnp-2009-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1rb2xucC0yMDA5LWNvcnJlc3BvbmRlbmNlLnBkZg==" target="_blank" style="word-wrap:break-word;">1025-kolnp-2009-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1rb2xucC0yMDA5LWRlc2NyaXB0aW9uIChjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">1025-kolnp-2009-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1rb2xucC0yMDA5LWZvcm0gMS5wZGY=" target="_blank" style="word-wrap:break-word;">1025-kolnp-2009-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1LT0xOUC0yMDA5LUZPUk0gMTgucGRm" target="_blank" style="word-wrap:break-word;">1025-KOLNP-2009-FORM 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1rb2xucC0yMDA5LWZvcm0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">1025-kolnp-2009-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1rb2xucC0yMDA5LWZvcm0gNS5wZGY=" target="_blank" style="word-wrap:break-word;">1025-kolnp-2009-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1rb2xucC0yMDA5LWdwYS5wZGY=" target="_blank" style="word-wrap:break-word;">1025-kolnp-2009-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1rb2xucC0yMDA5LWludGVybmF0aW9uYWwgcHVibGljYXRpb24ucGRm" target="_blank" style="word-wrap:break-word;">1025-kolnp-2009-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1rb2xucC0yMDA5LWludGVybmF0aW9uYWwgc2VhcmNoIHJlcG9ydC5wZGY=" target="_blank" style="word-wrap:break-word;">1025-kolnp-2009-international search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1rb2xucC0yMDA5LXBjdCByZXF1ZXN0IGZvcm0ucGRm" target="_blank" style="word-wrap:break-word;">1025-kolnp-2009-pct request form.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1rb2xucC0yMDA5LXNwZWNpZmljYXRpb24ucGRm" target="_blank" style="word-wrap:break-word;">1025-kolnp-2009-specification.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTAyNS1rb2xucC0yMDA5LXRyYW5zbGF0ZWQgY29weSBvZiBwcmlvcml0eSBkb2N1bWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">1025-kolnp-2009-translated copy of priority document.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QtMTAyNS1rb2xucC0yMDA5LmpwZw==" target="_blank" style="word-wrap:break-word;">abstract-1025-kolnp-2009.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="264228-cold-and-or-heat-accumulator.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="264230-a-compact-eight-speed-automatic-transmission.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>264229</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1025/KOLNP/2009</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>51/2014</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>19-Dec-2014</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>16-Dec-2014</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>17-Mar-2009</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>SANOFI-AVENTIS</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>174, AVENUE DE FRANCE, F-75013 PARIS</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>BACQUE, ERIC</td>
											<td>C/O SANOFI-AVENTIS, DPARTEMENT DES BREVETS, 174 AVENUE DE FRANCE, F-75013 PARIS</td>
										</tr>
										<tr>
											<td>2</td>
											<td>LEROY, VINCENT</td>
											<td>C/O SANOFI-AVENTIS, DPARTEMENT DES BREVETS, 174 AVENUE DE FRANCE, F-75013 PARIS</td>
										</tr>
										<tr>
											<td>3</td>
											<td>CONSEILLER, EMMANUEL</td>
											<td>C/O SANOFI-AVENTIS, DPARTEMENT DES BREVETS, 174 AVENUE DE FRANCE, F-75013 PARIS</td>
										</tr>
										<tr>
											<td>4</td>
											<td>STEINMETZ, ANKE</td>
											<td>C/O SANOFI-AVENTIS, DPARTEMENT DES BREVETS, 174 AVENUE DE FRANCE, F-75013 PARIS</td>
										</tr>
										<tr>
											<td>5</td>
											<td>RONAN, BAPTISTE</td>
											<td>C/O SANOFI-AVENTIS, DPARTEMENT DES BREVETS, 174 AVENUE DE FRANCE, F-75013 PARIS</td>
										</tr>
										<tr>
											<td>6</td>
											<td>LETALLEC, JEAN-PHILIPPE</td>
											<td>C/O SANOFI-AVENTIS, DPARTEMENT DES BREVETS, 174 AVENUE DE FRANCE, F-75013 PARIS</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07D 471/04</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/FR2007/001651</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2007-10-10</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>0608924</td>
									<td>2006-10-12</td>
								    <td>France</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/264229-new-imidazolone-derivatives-preparation-thereof-as-drugs-pharmaceutical-compositions-and-use-thereof-as-protein-kinase-inhibitors-in-particular-cdc7 by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 00:21:07 GMT -->
</html>
